Saponin-Based Adjuvants and Vaccines
Novel triterpene glycoside saponin adjuvants with an oxime group at the C4 position address the limitations of QS-21 by enhancing immune responses and providing a safer, more effective vaccine adjuvant solution.
Patent Information
- Application Number
- JP2024532970
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-12-03
- Filing Date
- 2022-12-02
- Publication Date
- 2024-11-26
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current adjuvants like QS-21 face limitations such as limited availability, toxicity, and chemical instability, hindering their use in human vaccines, and there is a need for new derivatives with improved efficacy and reduced toxicity.
Development of novel triterpene glycoside saponin adjuvants with an oxime group at the C4 position, enhancing immune response through both carbohydrate and oxime bond interactions, and potentially used as self-adjuvanted vaccines.
The new saponin adjuvants elicit stronger antibody responses and induce immune reactions, offering a safer and more effective alternative to traditional adjuvants.
Smart Images

Figure 2024544007000109 
Figure 2024544007000110 
Figure 2024544007000111
Abstract
Description
[Technical field]
[0001] This application is encompassed in the field of chemical immunology. More specifically, this application relates to synthetic adjuvants and vaccines based on triterpene glycoside saponin scaffolds and pharmaceutical compositions thereof, and the use of said compounds and compositions in the treatment and immunization for diseases such as neurodegenerative diseases, infectious diseases, and cancer. [Background technology]
[0002] Vaccines have been approved over the past decades and have improved medical care. Attenuated or inactivated pathogens and their toxins have historically been used as vaccines. Recent subunit vaccines based on homogenous antigens offer more precise targeting and improved safety compared to traditional whole pathogen vaccines. However, they are also less immunogenic and require adjuvants to increase the immunogenicity of antigens and enhance immune responses (Pifferi, C. et al. Nat. Rev. Chem. 2021, 25(4), 3-7). Adjuvants enhance antigen-specific immune responses by modulating and enhancing innate and adaptive immunity (acquired immunity) when delivered together with an antigen (Bergmann-Leitner, E. et al. Vaccines 2014, 2(2), 252-296). Furthermore, they can reduce the dose of expensive antigens, reduce booster immunizations, generate more rapid and sustained immune responses, and increase vaccine efficacy in poor responders (Reed, SGet al. Nat. Med. 2013, 19(12), 1597-1608).
[0003] However, few adjuvants have sufficient efficacy and acceptable toxicity for clinical use. Aluminum-containing adjuvants are the first human vaccine adjuvants approved for clinical use. Aluminum salts have been used as adjuvants in many vaccines, either alone (alum) or in proprietary mixtures (AS04) and oil-in-water emulsions with squalene (MF59, AS03), but each has relatively low efficacy and significant side effects. These limitations highlight the urgent need for new, potent, and safe adjuvants.
[0004] QS-21 is one of the most promising adjuvants currently being investigated. It is isolated from the bark of Quillaja saponaria and is composed of four structural domains: a branched trisaccharide, a quillic acid triterpene, a bridged linear tetrasaccharide, and a pseudodimeric acyl chain. QS-21 is not a single molecule, but rather a mixture of two isomers in a ratio of approximately 2:1 that differ in the terminal sugars of the linear tetrasaccharide domain, with the first isomer having a terminal apiose (QS-21-Api) and the second having a xylose (QS-21-Xyl).
[0005] [ka]
[0006] Vaccines containing QS-21 are being studied or are in development for several cancers and infectious and neurodegenerative diseases (malaria, acquired immune deficiency syndrome, hepatitis, tuberculosis, and Alzheimer's disease). Despite its promise, QS-21 has several drawbacks, including limited availability from natural sources, toxic side effects, and chemical instability due to spontaneous hydrolysis of the acyl chains. Apart from its recent approval as part of malaria and varicella-zoster vaccines, the rarity, heterogeneity, and dose-limiting toxicity of QS-21 have prevented its further use in human vaccines.
[0007] Adjuvants derived from triterpene glycoside saponins have been disclosed in WO2009 / 126737, WO2015 / 184451, WO2017 / 079582, WO2017 / 106836, WO2018 / 191598, WO2018 / 200645, WO2018 / 200656, and WO2019 / 079160.
[0008] However, the difficulty in obtaining pure species from Quillaja saponin extracts, the difficulty in correctly identifying their structures, and the incomplete understanding of the molecular mechanism of action of these saponin-based adjuvants have hindered the rational development of analogues with improved efficacy and reduced toxicity.Therefore, there remains a need for new derivatives that exhibit potent adjuvant activity and / or low toxicity.
[0009] Furthermore, in the development of new monomolecular vaccine constructs, it is also highly desirable for new adjuvants to function as self-adjuvanting built-in moieties. Compared with the traditional approach of using co-formulation of adjuvant and antigen mixtures, the self-adjuvanting vaccine strategy consists of binding antigen to a clearly defined adjuvant. In this way, immune cells can simultaneously take up both covalently linked components, which enhances the immune response against the bound antigen. Thus, self-adjuvanting vaccines do not require the co-administration of additional adjuvants or binding to carrier proteins, avoiding the use of toxic adjuvants and the induction of undesirable responses. Summary of the Invention
[0010] The present invention solves one or more of the above needs by providing novel triterpene glycoside saponin adjuvants and conjugates thereof. In particular, it has been found that the active compounds of the present invention, characterized by having an oxime group (-C=NO-) at the C4 position of the triterpene domain, enhance the antibody response to antigens much more than similar state-of-the-art saponins having a C4-aldehyde. Furthermore, some of the saponins of the present invention are linked to or functionalized with substances (i.e., having at least one immunogenic region) that can induce an immune response via both the carbohydrate domain chain and the oxime bond at the C4 position of the triterpene domain, and are therefore useful as efficient self-adjuvanting vaccines.
[0011] One aspect of the present invention relates to a compound selected from: - a compound of formula (I) or a pharma- ceutically acceptable salt thereof
[0012] [ka]
[0013] wherein G is hydrogen, a branched trisaccharide of formula (VI) or a stereoisomer of formula (VI);
[0014] [ka]
[0015] In the formula, R p Each occurrence of is independently hydrogen or OR q and R q Each occurrence of is independently hydrogen, or a 6-10 membered aryl, benzyl, C 1~6 Aliphatic or C having 1 to 2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur 1~6 or two R qtaken together form a 5-7 membered heterocycle having 1-2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; --- is a single bond or a double bond, V is H or OR x and Y is CH2, -O-, -S-, -NR, or -NH-; Z is a carbohydrate domain having the structure
[0016] [ka] [ka]
[0017] In the formula, R 1 Each occurrence of R X or a carbohydrate domain having the structure:
[0018] [ka]
[0019] During the ceremony, each occurrence of a, b, and c is independently 0, 1, or 2; D is an integer from 1 to 5, the bracketed structures of each d may be the same or different, provided that the bracketed structure of d represents a furanose moiety or a pyranose moiety, and the sum of b and c is 1 or 2; R 0 is hydrogen; an oxygen protecting group selected from the group consisting of alkyl ether, benzyl ether, silyl ether, acetal, ketal, ester, carbamate, and carbonate; or acyl, C 1~10 aliphatic, C 1~6an optionally substituted moiety selected from the group consisting of heteroaliphatic, 6-10 membered aryl, arylalkyl, 5-10 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and 4-7 membered heterocyclyl having 1-2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; R a , R b , R c , and R d Each occurrence of is independently hydrogen, halogen, OH, OR, OR x , NR2, NHCOR, or acyl, C 1~10 aliphatic, C 1~6 an optionally substituted group selected from the group consisting of heteroaliphatic, 6- to 10-membered aryl, arylalkyl, 5- to 10-membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 4- to 7-membered heterocyclic groups having 1-2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; R 2 are hydrogen, halogen, OH, OR, OC(O)R 4 , O.C.(O)O.R. 4 , O.C.(O)N.H.R. 4 , O.C.(O)N.R.R. 4 , O.C.(O)S.R. 4 , NHC(O)R 4 , NRC(O)R 4 , NHC(O)OR 4 , NHC(O)NHR 4 , NHC(O)NRR 4 , N.H.R. 4 , N(R 4 )2, NHR 4 , N.R.R. 4 , N3, or C 1~10 aliphatic, C 1~6 an optionally substituted group selected from heteroaliphatic, 6- to 10-membered aryl, arylalkyl, 5- to 10-membered heteroaryl having 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, and 4- to 7-membered heterocyclyl having 1-2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; R 3is hydrogen, halogen, CH2OR 1 , or acyl, C 1~10 aliphatic, C 1~6 an optionally substituted group selected from the group consisting of heteroaliphatic, 6- to 10-membered aryl, arylalkyl, 5- to 10-membered heteroaryl having 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, and 4- to 7-membered heterocyclyl having 1-2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; R 4 -TR z , -C(O)-TR z , -NH-TR z , -OTR z , -STR z , -C(O)NH-TR z , C(O)OTR z , C(O)STR z , C(O)NH-TOTR z , -OTR z , -TOTR z , -TSTR z or
[0020] [ka]
[0021] and During the ceremony, X is -O-, -NR-, or TR z and T is a covalent bond or a divalent C 1~26 saturated or unsaturated, linear or branched, aliphatic or heteroaliphatic chains,
[0022] R z is hydrogen, halogen, -OR, -OR x , -OR 1 , -SR, NR2, -C(O)OR, -C(O)R, -NHC(O)R, -NHC(O)OR, -NC(O)OR, or acyl, arylalkyl, heteroarylalkyl, C 1~6an optionally substituted group selected from an aliphatic group, a 6- to 10-membered aryl group, a 5- to 10-membered heteroaryl group having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and a 4- to 7-membered heterocyclyl group having 1 to 2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; R x each occurrence of is independently hydrogen or an oxygen protecting group selected from the group consisting of alkyl ethers, benzyl ethers, silyl ethers, acetals, ketals, esters, carbamates, and carbonates; Each occurrence of R is independently selected from hydrogen, acyl, arylalkyl, 6- to 10-membered aryl, C 1~6 Aliphatic or C having 1 to 2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur 1~6 an optionally substituted group selected from heteroaliphatic; or two R on the same nitrogen atom together with the nitrogen atom form a 4-7 membered heterocycle having 1-2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; and - a compound of general formula (II) or a pharma- ceutically acceptable salt thereof
[0023] [ka]
[0024] (In the formula, --- , G, V, and Y have the same meaning as in formula (I); W is H or a moiety that contains either i) at least one T cell epitope, ii) at least one B cell epitope, or iii) at least one T cell epitope and at least one B cell epitope; Z* represents Z as defined in formula (I) optionally linked to a moiety comprising either i) at least one T cell epitope, ii) at least one B cell epitope, or iii) at least one T cell epitope and at least one B cell epitope; provided that at least one T cell epitope and at least one B cell epitope are present in the compound of formula (II); The at least one T cell epitope is in all cases independently selected from a helper T cell epitope or a CD8 epitope).
[0025] Another aspect of the present invention relates to a compound selected from: - a compound of general formula (III) or a pharma- ceutically acceptable salt thereof
[0026] [ka]
[0027] (In the formula, --- , G, V, and Y have the meanings defined above in formula (I), and Z* denotes that Z as defined in formula (I) is linked to a moiety comprising either i) at least one T cell epitope selected from a helper T cell epitope or a CD8 epitope, ii) at least one B cell epitope, or iii) at least one T cell epitope and at least one B cell epitope selected from a helper T cell epitope or a CD8 epitope. and - a compound of general formula (IV) or a pharma- ceutically acceptable salt thereof
[0028] [ka]
[0029] (In the formula, --- , G, V, Y and Z have the meanings defined above in formula (I), W is a moiety that includes either i) at least one T cell epitope selected from a helper T cell epitope or a CD8 epitope, ii) at least one B cell epitope, or iii) selected from a helper T cell epitope or a CD8 epitope, at least one T cell epitope and at least one B cell epitope).
[0030] Another aspect of the present invention relates to a method of synthesizing a compound of formula (I) or formula (II).
[0031] A method for synthesizing a compound of formula (I) comprises the steps of: a) providing a compound of formula (V) or a salt thereof;
[0032] [ka]
[0033] (In the formula, --- , G, V, Y and Z have the meanings defined above in formula (I).
[0034] b) reacting a compound of formula (V) with NHOH or a salt thereof to form a compound of formula (I) or a salt thereof;
[0035] [ka] Includes.
[0036] The method for synthesizing the compound of formula (II) comprises the steps of: a) providing a compound of formula (V) or a salt thereof;
[0037] [ka]
[0038] (In the formula, --- , G, V, Y and Z have the meanings defined above in formula (I).
[0039] b) combining a compound of formula (V) or a salt thereof with a moiety comprising either i) at least one T cell epitope selected from a helper T cell epitope or a CD8 epitope, ii) at least one B cell epitope, or iii) at least one T cell epitope and at least one B cell epitope selected from a helper T cell epitope or a CD8 epitope to form a compound of formula (III) or a salt thereof;
[0040] [ka]
[0041] c) reacting a compound of formula (III) or a salt thereof with a compound of the formula:
[0042] [ka]
[0043] or a salt thereof, wherein W is H or a moiety comprising either i) at least one T cell epitope selected from a helper T cell epitope or a CD8 epitope, ii) at least one B cell epitope, or iii) a helper T cell epitope or a CD8 epitope, at least one T cell epitope and at least one B cell epitope, to form a compound of formula (II) or a salt thereof;
[0044] [ka] A method comprising:
[0045] a) providing a compound of formula (V) or a salt thereof;
[0046] [ka]
[0047] (In the formula, ---, G, V, Y and Z have the meanings defined above in formula (I).
[0048] b) reacting a compound of formula (V) or a salt thereof with a compound of the formula:
[0049] [ka]
[0050] or a salt thereof, wherein W is H or a moiety comprising either i) at least one T cell epitope selected from a helper T cell epitope or a CD8 epitope, ii) at least one B cell epitope, or iii) at least one T cell epitope and at least one B cell epitope, a helper T cell epitope or a CD8 epitope, to form a compound of formula (IV) or a salt thereof;
[0051] [ka]
[0052] (A compound of formula (IV) corresponds to formula (II) when W is a moiety comprising at least one T cell epitope selected from a helper T cell epitope or a CD8 epitope and at least one B cell epitope.)
[0053] c) optionally combining the compound of formula (IV) or a salt thereof with a moiety comprising i) at least one T cell epitope selected from a helper T cell epitope or a CD8 epitope, ii) at least one B cell epitope, or iii) at least one T cell epitope and at least one B cell epitope selected from a helper T cell epitope or a CD8 epitope to form a compound of formula (II) or a salt thereof;
[0054] [ka] The method is selected from the following:
[0055] Another aspect of the invention relates to a pharmaceutical composition comprising: a compound of formula (I) as defined above or a pharma- ceutically acceptable salt thereof, a pharma- ceutically acceptable carrier, and an antigen, or - a compound of formula (II) as defined above or a pharma- ceutically acceptable salt thereof and a pharma- ceutically acceptable carrier.
[0056] Another aspect of the invention relates to a compound of formula (I), formula (II) or a pharma- ceutically acceptable salt thereof as defined above for use in medicine.
[0057] Another aspect of the present invention relates to a compound of formula (I), formula (II) or a pharma- ceutically acceptable salt thereof or a pharmaceutical composition thereof for use in the treatment and / or prophylaxis of cancer, an infectious disease, or a neurodegenerative disease.
[0058] These aspects and preferred embodiments thereof are also further defined in the detailed description and claims that follow. [Brief description of the drawings]
[0059] For a better understanding of the present invention, its objects and advantages, the following figures are attached hereto, in which:
[0060] [Figure 1]Figure 1 shows the complete structure of vaccine constructs 1-4. Compounds 1 and 2 are two-component synthetic vaccines containing a saponin adjuvant core scaffold based on quilacic acid linked to MUC1 (1) or TnMUC1 (2) B-cell epitopes via a polyethylene glycol (PEG) spacer. Compounds 3 and 4 are three-component vaccines containing the KLFAVWKITYKDT peptide sequence from poliovirus [PV(103-115)] as a helper T-cell epitope. Such peptide sequences are covalently linked to the quilacic acid triterpene of the saponin via an oxime linker with aldehyde functionalization. Abbreviations of compounds: 1 → QA-MUC1; 2 → QA-TnMUC1; 3 → QA(PV)-MUC1; 4 → QA(PV)-TnMUC1. [Diagram 2] Figure 2 shows the complete structures of synthetic vaccine constructs 26-29. Compounds 26 and 28 are two-component synthetic conjugates containing a saponin adjuvant core scaffold based on quilacic acid linked to the Tn-Thr (26) or Gb3 (28) B-cell epitopes via a polyethylene glycol (PEG) spacer. Compounds 27 and 29 are three-component conjugates containing the KLFAVWKITYKDT peptide sequence from poliovirus [PV(103-115)] as the helper T-cell epitope. Such peptide sequences are covalently linked to the saponin quilacic acid triterpene at the C4 aldehyde substituent via an oxime bond. Abbreviations of compounds: 26 → QA-Tn-Thr; 27 → QA(PV)-Tn-Thr; 28 → QA-Gb3; 29 → QA(PV)-Gb3. [Diagram 3] FIG. 3 shows the preparation of MUC1 and TnMUC1 functionalized BSA (23 and 24). [Figure 4]Figure 4 shows the total IgG production (endpoint) of anti-OVA antibodies in mouse serum obtained from in vivo experiment 1 (below) to compare the adjuvant activity of prior art compound 13 and compound 25 of the present invention. Total IgG values were calculated for four groups of mice treated subcutaneously using chicken ovalbumin (OVA) as a model antigen: i) non-toxic OVA antigen (20 μg) combined with known QA-based adjuvant 13 (50 μg) (identified as QA+OVA), ii) non-toxic OVA antigen (20 μg) combined with new adjuvant 25 (50 μg) (identified as QA(oxime)+OVA), iii) non-toxic OVA (20 μg) alone as a no-adjuvant control group (identified as OVA), and iv) PBS alone as a negative control (identified as PBS). [Diagram 5] Figure 5 depicts the immunization schedule followed in in vivo experiment 2 (below), including sera bleeding (day 21), end-point serum collection (day 42), and immunization groups (A-D) against MUC1-containing synthetic antigen. In the experiment, mice were immunized with the following synthetic molecules: (A) MUC1 peptide epitope alone (compound 5) [group A], (B) a mixture of MUC1 peptide (5) and PV Th epitope (compound 22) [group B], (C) a mixture of binary saponin-MUC1 conjugate 1 and Th epitope (22) [group C], and (D) a ternary saponin construct incorporating both MUC1 and PV peptides, QA(PV)-MUC1(3) [group D]. [Figure 6] Figure 6 shows anti-MUC1 total IgG antibody titers from a) midpoint (day 21) and b) endpoint (day 42) sera from in vivo experiment 2 (below). ELISA plates were coated with MUC1-functionalized BSA conjugate (conjugate 23). [Figure 7] FIG. 7 shows IgG subtyping of anti-MUC1 antibodies in endpoint (day 42) sera from in vivo study 2 (below). [Figure 8]Figure 8 depicts the immunization schedule performed in in vivo experiment 3 (below), including serum bleeds (day 10), end-point serum collection (day 24), and immunization groups (A-G) against TnMUC1-containing synthetic antigens. Three immunization groups received free TnMUC1 glycopeptides (6) co-administered with either: (i) a known QA-based saponin adjuvant 13 [group B], (ii) a mixture of QA saponin 13 and PV epitope 22 [group C], or (iii) a newly synthesized QA saponin-(PV) conjugate (i.e., molecule 14) [group F]. Two immunization groups received the binary QA saponin-TnMUC1 construct 2 alone [group D] or mixed with the PV epitope 22 [group E], and another group was injected with the ternary QA(PV)-TnMUC1 construct 4 incorporating both the PV and TnMUC1 peptides (22 and 6, respectively) [group G]. Finally, a negative control group receiving only PBS was included [group A]. [Figure 9] FIG. 9 shows anti-TnMUC1 total IgG antibody titers for endpoint (day 24) sera from in vivo study 3 (below). [Figure 10] FIG. 10 shows IgG subtyping of anti-TnMUC1 antibodies for endpoint (day 24) sera from in vivo experiment 3 (below). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0061] The clinical success of anticancer, antiviral, and antibacterial vaccines depends heavily on the identification and availability of new potent adjuvants that are attenuated. In this context, certain fractions from Quillaja saponaria (QS) bark extract have proven to be extremely potent adjuvants in immunotherapy. The QS-21 fraction is one of the most potent adjuvants known. QS-21 stimulates both antibody-based humoral immune responses (Th2) and cellular immunity (Th1), including the production of antigen-specific cytotoxic T lymphocytes. Vaccines containing QS-21, either alone in purified form or as the main component of adjuvant mixtures (e.g., QuilA, ISCOMs, ISCOMATRIX, AS01, AS02), have been investigated in clinical trials against cancer (melanoma, sarcoma, breast, prostate, ovarian, lung cancer), infectious diseases (hepatitis, HIV, malaria, tuberculosis), and Alzheimer's disease.
[0062] Despite its remarkable efficacy and extensive clinical investigation (which led to its approval as part of recently licensed vaccines against malaria and shingles), QS-21 suffers from several limitations. First, the isolated yield of crude extracts from Quillaja saponaria is very low and heterogeneous, limiting the availability of homogenous QS-21. Second, QS-21 has been associated with clinical toxicity, including swelling and erythema at the injection site, as well as systemic flu-like symptoms. Third, QS-21 undergoes spontaneous hydrolysis of the ester bonds of the acyl chain domain, generating adjuvant-inactive and hemolytic by-products, complicating formulation and storage. Finally, the mechanism of action of QS-21 is poorly understood, hindering the rational design of improved variants and optimal matching of adjuvants to vaccine antigens based on desired immunological endpoints. The inherent shortcomings of QS-21 highlight the need for improved analogues.
[0063] After extensive research, the present inventors have unexpectedly found new saponin compounds in which the natural C4-aldehyde substituent of QS-21 and other prior art variants is replaced with an oxime group. The compounds of the present invention function as potent adjuvants when co-administered with antigens and induce significantly higher antibody responses than saponin analogs with C4-aldehyde substituents. Furthermore, it has been found that the oxime bond at the C4 position and the conjugation via the carbohydrate domain chain can functionalize the saponin scaffold with substances capable of stimulating the immune response, thereby resulting in a self-adjuvanting vaccine.
[0064] Unless otherwise defined, all technical and scientific terms and expressions used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs.
[0065] The term "aliphatic" or "aliphatic group," as used herein, refers to a linear (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is fully saturated or contains one or more units of unsaturation; or a monocyclic or bicyclic hydrocarbon (also referred to herein as "carbocyclic," "cycloaliphatic," or "cycloalkyl") that is fully saturated or contains one or more units of unsaturation, but is not aromatic, and has one point of attachment to the remainder of the molecule. Unless otherwise specified, an aliphatic group contains 1-12 aliphatic carbon atoms. In some embodiments, an aliphatic group contains 1-6 aliphatic carbon atoms. In some embodiments, an aliphatic group contains 1-5 aliphatic carbon atoms. In other embodiments, an aliphatic group contains 1-4 aliphatic carbon atoms. In still other embodiments, an aliphatic group contains 1-3 aliphatic carbon atoms, and in still other embodiments, an aliphatic group contains 1-2 aliphatic carbon atoms. In some embodiments, "cycloaliphatic" (or "carbocycle" or "cycloalkyl") refers to a monocyclic C3-C6 hydrocarbon that is fully saturated or contains one or more units of unsaturation, but is not aromatic, and has one point of attachment to the remainder of the molecule. Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl groups, and hybrids thereof, such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl, or (cycloalkyl)alkenyl.
[0066] The term "lower alkyl" refers to a C1-4 straight or branched alkyl group. Examples of lower alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, and tert-butyl.
[0067] The term "lower haloalkyl" refers to a C1-4 straight or branched alkyl group substituted with one or more halogen atoms.
[0068] The term "heteroatom" means one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon (including any oxidized form of nitrogen, sulfur, phosphorus, or silicon, the quaternized form of any basic nitrogen, or a substitutable nitrogen of a heterocycle, for example, N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl), or NR+ (as in N-substituted pyrrolidinyl)).
[0069] As used herein, the term "unsaturated" means that a moiety has one or more units of unsaturation.
[0070] As used herein, "divalent C 1~12 (or C 1~26 , C 1~16 , C 1~8 The term "saturated or unsaturated, straight or branched hydrocarbon chain" refers to divalent alkylene, alkenylene, and alkynylene chains, which are straight or branched, as defined herein.
[0071] The term "alkylene" refers to a divalent alkyl group. An "alkylene chain" is a polymethylene group, i.e., -(CH2)n-, where n is a positive integer, preferably 1-30, 1-28, 1-26, 1-24, 1-22, 1-20, 1-18, 1-16, 1-14, 1-12, 1-10, 1-8, 1-6, 1-4, 1-3, 1-2, or 2-3. A substituted alkylene chain is a polymethylene group in which one or more methylene hydrogen atoms have been replaced with a substituent. Suitable substituents include those described below for substituted aliphatic groups.
[0072] The term "alkenylene" refers to a divalent alkenyl group. A substituted alkenylene chain is a polymethylene group containing at least one double bond and in which one or more hydrogen atoms have been replaced with a substituent. Suitable substituents include those described below for substituted aliphatic groups.
[0073] The term "alkynylene" refers to a divalent alkynyl group. A substituted alkynylene chain is a polymethylene group containing at least one double bond and in which one or more hydrogen atoms have been replaced with a substituent. Suitable substituents include those described below for substituted aliphatic groups.
[0074] The term "acyl" used alone or as part of a larger moiety refers to a group formed by removal of the hydroxy group from a carboxylic acid.
[0075] The term "halogen" means F, CI, Br, or I.
[0076] The terms "aralkyl" and "arylalkyl" are used interchangeably and refer to an alkyl group (e.g., C aryl) in which a hydrogen atom is replaced with an aryl group (e.g., 6-10 membered aryl). 1~6 Alkyl). Such groups include, but are not limited to, benzyl, cinnamyl, and dihydrocinnamyl.
[0077] The term "aryl," used alone or as part of a larger moiety such as "aralkyl," "aralkoxy," or "aryloxyalkyl," refers to a monocyclic or bicyclic ring system having a total of 5 to 14 ring members, where at least one ring in the system is aromatic and where each ring in the system contains 3 to 7 ring members. The term "aryl" may be used interchangeably with the term "aryl ring."
[0078] In certain embodiments of the invention, "aryl" refers to an aromatic ring system, including but not limited to phenyl, biphenyl, naphthyl, anthracyl, etc., optionally bearing one or more substituents. Also included within the scope of the term "aryl" as used herein are groups in which an aromatic ring is fused to one or more non-aromatic rings, such as, for example, indanyl, phthalimidyl, naphthimimidyl, phenanthridinyl, or tetrahydronaphthyl.
[0079] The terms "heteroaryl" and "heteroar-", used alone or as part of a larger moiety such as "heteroaralkyl" or "heteroaralkoxy", refer to groups having 5 to 10 ring atoms, preferably 5, 6, or 9 ring atoms, having 6, 10, or 14 pi-electrons shared in a cyclic array, and having 1 to 5 heteroatoms in addition to the carbon atoms. The term "heteroatom" refers to nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quaternized form of a basic nitrogen. Heteroaryl groups include, but are not limited to, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl. As used herein, the terms "heteroaryl" and "heteroar-" also include groups in which a heteroaromatic ring is fused to one or more aryl, cycloaliphatic, or heterocyclyl rings, where the radical or point of attachment is on the heteroaromatic ring. Non-limiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H-quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and pyrido[2,3-b]-1,4-oxazin-3(4H)-one. Heteroaryl groups may be monocyclic or bicyclic. The term "heteroaryl" may be used interchangeably with the terms "heteroaryl ring," "heteroaryl group," or "heteroaromatic," any of which terms include optionally substituted rings. The terms "heteroaralkyl" and "heteroarylalkyl" refer to an alkyl group substituted by a heteroaryl moiety, where the alkyl and heteroaryl moieties independently are optionally substituted.
[0080] As used herein, the term "heteroaliphatic" refers to an aliphatic group in which one or two carbon atoms are independently replaced by one or more of oxygen, sulfur, nitrogen, or phosphorus. Heteroaliphatic groups may be substituted or unsubstituted, branched or unbranched, cyclic or acyclic, and include "heterocycle," "heterocyclyl," "heterocycloaliphatic," or "heterocyclic" groups.
[0081] As used herein, the terms "heterocycle", "heterocyclyl", "heterocyclic radical", and "heterocyclic ring" are used interchangeably and refer to a stable 5-7 membered monocyclic or 7-10 membered bicyclic heterocyclic moiety that is saturated or partially unsaturated and has, in addition to carbon atoms, one or more, preferably one to four, heteroatoms as defined above. When used in reference to a ring atom of a heterocycle, the term "nitrogen" includes substituted nitrogen. By way of example, in a saturated or partially unsaturated ring having 0-3 heteroatoms selected from oxygen, sulfur, or nitrogen, the nitrogen can be N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl), or +NR (as in N-substituted pyrrolidinyl).
[0082] A heterocyclic ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure, and any of the ring atoms can be optionally substituted. Examples of such saturated or partially unsaturated heterocyclic groups include, but are not limited to, tetrahydrofuranyl, tetrahydrothiophenylpyrrolidinyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, and quinuclidinyl. The terms "heterocycle", "heterocyclyl", "heterocyclyl ring", "heterocyclic group", "heterocyclic moiety", and "heterocyclic radical" are used interchangeably herein and include groups in which a heterocyclyl ring is fused to one or more aryl, heteroaryl, or cycloaliphatic cyclic rings, such as indolinyl, 3H-indolyl, chromanyl, phenanthridinyl, or tetrahydroquinolinyl, where the binding group or point of attachment is on the heterocycle. Heterocyclyl groups may be monocyclic or bicyclic. The term "heterocyclylalkyl" refers to an alkyl group substituted by heterocyclyl, where the alkyl and heterocycle moieties, independently, are optionally substituted.
[0083] As used herein, the term "partially unsaturated" refers to a ring moiety that contains at least one double or triple bond. The term "partially unsaturated" is intended to encompass rings having multiple sites of unsaturation, but is not intended to include aryl or heteroaryl moieties as defined herein.
[0084] In another aspect, the present invention provides "pharmaceutical acceptable" compositions comprising a therapeutically effective amount of one or more of the compounds described herein formulated together with one or more pharma- ceutically acceptable carriers (additives) and / or diluents. As described in detail, the pharmaceutical compositions of the present invention may be specially formulated for administration by injection.
[0085] The phrase "pharmacologically acceptable" is used herein to refer to compounds, materials, compositions, and / or dosage forms that are suitable for use in contact with the tissues of human beings and animals without undue toxicity, irritation, allergic response, or other problem or complication, within the scope of sound medical judgment, and commensurate with a reasonable benefit / risk ratio.
[0086] As used herein, the phrase "pharmacologically acceptable carrier" refers to a pharma- ceutically acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, or solvent encapsulating material, used to carry or transport a compound of interest from one organ or part of the body to another. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials that can be used as pharma- ceutically acceptable carriers include sugars, such as lactose, glucose, and sucrose; starches, such as corn starch and potato starch; cellulose and its derivatives, such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol, and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffers, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; pH buffer solutions; polyesters, polycarbonates, and / or polyanhydrides; and other non-toxic compatible substances used in pharmaceutical formulations.
[0087] As used herein, the term "pharmaceutically acceptable salt" refers to a salt that is suitable for use in contact with the tissues of humans and lower animals without excessive toxicity, irritation, allergic reaction, etc., within the scope of sound medical judgment, and commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S.M. Berge et al. describe pharmaceutically acceptable salts in detail in J.Pharmaceutical Sciences, 1977, 66, 1-19, which is incorporated herein by reference. Pharmaceutically acceptable salts of the compounds of the present invention include salts derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable non-toxic acid addition salts include salts of amino groups formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid, or organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid, or formed using other methods used in the art, such as ion exchange. Other pharma- ceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecyl sulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxyethanesulfonate, and the like. These include the salts of lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate, and the like.
[0088] In other cases, the compounds of the present invention may contain one or more acidic functional groups and thus can form pharma-ceutically acceptable salts with pharma-ceutically acceptable bases. In these cases, the term "pharma-ceutically acceptable salts" refers to the relatively non-toxic inorganic and organic base addition salts of the compounds of the present invention. These salts can be prepared in situ during the administration vehicle or dosage form manufacturing process as well, or can be prepared by separately reacting the purified compound in free acid form with a suitable base, such as a hydroxide, carbonate, or bicarbonate of a pharma-ceutically acceptable metal cation, ammonia, or a pharma-ceutically acceptable organic primary, secondary, tertiary, or quaternary amine. Salts derived from suitable bases include alkali metal, alkaline earth metal, ammonium, and N+(C1-4 alkyl)4 salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Additionally, pharma- ceutically acceptable salts include non-toxic ammonium, quaternary ammonium, and amine cations, formed where appropriate with counterions such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, lower alkylsulfonates, and arylsulfonates.Representative organic amines useful for the formation of base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, and the like. (See, e.g., Berge et al., supra).
[0089] Unless otherwise stated, structures depicted herein also include all isomers of the structure (e.g., enantiomeric, diastereomeric, and geometric (or conformational) isomers), such as the R and S configurations about each stereocenter, Z and E double bond isomers, and Z and E conformational isomers. Thus, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the compounds of the invention are within the scope of the invention. Unless otherwise stated, all tautomers of the compounds of the invention are within the scope of the invention.
[0090] The provided compounds may contain one or more sugar moieties. Unless otherwise specified, both D- and L-configurations and mixtures thereof are within the scope of the present invention. Unless otherwise specified, both α-linked and β-linked embodiments and mixtures thereof are contemplated by the present invention.
[0091] For example, if a particular enantiomer of a compound of the invention is desired, it may be prepared by asymmetric synthesis, chiral chromatography, or derivatization with a chiral auxiliary, the resulting diastereomeric mixture separated, and the auxiliary group cleaved to provide the pure desired enantiomer. Alternatively, if the molecule contains a basic functional group such as amino, or an acidic functional group such as carboxyl, a diastereomeric salt can be formed with a suitable optically active acid or base, and the diastereomers thus formed can then be resolved by fractional crystallization or chromatographic means well known in the art, after which the pure enantiomers are recovered.
[0092] Additionally, unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, a hydrogen is replaced by a deuterium or tritium, or a carbon is replaced by a 13 C or 14 Compounds having structures replaced with C-enriched carbons are within the scope of the invention. Such compounds are useful, for example, as analytical tools, as probes in biological assays, or as therapeutic agents according to the invention.
[0093] Those skilled in the art will appreciate that the synthetic methods described herein utilize a variety of protecting groups. The term "protecting group" as used herein means that a particular functional moiety, e.g., O, S, or N, is masked or blocked, allowing a reaction to be selectively performed at another reactive site of a multifunctional compound, if desired. In a preferred embodiment, the protecting group reacts selectively in good yield to give a protected substrate that is stable for the planned reaction. The protecting group is preferably selectively removable by a readily available, non-toxic reagent that preferably does not attack other functional groups. The protecting group forms a separable derivative (more preferably does not create a new stereocenter). The protecting group preferably has a minimum of additional functionality to avoid further reactive sites. As described in detail herein, oxygen, sulfur, nitrogen, and carbon protecting groups may be utilized. Suitable carboxyl protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, T.W. Greene and P.G.M. Huts, 3rd edition, John Wiley & Sons, 1999, which is incorporated herein by reference in its entirety. Non-limiting examples of hydroxyl protecting groups include methyl, methoxymethyl (MOM), methylthiomethyl (MTM), t-butylthiomethyl, (phenyldimethylsilyl)methoxymethyl (SMOM), benzyloxymethyl (BOM), p-methoxybenzyloxymethyl (PMBM), (4-methoxyphenoxy)methyl (p-AOM), guaiacolmethyl (GUM), t-butoxymethyl, 4-pentenyloxymethyl (POM), siloxymethyl, 2-methoxyethoxymethyl (MEM), 2,2,2-trichloroethoxymethyl, bis(2-chloroethoxy)methyl, 2-(trimethylsilyl)ethoxymethyl (SEMOR), tetrahydropyranyl (THP), 3-bromotetrahydropyranyl, tetrahydrothiopyranyl, 1-methoxycyclohexyl, 4-methoxytetrahydropyranyl (MTHP), 4-methoxytetrahydrothiopyranyl, 4-methoxytetrahydrothiopyranylS,S-dioxide, 1-[(2-chloro-4-methyl)phenyl]-4-methoxypiperidin-4-yl (CTMP), 1,4-dioxan-2-yl, tetrahydrofuranyl, tetrahydrothiofuranyl, 2,3,3a,4,5,6,7,7a-octahydro-7,8,8-trimethyl-4,7-methanobenzofuran-2-yl, 1-ethoxyethyl, 1-(2-chloroethoxy)ethyl, 1-methyl-1-methoxyethyl, 1-methyl-1-benzyloxyethyl, 1-Methyl-1-benzyloxy-2-fluoroethyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 2-(phenylselenyl)ethyl, t-butyl, allyl, p-chlorophenyl, p-methoxyphenyl, 2,4-dinitrophenyl, benzyl, p-methoxybenzyl, 3,4-dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, p-halobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl, p-phenylbenzyl, 2-pyridyl cholyl, 4-picolyl, 3-methyl-2-picolyl N-oxide, diphenylmethyl, p,p'-dinitrobenzhydryl, 5-dibenzosuberyl, triphenylmethyl, α-naphthyldiphenylmethyl, p-methoxyphenyldiphenylmethyl, di(p-methoxyphenyl)phenylmethyl, tri(p-methoxyphenyl)methyl, 4-(4'-bromophenacyloxyphenyl)diphenylmethyl, 4,4',4"-tris(4,5-dichlorophthalimidophenyl) (yl)methyl, 4,4',4"-tris(levulinoyloxyphenyl)methyl, 4,4',4"-tris(benzoyloxyphenyl)methyl, 3-(imidazol-1-yl)bis(4',4"-dimethoxyphenyl)methyl, 1,1-bis(4-methoxyphenyl)-1'-pyrenylmethyl, 9-anthryl, 9-(9-phenyl)xanthenyl, 9-(9-phenyl-10-oxo)anthryl, 1,3-benzodithiolan-2-yl, benzisothiazolyl S,S-dioxide, trimethylsilyl (TMS), triethylsilyl (TES), triisopropylsilyl (TIPS), dimethylisopropylsilyl (IPDMS), diethylisopropylsilyl (DEIPS), dimethylthexylsilyl, t-butyldimethylsilyl (TBDMS), t-butyldiphenylsilyl (TBDPS), tribenzylsilyl, tri-p-xylylsilyl, triphenylsilyl, diphenylmethylsilyl (DPMS), t-butylmethoxyphenylsilyl (TBMPS), formate, benzoylformate, acetate, chloroacetate, dichloroacetate, trichloroacetate, trifluoroacetate, methoxyacetate, triphenylmethoxyacetate, phenoxyacetate, p-chlorophenoxyacetate, 3-phenylpropionate, 4-oxopentanoate (levulinate), 4,4-(ethylenediaminetetraacetate), Thio) pentanoate (levulinoyl dithioacetal), pivaloate, adamantoate, crotonate, 4-methoxycrotonate, benzoate, p-phenylbenzoate, 2,4,6-trimethylbenzoate (mesitoate), alkyl methyl carbonate, 9-fluorenylmethyl carbonate (Fmoc), alkyl ethyl carbonate, alkyl 2,2,2-trichloroethyl carbonate (Troc), 2-(trimethylsilyl)ethyl carbonate (TMSEC), 2-(phenylsulfonyl)ethyl carbonate (Psec), 2-(triphenylphosphonio)ethyl carbonate (Peoc), alkyl isobutyl carbonate, alkyl vinyl carbonate, alkyl aryl carbonate, alkyl p-nitrophenyl carbonate, alkyl benzyl carbonate, alkyl p-methoxybenzyl carbonate, alkyl 3,4-Dimethoxybenzyl carbonate, alkyl o-nitrobenzyl carbonate, alkyl p-nitrobenzyl carbonate, alkyl S-benzylthiocarbonate, 4-ethoxy-1-naphthyl carbonate, methyl dithiocarbonate, 2-iodobenzoate, 4-azidobutyrate, 4-nitro-4-methylpentanoate, o-(dibromomethyl)benzoate, 2-formylbenzenesulfonate, 2-(methylthiomethoxy)ethyl, 4-(methylthiomethoxy)butyrate, 2-(methylthiomethoxymethyl)benzoate, 2,6-dichloro-4-methylphenoxyacetate, 2,6-dichloro-4-(1,1 ,3,3-tetramethylbutyl)phenoxyacetate, 2,4-bis(1,1-dimethylpropyl)phenoxyacetate, chlorodiphenylacetate, isobutyrate, monosuccinoate, (E)-2-methyl-2-butenoate, o-(methoxycarbonyl)benzoate, α-naphthoate, nitrate, alkyl N,N,N',N'-tetramethylphosphorodiamidate, alkyl N-phenylcarbamate, borate, dimethylphosphinothioyl, alkyl 2,4-dinitrophenylsulfenate, sulfenate, methanesulfonate (mesylate), benzylsulfonate, and tosylate (Ts). For protecting 1,2-diols or 1,3-diols, the protecting groups include methylene acetal, ethylidene acetal, 1-t-butylethylidene ketal, 1-phenylethylidene ketal, (4-methoxyphenyl)ethylidene acetal, 2,2,2-trichloroethylidene acetal, acetonide, cyclopentylidene ketal, cyclohexylidene ketal, cycloheptylidene ketal, benzylidene acetal, p-methoxybenzylide ... ,4-Dimethoxybenzylidene ketal, 3,4-dimethoxybenzylidene acetal, 2-nitrobenzylidene acetal, methoxymethylene acetal, ethoxymethylene acetal, dimethoxymethylene orthoester, 1-methoxyethylidene orthoester, 1-ethoxyethylidine orthoester, 1,2-dimethoxyethylidene orthoester, α-methoxybenzylidene orthoester, 1-(N,N-dimethylamino)ethylidene derivatives, α-(N,N'-dimethylamino)benzylidene derivatives, 2-oxacyclopentylidene orthoesters, di-t-butylsilylene groups (DTBS), 1,3-(1,1,3,3-tetraisopropyldisiloxanylidene) derivatives (TIPDS), tetra-t-butoxydisiloxane-1,3-diylidene derivatives (TBDS), cyclic carbonates, cyclic boronates, ethyl boronate, and phenyl boronate. Amino protecting groups include methyl carbamate, ethylcarbamante, 9-fluorenylmethyl carbamate (Fmoc), 9-(2-sulfo)fluorenylmethyl carbamate, 9-(2,7-dibromo)fluoroenylmethyl carbamate, 2,7-di-t-butyl-[9-(10,10-dioxo-10,10,10,10-tetrahydrothioxanthy]methyl carbamate (DBD-Tmoc), 4-methoxyphenacyl carbamate (Phenoc), 2,2,2-trichloroethyl carbamate (Troc), 2-trimethylsilylethyl carbamate (Tmoc), and 2-trimethylsilylethyl carbamate (Tmoc). eoc), 2-phenylethyl carbamate (hZ), 1-(1-adamantyl)-1-methylethyl carbamate (Adpoc), 1,1-dimethyl-2-haloethyl carbamate, 1,1-dimethyl-2,2-dibromoethyl carbamate (DB-t-BOC), 1,1-dimethyl-2,2,2-trichloroethyl carbamate (TCBOC), 1-methyl-1-(4-biphenylyl)ethyl carbamate (Bpoc), 1-(3,5-di-t-butylphenyl)-1-methylethyl carbamate (t-Bumeoc), 2-(2'- and 4'-pyridyl)ethyl carbamate (Pyoc), 2-(N,N-Dicyclohexylcarboxamido)ethyl carbamate, t-butyl carbamate (BOC), 1-adamantyl carbamate (Adoc), vinyl carbamate (Voc), allyl carbamate (Alloc), 1-isopropyl allyl carbamate (Ipaoc), cinnamyl carbamate (Coc), 4-nitrocinnamyl carbamate (Noc), 8-quinolyl carbamate, N-hydroxypiperidinyl carbamate, a alkyldithiocarbamate, benzyl carbamate (Cbz), p-methoxybenzyl carbamate (Moz), p-nitrobenzyl carbamate, p-bromobenzyl carbamate, p-chlorobenzyl carbamate, 2,4-dichlorobenzyl carbamate, 4-methylsulfinylbenzyl carbamate (Msz), 9-anthrylmethyl carbamate, diphenylmethyl carbamate, 2-methylthioethyl carbamate, 2-methylthioethyl carbamate, 2-(p-toluenesulfonyl)ethyl carbamate, [2-(1,3-dithianyl)]methyl carbamate (Dmoc), 4-methylthiophenyl carbamate (Mtpc), 2,4-dimethylthiophenyl carbamate (Bmpc), 2-phosphonioethyl carbamate (Peoc), 2-triphenylphosphonioisopropyl carbamate (Ppoc), 1,1-dimethyl-2-cyanoethyl carbamate (Peoc), carbamate, m-chloro-p-acyloxybenzyl carbamate, p-(dihydroxyboryl)benzyl carbamate, 5-benzisoxazolylmethyl carbamate, 2-(trifluoromethyl)-6-chromonylmethyl carbamate (Tcroc), m-nitrophenyl carbamate, 3,5-dimethoxybenzyl carbamate, o-nitrobenzyl carbamate, 3,4-dimethoxy-6-nitrobenzyl carbamate, phen, Nyl(o-nitrophenyl)methyl carbamate, phenothiazinyl-(10)-carbonyl derivatives, N'-p-toluenesulfonylaminocarbonyl derivatives, N'-phenylaminothiocarbonyl derivatives, t-amyl carbamate, S-benzylthiocarbamate, p-cyanobenzyl carbamate, cyclobutyl carbamate, cyclohexyl carbamate, cyclopentyl carbamate, cyclopropylmethyl carbamate, p-decyloxybenzyl carbamate, 2,2-dimethoxycarbonylvinyl carbamate, o-(N,N-dimethylcarboxamido)benzyl carbamate, 1,1-dimethyl-3-(N,N-dimethylcarboxamido)propyl carbamate, 1,1-dimethylpropynyl carbamate, di(2-pyridyl)methyl carbamate, 2-furanylmethyl carbamate ester, 2-iodoethyl carbamate, isoborynl carbamate, isobutyl carbamate, isonicotinyl carbamate, p-(p'-methoxyphenylazo)benzyl carbamate, 1-methylcyclobutyl carbamate, 1-methylcyclohexyl carbamate, 1-methyl-1-cyclopropylmethyl carbamate, 1-methyl-1-(3,5-dimethoxyphenyl)ethyl carbamate, 1-methyl-1-(p-phenylazophenyl)ethyl carbamate, 1-methyl-1-phenylethyl carbamate, 1-methyl-1-(4-pyridyl)ethyl carbamate, phenyl carbamate, p-(phenylazo)benzyl carbamate, 2,4,6-tri-t-butylphenyl carbamate, 4-(trimethylammonium)benzyl carbamate, 2,4,6-Trimethylbenzylcarbamate, formamide, acetamide, chloroacetamide, trichloroacetamide, trifluoroacetamide, phenylacetamide, 3-phenylpropanamide, picolinamide, 3-pyridylcarboxamide, N-benzoylphenylalanyl derivatives, benzamide, p-phenylbenzamide, o-nitophenylacetamide, o-nitrophenoxyacetamide, acetoacetamide, (N'-dithiobenzyloxycarbonylamino)a Setamide, 3-(p-hydroxyphenyl)propanamide, 3-(o-nitrophenyl)propanamide, 2-methyl-2-(o-nitrophenoxy)propanamide, 2-methyl-2-(o-phenylazophenoxy)propanamide, 4-chlorobutanamide, 3-methyl-3-nitrobutanamide, o-nitrocinamide, N-acetylmethionine derivatives, o-nitrobenzamide, o-(benzoyloxymethyl)benzamide, 4,5-diphenyl-3-oxazolin-2-one, N-phthalimide, N-dithiasuccinimide (Dts), N-2,3-diphenylmaleimide, N-2,5-dimethylpyrrole, N-1,1,4,4-tetramethyldisilylazacyclopentane adduct (STABASE), 5-substituted 1,3-dimethyl-1,3,5-triazacyclohexan-2-one, 5-substituted 1,3-dibenzyl-1,3,5-triazacyclohexan-2-one, 1-substituted 3,5-dinitro-4-pyridone, N-methylamine, N-allylamine, N-[2-(trimethylsilyl)ethoxy]methylamine (SEM), N-3-acetoxypropylamine, N-( 1-Isopropyl-4-nitro-2-oxo-3-pyrrolin-3-yl)amine, quaternary ammonium salts, N-benzylamine, N-di(4-methoxyphenyl)methylamine, N-5-dibenzosuberylamine, N-triphenylmethylamine (Tr), N-[(4-methoxyphenyl)diphenylmethyl]amine (MMTr), N-9-phenylfluorenylamine (PhF), N-2,7-dichloro-9-fluorenylmethyleneamine, N-ferrocenylmethylamino (Fern), N-2-picolylamino N'-oxide, N-1,1-Dimethylthiomethyleneamine, N-benzylideneamine, Np-methoxybenzylideneamine, N-diphenylmethyleneamine, N-[(2-pyridyl)mesityl]methyleneamine, N-(N',N'-dimethylaminomethylene)amine, N',N'-isopropylidenediamine, Np-nitrobenzylideneamine, N-salicylideneamine, N-5-chlorosalicylideneamine, N-(5-chloro-2-hydroxyphenyl)phenylmethyleneamine, N-cyclohexylideneamine, N-(5,5-dimethyl-3-oxo- 1-Cyclohexenyl)amine, N-borane derivatives, N-diphenylborinic acid derivatives, N-[phenyl(pentacarbonylchromium or tungsten)carbonyl]amine, N-copper chelates, N-zinc chelates, N-nitroamines, N-nitrosamines, amine N-oxides, diphenylphosphinamide (Dpp), dimethylthiophosphinamide (Mpt), diphenylthiophosphinamide (Ppt), dialkyl phosphoramidates, dibenzyl phosphoramidates, diphenyl phosphoramidates, benzenesulfenamides , o-nitrobenzenesulfenamide (Nps), 2,4-dinitrobenzenesulfenamide, pentachlorobenzenesulfenamide, 2-nitro-4-methoxybenzenesulfenamide, triphenylmethylsulfenamide, 3-nitropyridine sulfenamide (Npys), p-toluenesulfonamide (Ts), benzenesulfonamide, 2,3,6-trimethyl-4-methoxybenzenesulfonamide (Mtr), 2,4,6-trimethoxybenzenesulfonamide (Mtb), 2,6-dimethyl-4-meth 2,3,5,6-tetramethyl-4-methoxybenzenesulfonamide (Mte), 4-methoxybenzenesulfonamide (Mbs), 2,4,6-trimethylbenzenesulfonamide (Mts), 2,6-dimethoxy-4-methylbenzenesulfonamide (iMds), 2,2,5,7,8-pentamethylchroman-6-sulfonamide (Pmc), methanesulfonamide (Ms), β-trimethylsilylethanesulfonamide (SES), 9-anthracenesulfonamide, 4-(4',8'-dimethoxynaphthylmethyl)benzenesulfonamide (DNMBS), benzylsulfonamide, trifluoromethylsulfonamide, and phenacylsulfonamide.
[0094] Although exemplary protecting groups are detailed herein, it will be understood that the invention is not intended to be limited to these protecting groups, but rather, using the above criteria, a variety of additional equivalent protecting groups can be readily identified and used in the methods of the invention. Additionally, a variety of protecting groups are described by Greene and Wuts (supra).
[0095] As described herein, the compounds of the invention may include "optionally substituted" moieties. In general, the term "substituted", whether preceded by the term "optionally", means that one or more hydrogens of the specified moiety are replaced with a suitable substituent. Unless otherwise specified, an "optionally substituted" group may have a suitable substituent at each substitutable position of the group, and if more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituents may be the same or different at all positions. The combinations of substituents contemplated by the present invention are preferably those that result in the formation of stable or chemically feasible compounds. As used herein, the term "stable" refers to compounds that are substantially unchanged when subjected to conditions that allow for their production, detection, and, in certain embodiments, their recovery, purification, and use for one or more purposes disclosed herein.
[0096] Suitable monovalent substituents at a substitutable carbon atom of an "optionally substituted" group are independently halogen; (CH) 0~4 R°;-(CH2) 0~4 OR°;-O(CH2) 0~4 R°, -O-(CH2) 0~4 C(O)OR°;-(CH2) 0~4 CH(OR°)2;-(CH2) 0~4 SR°; optionally substituted with R° -(CH2)0~4 Ph; optionally substituted with R° -(CH2) 0~4 O(CH2) 0~1 Ph; optionally substituted with R° -CH=CHPh; optionally substituted with R° -(CH2) 0~4 O(CH2) 0~1 -Pyridyl; -NO2; -CN; -N3; -(CH2) 0~4 N(R°)2;-(CH2) 0~4 N(R°)C(O)R°;-N(R°)C(S)R°;-(CH2) 0~4 N(R°)C(O)NR°2;-N(R°)C(S)NR°2;-(CH2) 0~4 N(R°)C(O)R°;-N(R°)N(R°)C(O)R°;-N(R°)N(R°)C(O)NR°2;-N(R°)N(R°)C(O)OR°;-(CH2) 0~4 C(O)R°;-C(S)R°;-(CH2) 0~4 C(O)OR°;-(CH2) 0~4 C(O)SR°;-(CH2) 0~4 C(O)OSiR°3;-(CH2) 0~4 OC(O)R°;-OC(O)(CH2) 0~4 SR, -SC(S)SR°;-(CH2) 0~4 SC(O)R°;-(CH2) 0~4 C(O)NR°2;-C(S)NR°2;-C(S)SR°;-SC(S)SR°;-(CH2) 0~4 OC(O)NR°2;-C(O)N(OR°)R°;-C(O)C(O)R°;-C(O)CH2C(O)R°;-C(NOR°)R°;-(CH2) 0~4 SSR°;-(CH2) 0~4 S(O)2R°;-(CH2) 0~4 S(O)2OR°;-(CH2) 0~4 OS(O)2R°;-S(O)2NR°2;-(CH2) 0~4 S(O)R°;-N(R°)S(O)2NR°2;-N(R°)S(O)2R°;-N(OR°)R°;-C(NH)NR°2;-P(O)2R°;-P(O)R°2;-OP(O)R°2;-OP(O)(OR°)2;SiR°3;-(C 1~4 linear or branched) alkylene) ON (R°) 2; or - (C1~4 linear or branched)alkylene)C(O)ON(R°)2, where each R° may be optionally substituted as defined below and is independently hydrogen, C 1~6 Aliphatic, -CH2Ph, -O(CH2) 0~1 Ph, -CH2- (a 5-6 membered heteroaryl ring), or a 5-6 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or, notwithstanding the above definitions, two independent occurrences of R° taken together with their intervening atoms form a 3-12 membered saturated, partially unsaturated, or aryl monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, which may be substituted as defined below.
[0097] R o (or R o Preferred monovalent substituents in the ring formed by two independent occurrences of -(CH) together with their intervening atoms are independently halogen, -(CH) 0-2 R Δ , -(Halo R Δ ), -(CH2) 0-2 OH, -(CH2) 0-2 OR Δ , -(CH2) 0-2 CH(OR Δ )2;-O(HaloR Δ ), -CN, -N3, -(CH2) 0-2 C(O)R Δ , -(CH2) 0-2 C(O)OH, -(CH2) 0-2 C(O)OR Δ , -(CH2) 0-2 S.R. Δ , -(CH2) 0-2 SH, -(CH2) 0-2 NH2, -(CH2) 0-2 NHR Δ , -(CH2) 0-2 NR Δ 2, -NO2, -SiR Δ 3. -OSiR Δ 3. -C(O)SR Δ , -(C 1~4Linear or branched alkylene)C(O)OR Δ or -SSR, where each R Δ is unsubstituted or, if preceded by "halo", is substituted only with one or more halogens, and independently represents C 1~4 Aliphatic, -CH2Ph, -O(CH2) 0~1 R is selected from the group consisting of Ph, a 5-6 membered saturated ring, a partially unsaturated ring, and an aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. o Suitable divalent substituents at a saturated carbon atom of include ═O and ═S.
[0098] Suitable divalent substituents at a saturated carbon atom of an "optionally substituted" group include ═O, ═S, ═NNR * 2, =NNHC(O)R * , =NNHC(O)OR * , =NNHS(O)2R * , =NR * , =NOR * , -O(C(R * 2)) 2~3 O- or -S(C(R * 2)) 2~3 S-, where R * Each independent occurrence of is hydrogen, optionally substituted as defined below C 1~6 The "optionally substituted" groups are selected from the group consisting of aliphatic, unsubstituted 5-6 membered saturated, partially unsaturated, or aryl rings having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Preferred divalent substituents attached to vicinal substitutable carbons of the "optionally substituted" groups include -O(CR * 2) 2~3 O-, wherein R * Each independent occurrence of is hydrogen, optionally substituted as defined below C 1~6 It is selected from an aliphatic, or an unsubstituted 5- to 6-membered saturated ring, partially unsaturated ring, or aryl ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
[0099] R *Suitable substituents on the aliphatic groups include halogen, -R Δ , -(Halo R Δ ), -OH, -OR Δ , -O(HaloR Δ ), -CN, -C(O)OH, -C(O)OR Δ , -NH2, -NHR Δ , -NR Δ 2, or -NO2, where each R Δ is unsubstituted or, if preceded by "halo", is substituted only with one or more halogens, and is independently an aliphatic, -CH2Ph, -O(CH2) 0~1 Ph, or a 5-6 membered saturated ring, partially unsaturated ring, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
[0100] Suitable substituents at a substitutable nitrogen of an "optionally substituted" group include -R † , -NR † 2. -C(O)R † , -C(O)OR † , -C(O)C(O)R † , -C(O)CH2C(O)R † , -S(O)2R † , -S(O)NR † 2. -C(S)NR † 2. -C(NH)NR † 2, or -N(R † )S(O)2R † wherein each R † are independently hydrogen, optionally substituted as defined below, 1~6 aliphatic, unsubstituted -OPh, or an unsubstituted 5-6 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or, regardless of the above definitions, R †two independent occurrences of together with their intervening atoms form an unsubstituted 3-12 membered saturated, partially unsaturated, or aryl monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Suitable substituents on the aliphatic groups of R† are independently halogen, -R Δ , -(Halo R Δ ), -OH, -OR Δ , -O(HaloR Δ ), -CN, -C(O)OH, -C(O)OR Δ , -NH2, -NHR Δ , -NR Δ 2, or -NO2, where each R Δ is unsubstituted or, if preceded by "halo", is substituted with only one or more halogens, and is independently selected from C1-4 aliphatic, -CH2Ph, -O(CH2) 0~1 Ph, or a 5-6 membered saturated ring, partially unsaturated ring, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
[0101] The phrases "parenteral administration" and "administered parenterally" as used herein refer to modes of administration other than enteral and topical administration, usually by injection, and include, but are not limited to, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, and intrasternal injection and infusion.
[0102] As used herein, the phrases "systemic administration," "administered systemically," "peripheral administration," and "administered peripherally" mean that a compound, agent, or other substance is administered other than by direct administration into the central nervous system so that it enters the patient's system and is subjected to metabolic and other similar processes, for example, subcutaneous administration.
[0103] As used herein, "liposome" refers to a closed bilayer membrane containing an entrapped aqueous volume. Liposomes may also be unilamellar vesicles having a single membrane bilayer or multilamellar vesicles having multiple membrane bilayers, each separated from the next by an aqueous layer. The resulting membrane bilayer structure is one in which the hydrophobic (non-polar) tails of the lipids point toward the center of the bilayer and the hydrophilic (polar) heads point toward the aqueous phase. Liposomes, as commonly used, are composed of smectic mesophases, which can be composed of either phospholipid or non-phospholipid smectic mesophases. Smectic mesophases are most accurately described in Small, HANDBOOK OF LIPID RESEARCH, Vol. 4, Plenum, NY, 1986, pp. 49-50. According to Small, "When a given molecule is heated, it does not melt directly to an isotropic liquid, but instead may pass through an intermediate state called a mesophase or liquid crystal, characterized by remaining order in some directions but not others.... Generally, liquid crystal molecules are somewhat longer than they are wide and have polar or aromatic moieties somewhere along the length of the molecule. Due to molecular shape and polar-polar or aromatic interactions, the molecules are able to align into partially ordered arrays.... These structures occur characteristically in molecules that have a polar group at one end. Liquid crystals with long-range order along the long axis of the molecule are called smectic, layered, or lamellar liquid crystals.... In the smectic state, the molecules are monolayers or bilayers, perpendicular or tilted to the plane of the layer, and have frozen or melted aliphatic chains."
[0104] The term "enriched" as used herein refers to a mixture having an increased proportion of one or more species. In some embodiments, a mixture is "enriched" according to a process that increases the proportion of one or more desired species in the mixture. In some embodiments, the desired species comprises more than 10% of the mixture. In some embodiments, the desired species comprises more than 25% of the mixture. In some embodiments, the desired species comprises more than 40% of the mixture. In some embodiments, the desired species comprises more than 60% of the mixture. In some embodiments, the desired species comprises more than 75% of the mixture. In some embodiments, the desired species comprises more than 85% of the mixture. In some embodiments, the desired species comprises more than 90% of the mixture. In some embodiments, the desired species comprises more than 95% of the mixture. Such proportions can be measured in many ways, such as molar ratio, volume to volume, weight to weight, etc.
[0105] The term "pure" refers to a compound that is substantially free of related non-target structures or chemical precursors (if chemically synthesized). This quality may be measured or expressed as "purity." In some embodiments, the target compound has less than about 30%, 20%, 10%, 5%, 2%, 1%, 0.5%, and 0.1% of non-target structures or chemical precursors.
[0106] The term "carbohydrate" refers to a sugar or a polymer of sugar. The terms "saccharide," "polysaccharide," "carbohydrate," and "oligosaccharide" may be used interchangeably. Most carbohydrates are aldehydes or ketones with many hydroxyl groups, usually one on each carbon atom of the molecule. Carbohydrates generally have the molecular formula C n H 2n O nCarbohydrates can be monosaccharides, disaccharides, trisaccharides, oligosaccharides, or polysaccharides. The most basic carbohydrates are monosaccharides, such as glucose, sucrose, galactose, mannose, ribose, arabinose, xylose, and fructose. Disaccharides are two monosaccharides joined together. Representative disaccharides include sucrose, maltose, cellobiose, and lactose. Typically, oligosaccharides contain 3-6 monosaccharide units (e.g., raffinose, stachyose), while polysaccharides contain 6 or more monosaccharide units. Representative polysaccharides include starch, glycogen, and cellulose. Carbohydrates may include modified sugar units such as 2'-deoxyribose, where the hydroxyl group has been removed, 2'-fluororibose, where the hydroxyl group has been replaced with fluorine, or N-acetylglucosamine, which is a nitrogen-containing form of glucose (e.g., 2'-fluororibose, deoxyribose, and hexose). Carbohydrates may exist in many different forms, such as conformational isomers, cyclic forms, acyclic forms, stereoisomers, tautomers, anomers, and isomers.
[0107] Compounds of formula (I): Adjuvants In one aspect, the present application provides a compound of formula (I) or a pharma- ceutically acceptable salt thereof, useful as an adjuvant:
[0108] [ka]
[0109] In the formula, the variable --- , G, V, Y and Z have the meanings defined above in formula (I).
[0110] In some embodiments, the present application provides a compound of formula (I) or a pharma- ceutically acceptable salt thereof: In the formula, G is hydrogen or
[0111] [ka]
[0112] and; --- is a single bond or a double bond, V is H or OH; Y is -O-; Z is a carbohydrate domain having the structure
[0113] [ka]
[0114] During the ceremony, R 1 are independently H or
[0115] [ka]
[0116] R 2 NHR 4 and R 3 is CHOH, R 4 -TR z , -C(O)-TR z , -NH-TR Z , -OTR z , -STR z , -C(O)NH-TR z , C(O)OTR z , C(O)STR z , C(O)NH-TOTR z , -OTR z , -TOTR z , -TSTR z or
[0117] [ka]
[0118] and During the ceremony, X is -O-, -NR-, or TR z and T is a covalent bond or a divalent C 1~26 a saturated or unsaturated, linear or branched aliphatic or heteroaliphatic chain;
[0119] R z is hydrogen, halogen, -OR, -OR x , -OR 1 , -SR, -NR2, -C(O)OR, -C(O)R, -NHC(O)R, -NHC(O)OR, -NC(O)OR, or acyl, arylalkyl, heteroarylalkyl, C 1~6 an optionally substituted group selected from an aliphatic group, a 6- to 10-membered aryl group, a 5- to 10-membered heteroaryl group having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and a 4- to 7-membered heterocyclyl group having 1 to 2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; R x are independently hydrogen or an oxygen protecting group selected from the group consisting of alkyl ethers, benzyl ethers, silyl ethers, acetals, ketals, esters, carbamates, and carbonates;
[0120] R is independently hydrogen, acyl, arylalkyl, 6- to 10-membered aryl, C 1~6 Aliphatic or C having 1 to 2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur 1~6 or two R on the same nitrogen atom together with the nitrogen atom form a 4-7 membered heterocyclic ring having 1-2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur. In certain embodiments, G is hydrogen. In certain embodiments, G is a branched trisaccharide of formula (VI) or a stereoisomer of formula (VI):
[0121] [ka]
[0122] In the formula, R p Each occurrence of is independently hydrogen or OR q and In the formula, R q Each occurrence is independently hydrogen, or 6-10 membered aryl, benzyl, C 1~6 Aliphatic or C having 1 to 2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur 1~6 or two R q taken together form a 5-7 membered heterocycle having 1-2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur. In formula (VI), R q is preferably OH.
[0123] In certain embodiments, V is OR x In certain embodiments, V is OH. In certain embodiments, V is H.
[0124] In certain embodiments, Y is -O-. In certain embodiments, Y is -NH-. In certain embodiments, Y is -NR-. In certain embodiments, Y is CH2. In certain embodiments, Y is -S-. In certain embodiments, Z is a carbohydrate domain having the structure:
[0125] [ka]
[0126] During the ceremony, R 1 are independently H or
[0127] [ka]
[0128] R 2 NHR 4 and R 3 is CHOH, R 4 -TR z , -C(O)-TR z , -NH-TR Z , -OTR z , -STR z , -C(O)NH-TR z , -C(O)OTR z , C(O)STR z , C(O)NH-TOTR z , -OTR z , -TOTR z , -TSTR z or
[0129] [ka]
[0130] and During the ceremony, X is -O-, -NR-, or TR z and T is a covalent bond or a divalent C 1~26 a saturated or unsaturated, linear or branched aliphatic or heteroaliphatic chain; R z is hydrogen, halogen, -OR, -OR x , -OR 1 , -SR, -NR2, -C(O)OR, -C(O)R, -NHC(O)R, -NHC(O)OR, -NC(O)OR, or acyl, arylalkyl, heteroarylalkyl, C 1~6 an optionally substituted group selected from an aliphatic group, a 6- to 10-membered aryl group, a 5- to 10-membered heteroaryl group having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and a 4- to 7-membered heterocyclyl group having 1 to 2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; R xare independently hydrogen or an oxygen protecting group selected from the group consisting of alkyl ethers, benzyl ethers, silyl ethers, acetals, ketals, esters, carbamates, and carbonates; R is independently hydrogen, acyl, arylalkyl, 6- to 10-membered aryl, C 1~6 Aliphatic or C having 1 to 2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur 1~6 an optionally substituted group selected from heteroaliphatic, or Two R on the same nitrogen atom together with the nitrogen atom form a 4- to 7-membered heterocycle having 1 to 2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur. In certain embodiments, Z is a carbohydrate domain having the structure:
[0131] [ka]
[0132] In the formula, R 4 is -C(O)-TR z and T is a divalent C 1~26 It is a saturated or unsaturated, linear or branched aliphatic or heteroaliphatic chain, preferably a divalent C1-15 saturated or unsaturated, linear or branched aliphatic or heteroaliphatic chain, more preferably a divalent C 1~15 (For example, C1, C2, C3, C4, C5, C6, C7, C8, C9, C 10 , C 11 , C 12 , C 13 , C 14 , or C 15 ) a saturated linear aliphatic chain; R z is hydrogen, halogen, -OR, -OR x , -OR 1 , -SR, -NR2, -C(O)OR, -C(O)R, -NHC(O)R, -NHC(O)OR, -NC(O)OR, or acyl, arylalkyl, heteroarylalkyl, C 1~6an optionally substituted group selected from an aliphatic group, a 6- to 10-membered aryl group, a 5- to 10-membered heteroaryl group having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and a 4- to 7-membered heterocyclyl group having 1 to 2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; R x are independently hydrogen or an oxygen protecting group selected from the group consisting of alkyl ethers, benzyl ethers, silyl ethers, acetals, ketals, esters, carbamates, and carbonates; R is independently hydrogen, acyl, arylalkyl, 6- to 10-membered aryl, C 1~6 6 Aliphatic or C having 1 to 2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur 1~6 an optionally substituted group selected from heteroaliphatic, or Two R on the same nitrogen atom together with the nitrogen atom form a 4- to 7-membered heterocycle having 1 to 2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur. In certain embodiments, R z is -OR, -OR x , -SR, -NR2, -C(O)OR, -C(O)R, -NHC(O)R, -NHC(O)OR, or -NC(O)OR; R x are independently hydrogen or an oxygen protecting group selected from the group consisting of alkyl ethers, benzyl ethers, silyl ethers, acetals, ketals, esters, carbamates, and carbonates; R is independently hydrogen, acyl, arylalkyl, 6- to 10-membered aryl, C 1~6 Aliphatic or C having 1 to 2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur 1~6 an optionally substituted group selected from heteroaliphatic, or Two R on the same nitrogen atom together with the nitrogen atom form a 4- to 7-membered heterocycle having 1 to 2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur.
[0133] In certain embodiments, R z is -NH2 or -C(O)OH. In certain embodiments, --- is a double bond, G is H, V is OH, Y is O, and Z is a carbohydrate domain having the structure:
[0134] [ka]
[0135] In certain embodiments, R 4 is selected from:
[0136] [ka]
[0137] In some embodiments, R 1 is R X In another embodiment, R 1 is a carbohydrate domain having the following structure:
[0138] [ka]
[0139] In some embodiments, each occurrence of a, b, and c is independently 0, 1, or 2. In some embodiments, d is an integer from 1 to 5. In some embodiments, the bracket structure of each d may be the same. In some embodiments, the bracket structure of each d may be different. In some embodiments, the bracket structure of d represents a furanose moiety or a pyranose moiety. In some embodiments, the sum of b and c is 1 or 2.
[0140] In some embodiments, R 0 is hydrogen. In some embodiments, R 0is an oxygen protecting group selected from the group. In some embodiments, R 0 is an alkyl ether.
[0141] In some embodiments, R 0 is a benzyl ether. In some embodiments, R 0 is a silyl ether. In some embodiments, R 0 is an acetal. In some embodiments, R 0 is a ketal. In some embodiments, R 0 is an ester. In some embodiments, R 0 is a carbamate. In some embodiments, R 0 is a carbonate. In some embodiments, R 0 is an optionally substituted moiety. In some embodiments, R 0 is acyl. In some embodiments, R 0 is C 1~10 In some embodiments, R 0 is C 1~6 In some embodiments, R 0 is 6-10 membered aryl. In some embodiments, R 0 is arylalkyl. In some embodiments, R 0 is a 5-10 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R 0 is a 4-7 membered heterocyclyl having 1 to 2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur.
[0142] In some embodiments, R a is hydrogen. In some embodiments, R a is a halogen. In some embodiments, R a is OH. In some embodiments, R a is OR. In some embodiments, R a OR x In some embodiments, Ra is NR2. In some embodiments, R a is NHCOR. In some embodiments, R a is acyl. In some embodiments, R a is C 1~10 In some embodiments, R a is C 1~6 It is heteroaliphatic. In some embodiments, R a is 6-10 membered aryl. In some embodiments, R a is arylalkyl. In some embodiments, R a is a 5-10 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R a is a 4-7 membered heterocyclyl having 1 to 2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur.
[0143] In some embodiments, R b is hydrogen. In some embodiments, R b is a halogen. In some embodiments, R b is OH. In some embodiments, R b is OR. In some embodiments, R b OR x In some embodiments, R b is NR2. In some embodiments, R b is NHCOR. In some embodiments, R b is acyl. In some embodiments, R b is C 1~10 In some embodiments, R b is C 1~6 In some embodiments, R b is 6-10 membered aryl. In some embodiments, R b is arylalkyl. In some embodiments, R bis a 5-10 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R b is a 4-7 membered heterocyclyl having 1 to 2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur.
[0144] In some embodiments, R c is hydrogen. In some embodiments, R c is a halogen. In some embodiments, R c is OH. In some embodiments, R c is OR. In some embodiments, R c OR x In some embodiments, R c is NR2. In some embodiments, R c is NHCOR. In some embodiments, R c is acyl. In some embodiments, R c is C 1~10 In some embodiments, R c is heteroaliphatic. In some embodiments, R c is 6-10 membered aryl. In some embodiments, R c is arylalkyl. In some embodiments, R c is a 5-10 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R c is a 4-7 membered heterocyclyl having 1 to 2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur.
[0145] In some embodiments, R d is hydrogen. In some embodiments, R d is a halogen. In some embodiments, R d is OH. In some embodiments, R d is OR. In some embodiments, R d OR xIn some embodiments, R d is NR2. In some embodiments, R d is NHCOR. In some embodiments, R d is acyl. In some embodiments, R d is C 1~10 In some embodiments, R d is C 1~6 In some embodiments, R d is 6-10 membered aryl. In some embodiments, R d is arylalkyl. In some embodiments, R d is a 5-10 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R d is a 4-7 membered heterocyclyl having 1 to 2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur.
[0146] In some embodiments, R 2 is hydrogen. In some embodiments, R 2 is a halogen. In some embodiments, R 2 is OH. In some embodiments, R 2 is OR. In some embodiments, R 2 is O.C.(O)R 4 In some embodiments, R 2 OC(O)OR 4 In some embodiments, R 2 OC(O)NHR 4 In some embodiments, R 2 is OC(O)NRR 4 In some embodiments, R 2 is OC(O)SR 4 In some embodiments, R 2 is NHC(O)R 4 In some embodiments, R 2 is NRC(O)R 4 In some embodiments, R 2is NHC(O)OR 4 In some embodiments, R 2 is NHC(O)NHR 4 In some embodiments, R 2 is NHC(O)NRR 4 In some embodiments, R 2 NHR 4 In some embodiments, R 2 is N(R 4 In some embodiments, R 2 NHR 4 In some embodiments, R 2 is NRR 4 In some embodiments, R 2 is N3. In some embodiments, R 2 is C 1~10 In some embodiments, R 2 is C 1~6 In some embodiments, R 2 is 6-10 membered aryl. In some embodiments, R 2 is arylalkyl. In some embodiments, R 2 is a 5-10 membered heteroaryl having 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur. 2 is a 4-7 membered heterocyclyl having 1 to 2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur.
[0147] In some embodiments, R 3 is hydrogen. In some embodiments, R 3 is a halogen. In some embodiments, R 3 is CH2OR 1 In some embodiments, R 3 is acyl. In some embodiments, R 3 is C 1~10 In some embodiments, R 3 is C 1~6In some embodiments, R 3 is 6-10 membered aryl. In some embodiments, R 3 is arylalkyl. In some embodiments, R 3 is a 5-10 membered heteroaryl having 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur. 3 is a 4- to 7-membered heterocyclyl having 1 to 2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur;
[0148] In some embodiments, R 4 -TR z In some embodiments, R 4 -C(O)-TR z In some embodiments, R 4 -NH-TR z In some embodiments, R 4 -OTR z In some embodiments, R 4 HA-STR z In some embodiments, R 4 -C(O)NH-TR z In some embodiments, R 4 -C(O)OTR z In some embodiments, R 4 -C(O)STR z In some embodiments, R 4 -C(O)NH-TOTR z In some embodiments, R 4 -OTR z In some embodiments, R 4 -TOTR z In some embodiments, R 4 -TSTR z In some embodiments, R 4 teeth,
[0149] [ka]
[0150] It is.
[0151] In some embodiments, X is -O-. In some embodiments, X is -NR-. In some embodiments, X is TR z It is.
[0152] In some embodiments, T is a covalent bond or a divalent C 1~26 It may be saturated or unsaturated, linear or branched, an aliphatic or heteroaliphatic chain.
[0153] In some embodiments, R z is hydrogen. In some embodiments, R z is a halogen. In some embodiments, R z In some embodiments, R z -OR x In some embodiments, R z -OR 1 In some embodiments, Rz is -SR. In some embodiments, Rz is -NR2. In some embodiments, R z is -C(O)OR. In some embodiments, R z is -C(O)R. In some embodiments, R z is -NHC(O)R. In some embodiments, R z In some embodiments, R is -NHC(O)OR. In some embodiments, R is -NC(O)OR. z is acyl. In some embodiments, R z is arylalkyl. In some embodiments, R z is heteroarylalkyl. In some embodiments, R z is C 1~6 In some embodiments, R z is 6-10 membered aryl. In some embodiments, R zis a 5-10 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R z is a 4-7 membered heterocyclyl having 1 to 2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur.
[0154] In some embodiments, R x is hydrogen. In some embodiments, R x is an oxygen protecting group. In some embodiments, R x is an alkyl ether. In some embodiments, R x is a benzyl ether. In some embodiments, R x is a silyl ether. In some embodiments, R x is an acetal. In some embodiments, R x is a ketal. In some embodiments, R x is an ester. In some embodiments, R x is a carbamate. In some embodiments, R x is a carbonate.
[0155] In some embodiments, R is hydrogen. In some embodiments, R is acyl. In some embodiments, R is arylalkyl. In some embodiments, R is 6-10 membered aryl. In some embodiments, R is C 1~6 In some embodiments, R is a C 1 -C 2 heteroatom having 1 to 2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur. 1~6 In some embodiments, two R on the same nitrogen atom are joined to the nitrogen atom to form a 4-7 membered heterocyclic ring having 1-2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur.
[0156] Exemplary compounds of formula (I) are shown below.
[0157] [ka] [ka] [ka] [ka] [ka] [ka]
[0158] Compounds of formula (II): Self-adjuvanting vaccines While conventional vaccines are formulated into a mixture of antigen and adjuvant, vaccines in which the two moieties are contained within one molecule are called self-adjuvanted vaccines.
[0159] The present invention provides compounds of general formula (II) or a pharma- ceutically acceptable salt thereof, useful as self-adjuvanting vaccines:
[0160] [ka]
[0161] During the ceremony, --- , G, V, and Y have the same meanings and specific embodiments as in formula (I); W is H or a moiety comprising either i) at least one T cell epitope selected from among a helper T cell epitope or a CD8 epitope, ii) at least one B cell epitope, or iii) at least one T cell epitope and at least one B cell epitope selected from among a helper T cell epitope or a CD8 epitope; Z* denotes Z as defined in formula (I) optionally linked to a moiety comprising either i) at least one T cell epitope selected from among helper T cell epitopes or CD8 epitopes, ii) at least one B cell epitope, or iii) at least one T cell epitope selected from among helper T cell epitopes or CD8 epitopes and at least one B cell epitope; However, the compound of formula (II) must contain at least one T cell epitope and at least one B cell epitope.
[0162] Thus, T cell epitopes and B cell epitopes may be incorporated in a compound of formula (II) in different configurations. For example, a compound of formula (II) may be provided with a portion comprising at least one T cell epitope and at least one B cell epitope at the C4 position of the triterpene domain. In another embodiment, a compound of formula (II) may be provided with a portion comprising at least one T cell epitope and at least one B cell epitope via the chain of the carbohydrate domain. In an alternative embodiment, a compound of formula (II) may be provided with a portion comprising at least one B cell epitope at the C4 position of the triterpene domain and with a portion comprising at least one T cell epitope via the chain of the carbohydrate domain. In an alternative preferred embodiment, a compound of formula (II) may be provided with a portion comprising at least one T cell epitope at the C4 position of the triterpene domain and with a portion comprising at least one B cell epitope via the chain of the carbohydrate domain. Thus, preferably, W in the compound of formula (II) is a moiety comprising at least one T cell epitope selected from a helper T cell epitope or a CD8 epitope, and Z* represents Z as defined in formula (I) linked to a moiety comprising at least one B cell epitope.
[0163] As used herein, the term "B cell epitope" refers to any antigenic part or region that can be recognized by secreted antibodies or B cell receptors and induce an immune response in B cells. Methods and techniques for determining whether a peptide / molecule is or contains a B cell epitope are well known to those skilled in the art and are described in the literature (Ahmad, TA, et al. Trials in Vaccinology 2016, Volume 5, Pages 71-83)).
[0164] As used herein, a T cell epitope is selected from a helper T cell epitope or a CD8 epitope.
[0165] The term "helper T cell epitope" as used herein refers to a peptide derived from an antigen and recognized by the helper T cell receptor (TCR) upon binding to a class II major histocompatibility complex (MHC-II) molecule presented on the cell surface of an antigen-presenting cell (APC), which results in activation of the helper T cell. The peptide is a specific amino acid sequence of the antigen recognized by the TCR. The peptide can also be used as a "helper epitope" that is recognized by and known to activate helper T cells, and is fused to or used in the vicinity of (e.g., co-expressed on the APC membrane) an antigen of interest (more preferably a B cell epitope) that is newly presented to the helper T cell to improve and enhance the immunological response of the helper T cell. Methods for identifying peptides that activate responses from helper T cells are well known in the art and examples of such methods can be found in the literature (Wang RF Methods. 2003, 29(3), 227-35; Singh R. et al. Immunology 2014, 141(4), 514-30).
[0166] The term "CD8 cell epitope" or "CD8 T cell epitope" as used herein refers to a peptide derived from an antigen that is recognized by the CD8 T cell receptor when the antigen binds to a class I (MHC1) or class II (MHCII) major histocompatibility complex (MHC) molecule on the surface of an antigen-presenting cell (APC). When the above peptide is recognized by the CD8 TCR, the cell is activated to become a cytotoxic T lymphocyte (CTL). Methods for identifying peptides that activate responses from CD8 T cells are well known in the art, and examples of such methods can be found in the literature (Reche, et al., 2004, Immunogenetics, vol. 56, 6, 405-419; Donnes and Kohlbacher, 2005, Protein Sci., vol. 14, 8, 2132-2140; Doytchinova, et al., 2006, BMC Bioinformatics, vol. 7, 1, 131).
[0167] In some embodiments, the B cell epitope or CD8 T cell epitope is selected from the group consisting of peptides, glycopeptides, and carbohydrates that can induce an immune response against a neurodegenerative disease (e.g., an immunogenic region of a neurodegeneration associated antigen), an infectious disease (e.g., an immunogenic region of a bacterial, viral, or protozoan associated antigen), or a cancer cell (e.g., an immunogenic region of a cancer associated antigen, also known as a tumor associated antigen or TACA).
[0168] In some embodiments, the B cell epitope or CD8 T cell epitope is or is found within an immunogenic region of a cancer associated antigen selected from the group consisting of: - Tn carbohydrate antigens, such as MUC1 peptide, TnMUC1 glycopeptide, Gb3 carbohydrate, and Tn(Thr) antigen; - glycoproteins such as PSA, mucins such as MUC1, MUC2, MUC4, MUC5AC, MUC6, MUC16, mucin-derived carbohydrate antigens such as Tn, TF, STn, gangliosides such as GM2, GM3, GD2, GD3, globosides such as Gb4, Gb5, Globo-H; -5T4, 8H9, av beta 6 integrin, alpha fetoprotein (AFP), B7-H6, CA-125, carbonic anhydrase 9 (CA9), CD19, CD20, CD22, CD30, CD33, CD38, CD44, CD44v6, CD44v7 / 8, CD52, CD123, CD171, carcinoembryonic antigen (CAR) antigen (CEA), EGFRvIII, epithelial glycoprotein 2 (EGP-2), epithelial glycoprotein 40 (EGP-40), ErbB1 / EGFR, ErbB2 / HER2 / neu / EGFR2, ErbB3, ErbB4, epithelial tumor antigen (ETA), FBP, fetal acetylcholine receptor (AchR), folate receptor a, G250 / CAIX, ganglioside 2 (GD2), ganglioside 3 (GD3), HLA-A1, HL A-A2, high molecular weight melanoma-associated antigen (HMW-MAA), IL-13 receptor a2, KDR, k light chain, Lewis Y (LeY), L1 cell adhesion molecule, melanoma-associated antigen (MAGE-A1), mesothelin, murine CMV-infected cells, mucin-1 (MUC1), mucin-16 (MUC16), natural killer group 2 member D (NKG2D) ligand, neural cell adhesion molecule (NCAM), NY-ESO-1, carcinoembryonic antigen (h5T4), prostate stem cell antigen (PSCA), prostate-specific membrane antigen (PSMA), receptor tyrosine kinase-like orphan receptor 1 (ROR1), TAA targeted by mAb IgE, tumor-associated glycoprotein 72 (TAG-72), tyrosinase, and vascular endothelial growth factor (VEGF) receptor; - human Her2 / neu, Her1 / EGF receptor (EGFR), Her3, A33 antigen, B7H3, CD5, CD19, CD20, CD22, CD23 (IgE receptor), C242 antigen, 5T4, IL-6, IL-13, vascular endothelial growth factor VEGF (e.g., VEGF-A), VEGFR-1, VEGFR-2, CD30, CD33, CD37, CD40, CD44, CD51, CD52, CD56, CD74, CD 80, CD152, CD200, CD221, CCR4, HLA-DR, CTLA-4, NPC-1C, tenascin, vimentin, insulin-like growth factor 1 receptor (IGF-1R), alpha-fetoprotein, insulin-like growth factor 1 (IGF-1), carbonic anhydrase 9 (CA-IX), carcinoembryonic antigen (CEA), integrin av beta 3, integrin a5 beta 1, folate receptor 1, transmembrane glycoprotein NMB, fibroblast activation protein alpha (FAP), glycoprotein 75, TAG-72, MUC1, MUC16 (or CA-125), phosphatidylserine, prostate-specific membrane antigen (PMSA), NR-LU-13 antigen, TRAIL-R1, tumor necrosis factor receptor superfamily member 10b (TNFRSF10B or TRAIL-R2), SLAM family member 7 (SLAMF7), EGP40 pancarcinoma antigen, B-cell activating factor (BAFF), platelet-derived growth factor receptor, glycoprotein EpCAM (17-1A), programmed death 1, protein disulfide isomerase (PDI), phosphatase of regenerating liver 3 (PRL-3), prostatic acid phosphatase, Lewis Y antigen, GD2 (disialoganglioside expressed in tumors of neuroectodermal origin), glypican 3 (GPC3), or mesothelin; - associated antigens belonging to specific gene products of mutated or modified cellular genes, in particular cyclin-dependent kinases, p15lnk4b, p53, AFP, B-catenin, caspase 8, p53, Bcr-abl fusion products, MUM-1, MUM-2, MUM-3, ELF2M, HSP70-2M, HST-2, KIAA0205, RAGE, myosin / m, 707-AP, CDC27 / m, ETV6 / AML, TEL / Amll, Deccain, LDLR / FUT, Pm1-RARa, TEL / AMLI, cancer testis (CT) antigens, members of the MAGE family, BAGE, DAM-6, DAM-10, members of the GAGE family, NY-ESO-1, N A-88A, CAG-3, RCC-associated antigen G250, tumor viral antigens, in particular E6E7 oncoprotein from human papillomavirus (HPV), Epstein-Barr virus EBNA2-6, LMP-1, LMP-2, gp77, gp100, MART-1 / Melan-A, p53, tyrosinase, tyrosinase-related proteins 1 and 2, PSA, PSM, MC1R, ART4, CAMEL, CEA, CypB, epithelial cell adhesion molecule (EpCAM), HER2 / neu, HER-3, hTERT, hTRT, ICE, Muc1, Muc2, PRAME, RU1, RU2, SART-1, SART-2, SART-3, and WT1, and fragments and derivatives thereof; -CD19; CD123; CD22; CD30; CD171; CS-1 (CD2 subset 1, also called CRACC, SLAMF7, CD319, and 19A24); C-type lectin-like molecule-1 (CLL-1 or CLECLI); CD33; epidermal growth factor receptor variant III (EGFRvIII); ganglioside G2 (GD2); ganglioside GD3 (αNeuSAc(2-8)αNeuSAc(2-3)βDGaip(1-4)βDGlcp(1- 1)Cer); ganglioside GM3 (αNeuSAc(2-8)αNeuSAc(2-3)βDGaip(1-4)bDGlcp(1-1)Cer); GM-CSF receptor; TNF receptor superfamily member 17 (TNFRSF17, BCMA); B-lymphocyte cell adhesion molecule; Tn antigen ((TnAg) or (GaINAc-α-Ser / Thr)); prostate-specific membrane antigen (PSMA); receptor tyrosine kinase-like orphan receptor 1 (RORI); tumor-associated glycoprotein 72 (TAG72); CD38; CD44v6; carcinoembryonic antigen (CEA); epithelial cell adhesion molecule (EPCAM); B7H3 (CD276); KIT (CD117); interleukin-13 receptor subunit alpha-2 (IL-13Ra2 or CD213A2); mesothelin; interleukin-11 receptor alpha (IL-11Ra); prostate stem cell antigen (PSCA); protease serine 21 (testisin or PRSS21); blood vascular endothelial growth factor receptor 2 (VEGFR2); HLA class I antigen A-2 alpha; HLA antigen; Lewis (Y) antigen; CD24; platelet-derived growth factor receptor beta (PDGFR-beta); stage-specific fetal antigen-4 (SSEA-4); CD20; delta-like 3 (DLL3); folate receptor alpha; folate receptor beta, GDNF alpha 4 receptor, receptor tyrosine protein kinase, ERBB2 (Her2 / neu); mucin 1, cell surface associated (MUC1);APRIL receptor, ADP-ribosyl cyclase 1, Ephb4 tyrosine kinase receptor, DCAMKL1 serine threonine kinase, aspartate beta hydroxylase, epidermal growth factor receptor (EGFR), neural cell adhesion molecule (NCAM), prostase, prostatic acid phosphatase (PAP), elongation factor 2 mutated (ELF2M), ephrin B2, fibroblast activation protein alpha (FAP), insulin-like growth factor 1 receptor (IGF-I receptor), carbonic anhydrase IX (CAIX), proteasome (prosome, macropain) beta sarcopenia These include the breakpoint cluster region (BCR) and Abelson murine leukemia viral oncogene homolog 1 (Abl) oncogene fusion protein (bcr-abl), tyrosinase, ephrin type A receptor 2 (EphA2), ephrin type A receptor 3 (EphA3), fucosyl-GM1, sialyl Lewis adhesion molecule (sLe), transglutaminase 5 (TGS5), high molecular weight melanoma-associated antigen (HMWMAA), o-acetyl-GD2 ganglioside (OAcGD2), and folate receptor vector. DATA;Tumor endothelial marker 1 (TEM1 / CD248);Tumor endothelial marker 7-related (TEM7R);Six-transmembrane epithelial antigen I of the prostate (STEAP1);Claudin 6 (CLDN6);Thyroid-stimulating hormone receptor (TSHR);G protein-coupled receptor class C group 5, member D (GPRCSD);IL-15 receptor (IL-15);Chromosome X open reading frame 61 (CXORF61);CD97;CD179a;Anaplastic lymphoma kinase (ALK);Polysialic acid, placenta-specific 1 (PLAC1);Hexasaccharide moiety of globo-H glycoceramide minute (GloboH), mammary differentiation antigen (NY-BR-1), uroplakin 2 (UPK2), hepatitis A virus cell receptor 1 (HAVCR1), adrenergic receptor beta 3 (ADRB3), pannexin 3 (PANX3), G protein-coupled receptor 20 (GPR20), lymphocyte antigen 6 complex, locus K9 (LY6K), olfactory receptor 51E2 (ORSIE2), TCR gamma alternative reading frame protein (TARP), Wilms tumor protein (WT1), cancer / testis antigen 1 (NY-ESO-1), cancer / testis antigen 2 (LAGE-1a);melanoma associated antigen 1 (MAGE-A1); melanoma associated antigen 3 (MAGE-A3); melanoma associated antigen 4 (MAGE-A4); T cell receptor beta 2 chain C; ETS translocation mutant gene 6 located on chromosome 12p (ETV6-AML); sperm protein 17 (SPA17); X antigen family, member 1A (XAGE1); angiopoietin-binding cell surface receptor 2 (Tie2); melanoma cancer testis antigen-1 (MADCT-1); melanoma cancer testis antigen-2 (MAD-CT-2); Fos-related antigen 1; tumor protein p53, (p53); p53 mutant; prostein; survivin; telomerase; prostate cancer tumor antigen-1 (PCTA-1 or galectin 8), melanoma antigen 1 recognized by T cells (MelanA or MARTI);Rat sarcoma (Ras) mutant, human telomerase reverse transcriptase (hTERT), sarcoma translocation breakpoints, melanoma inhibitor of apoptosis (ML-IAP), ERG (transmembrane protease, serine 2 (TMPRSS2) ETS fusion gene), N-acetylglucosaminyltransferase V (NA17), paired box protein Pax-3 (PAX3), androgen receptor, cyclin-Al, cyclin B1, v-myc avian myelocytomatosis viral oncogene neuroblastoma-derived homolog (MYCN), Ras homolog family member C (RhoC), tyrosinase-related protein 2 (TRP-2), cytochrome P450 1B1 (CYP IBI), CCCTC-binding factor (zinc finger protein)-like (BORIS or Brother of the Regulator of Imprinted sites), squamous cell carcinoma antigen recognized by T cells 3 (SART3), paired box protein Pax-5 (PAXS), proacrosin-binding protein sp32 (OY-TESI), lymphocyte-specific protein tyrosine kinase (LCK), A-kinase anchoring protein 4 (AKAP-4), peptidoglycan recognition protein, synovial sarcoma X breakpoint 2 (SSX2), receptor for advanced glycation end products (RAGE-I), renal ubiquitous 1 (RUI), renal ubiquitous 2 (RU2), legumain, human papillomavirus E6 (HPVE6), human papillomavirus E7 (HPVE7), and intestinal carboxylesterase. heat shock protein 70-2 variant (muthsp70-2); CD79a; CD79b; CD72; leukocyte-associated immunoglobulin-like receptor 1 (LAIRI); Fc fragment of IgA receptor (FCAR or CD89); leukocyte immunoglobulin-like receptor subfamily A member 2 (LILRA2); CD300 molecule-like family member f (CD300LF); C-type lectin domain family 12 member A (CLEC12A); bone marrow stromal cell antigen 2 (BST2); EGF-like module containing mucin-like hormone receptor-like 2 (EMR2); lymphocyte antigen 75 (LY75); glypican 2 (GPC2); glypican 3 (GPC3);Fc receptor-like 5 (FCRL5); and immunoglobulin lambda-like polypeptide 1 (IGLL1); and -CD150, 5T4, ActRIIA, B7, TNF receptor superfamily member 17 (TNFRSF17, BCMA), CA-125, CCNA1, CD123, CD126, CD138, CD14, CD148, CD15, CD19, CD20, CD200, CD21, CD22, CD23, CD24, CD25, CD26, CD261, CD262, CD30, CD33, CD362, CD37, CD38, CD4, CD40, CD4OL, CD44, CD46, CD5, CD52, CD53, CD54, CD56, CD66a-d, CD74, CD8, CD80, CD92, CE7, CS-1, CSPG4, ED-B fibronectin, EGFR, EGFRvIII, EGP-2, EGP-4, EPHa2, ErbB2, ErbB3, ErbB4, FBP, HER1-HER2 combination, HER2-HER3 combination, HERV-K, HIV-1 envelope glycoprotein gp120, HIV-1 envelope glycoprotein gp41, HLA-DR, HLA class I antigen alpha G, HM1.24, K-RasGTPase, HMW-MAA, Her2, Her2 / neu, IGF-1R, IL-11Ralpha, IL-13Ralpha2, IL-2, IL-22Ralpha, IL-6, IL-6R, la, li, L1-CAM, L1 cell adhesion molecule, Lewis Y, LI-CAM, MAGEA3, MAGE-A1, MART-1, MUC1, NKG2C ligand, NKG2D ligand, NYESO-1, OEPHa2, PIGF, PSCA, PSMA, ROR1, T101, TAC, TAG72, TIM-3, TRAIL-R1, TRAIL-R1(DR4), TRAIL-R2(DR5), VEGF, VEGFR2, WT-I, G protein-coupled receptor, alpha fetoprotein (AFP), angiogenic factor, exogenous cognate binding molecule (ExoCBM), oncogene product, antifolate receptor, c-Met, carcinoembryonic antigen (CEA), cyclin (D1), ephrin B2, epithelial tumor antigen, estrogen receptor, fetal acetylcholine E receptor, folate binding protein, gp100, hepatitis B surface antigen, Epstein-Barr nuclear antigen 1, latent membrane protein 1, secreted protein BARF1, P2X7 purinergic receptor, syndecan-1, kappa chain, kappa light chain, kdr, lambda chain, livin, melanoma-associated antigen, mesothelin, mouse double minute 2 homolog (MDM2), mucin 16 (MUC16), mutated p53, mutated ras, necrosis antigen, oncofetal antigen, ROR2, progesterone receptor, prostate-specific antigen, tEGFR, tenascin, beta2-microdiopulin, Fc receptor-like 5 (FcRL5).
[0169] These cancer associated antigens are shown in the listing of different sublists for illustrative purposes only, but it should be understood that one or more cancer associated antigens of a given sublist can be combined with one or more cancer associated antigens of one or more different sublists to form different lists.
[0170] In some embodiments, the helper T cell epitope is a peptide comprising less than about 20 amino acids and / or amino acid analogs.
[0171] In some embodiments, the helper T cell epitope is selected from the group consisting of: -Peptides derived from poliovirus, e.g., (PV103-115)KLFAVWKITYKDT; - pan-DR binding (PADRE) peptides, e.g., DAla-Lys-Cha-Val-Ala-Ala-Trp-Thr-Leu-Lys-Ala-Ala-DAla; - peptides derived from tetanus toxoid, such as (TT593-599) YSYFPSV, (TT830-843) QYIKANSKFIGITE, (TT830-844) QYIKANSKFIGITEL, (TT1084-1099) VSIDKFRIFCKANPK, (TT1174-1189) LKFIIKRYTPNNEIDS, (TT1064-1079) IREDNNITLKLDRCNN, and (TT947-967) FNNFTVSFWLRVPKVSASHLE; - peptides derived from Neisseria meningitidis, such as YAFKYARHANVGRNAFELFL ("YAF"); - Peptides derived from P. falciparum CSP, such as EKKIAKMEKASSVFNVNN.
[0172] In certain embodiments of compounds of formula (II), R 4 is selected from:
[0173] [ka] [ka]
[0174] wherein A is H or a moiety comprising either i) at least one T cell epitope selected from helper T cell epitopes or CD8 epitopes, ii) at least one B cell epitope, or iii) at least one T cell epitope selected from helper T cell epitopes or CD8 epitopes and at least one B cell epitope. Preferably, A is a moiety comprising at least one B cell epitope.
[0175] In certain embodiments, the compound of formula (II) is selected from the group consisting of:
[0176] [ka] [ka]
[0177] wherein W and A are independently H or a moiety comprising either i) at least one T cell epitope selected from a helper T cell epitope or a CD8 epitope, ii) at least one B cell epitope, or iii) at least one T cell epitope and at least one B cell epitope selected from a helper T cell epitope or a CD8 epitope; However, the compound of formula (II) contains at least one T cell epitope and at least one B cell epitope.
[0178] Preferably, A is a moiety that comprises at least one B cell epitope and W is a moiety that comprises at least one T cell epitope.
[0179] Compounds of formula (III) and (IV): intermediate compounds The present invention provides a compound of general formula (III) or a pharma- ceutically acceptable salt thereof:
[0180] [ka]
[0181] During the ceremony, --- , G, V, and Y have the same meanings and specific embodiments as in formula (I) or (II), and Z* has the same meanings and specific embodiments as in formula (II).
[0182] The present invention also provides a compound of general formula (IV) or a pharma- ceutically acceptable salt thereof:
[0183] [ka]
[0184] During the ceremony, --- , G, V, and Y have the same meanings and specific embodiments as in formula (I) or (II), Z has the same meaning as in formula (I), and W has the same meaning and specific embodiments as in formula (II).
[0185] The compounds of formula (III) and (IV) may be used as intermediate compounds for the preparation of the self-adjuvanted vaccine of formula (II).
[0186] Compound synthesis The compounds of formula (I) and (II) or pharma- ceutically acceptable salts thereof according to the invention may be obtained from a compound of formula (V) or a pharma- ceutically acceptable salt thereof:
[0187] [ka]
[0188] During the ceremony, --- , G, V, Y and Z have the same meanings and specific embodiments as in formula (I).
[0189] The C4-aldehyde saponin compound of formula (V) is available from known synthetic methods, such as those disclosed in WO2009 / 126737, WO2015 / 184451, WO2017 / 079582, WO2017 / 106836, WO2018 / 191598, WO2018 / 200645, WO2018 / 200656, and WO2019 / 079160.
[0190] In some embodiments, the method of synthesizing a compound of formula (I) or a salt thereof comprises: a) providing a compound of formula (V) or a salt thereof; b) reacting the compound of formula (V) or a salt thereof with NHOH or a salt thereof to form a compound of formula (I) or a salt thereof; Includes.
[0191] In some embodiments, the method of synthesizing a compound of formula (II) or a salt thereof comprises: a) providing a compound of formula (V) or a salt thereof; b) combining a compound of formula (V) or a salt thereof with a moiety comprising either i) at least one T cell epitope selected from a helper T cell epitope or a CD8 epitope, ii) at least one B cell epitope, or iii) a helper T cell epitope or a CD8 epitope, at least one T cell epitope and at least one B cell epitope to form a compound of formula (III) or a salt thereof; c) reacting a compound of formula (III) or a salt thereof with a compound of the formula:
[0192] [ka]
[0193] or a salt thereof, wherein W is H or a moiety comprising either i) at least one T cell epitope selected from a helper T cell epitope or a CD8 epitope, ii) at least one B cell epitope, or iii) a helper T cell epitope or a CD8 epitope, at least one T cell epitope and at least one B cell epitope, to form a compound of formula (II) or a salt thereof. Includes.
[0194] In some embodiments, the method of synthesizing a compound of formula (II) or a salt thereof comprises: a) providing a compound of formula (V); b) reacting a compound of formula (V) or a salt thereof with a compound of the formula:
[0195] [ka]
[0196] or a salt thereof, wherein W is H or a moiety comprising either i) at least one T cell epitope selected from a helper T cell epitope or a CD8 epitope, ii) at least one B cell epitope, or iii) at least one T cell epitope and at least one B cell epitope, a helper T cell epitope or a CD8 epitope, to form a compound of formula (IV) or a salt thereof; c) if desired or necessary (a compound of formula (IV) is already encompassed by formula (II) when W is a moiety comprising at least one T cell epitope and at least one B cell epitope), combining a compound of formula (IV) or a salt thereof with a moiety comprising either i) at least one T cell epitope selected from a helper T cell epitope or a CD8 epitope, ii) at least one B cell epitope, or iii) at least one T cell epitope selected from a helper T cell epitope or a CD8 epitope and at least one B cell epitope to form a compound of formula (II) or a salt thereof. Includes.
[0197] In some embodiments, the conjugation to a moiety containing at least one T cell epitope, at least one B cell epitope, or both epitopes via the carbohydrate domain chain, i.e., conversion of Z to Z*, is carried out by a click chemistry reaction.
[0198] The term "click chemistry" was introduced to describe certain chemical reactions that are rapid, reliable, and selectively applicable to the synthesis of functional materials and biomolecular conjugates. Click chemistry can be broadly defined as a ligation reaction in which two reactants combine under mild or ambient conditions to provide the desired product in high chemical yield and in a short time.
[0199] Thus, in some embodiments, Z in the compounds of formula (I), formula (IV) or formula (V) is functionalized, preferably via an R4 substituent, with a first functional group of a specific binding pair capable of forming a covalent bond with a complementary second functional group of the binding pair, which is suitable for the purpose of binding to a compound comprising an immune system activator (e.g., either a T-cell epitope or a B-cell epitope, or both epitopes) functionalized with a complementary second functional group of said binding pair capable of forming a covalent bond with said first functional group to form Z* in the compounds of formula (II) and (III).
[0200] The term "binding pair" as used herein refers to a pair of different molecules (e.g., a compound of formula (I), formula (IV), or formula (V) and (ii) a compound comprising an immune system activator), each containing its own specific functional group, both functional groups having a specific specificity (or complementarity) to each other. In other words, these groups are capable of covalently binding to each other under normal conditions in preference to binding to other molecules. Non-limiting examples of such binding pairs are carboxylic acid-amine, thiol-maleimide, azide-alkyne, aldehyde-hydroxylamine, etc.
[0201] In general, a functional group is a specific group or portion of an atom or bond in a molecule that is responsible for the characteristic chemical reaction of the molecule. In particular, a functional group or functional group of a binding pair as defined herein refers to a specific reactive group or portion of an atom or bond of a binding pair (hereinafter, the "first functional group") that can bind to another functional group of the binding pair (hereinafter, the "second functional group"). As mentioned above, the first functional group and the second functional group are complementary to each other. In the above non-limiting examples, the first functional group is a carboxylic acid, a thiol, an azide, or an aldehyde, and its complementary (second) functional group is an amine, a maleimide, an alkyne, or a hydroxylamine, respectively.
[0202] In certain embodiments, i) the first functional group of the specific binding pair is an aldehyde, ketone, isothiocyanate, carboxylic acid, or derivatives thereof, such as ester, anhydride, acyl halide, tosyl, and N-hydrosuccinimide (NHS), and the second functional group of the binding pair is an amine, or vice versa; ii) the first functional group of the specific binding pair is an alkyne or a phosphine, and the second functional group of the binding pair is an azide, or vice versa; and iii) the first functional group of the specific binding pair is a cycloalkene, cycloalkyne, cyclopropane, isonitrile (isocyanide), or vinylboronic acid, and the second functional group of the binding pair is a tetrazine. or vice versa, iv) the first functional group of the specific binding pair is an alkyne or maleimide and the second functional group of the binding pair is a thiol or vice versa, v) the first functional group of the specific binding pair is a conjugated diene and the second functional group of the binding pair is a substituted alkene or vice versa, vi) the first functional group of the specific binding pair is an alkene, alkyne, or copper acetylide and the second functional group of the binding pair is a nitrone or vice versa, vii) the first functional group of the specific binding pair is an aldehyde or ketone and the second functional group of the binding pair is an alkoxyamine, hydroxylamine, hydrazine, or hydrazide or vice versa. In more specific embodiments, the first functional group of the specific binding pair is a carboxylic acid or a derivative thereof, such as an ester, an anhydride, an acyl halide, a tosyl, and N-hydrosuccinimide (NHS) and the second functional group of the binding pair is an amine or vice versa. In more specific embodiments, the specific binding pair is a carboxylic acid or a derivative thereof, for example, an ester--amine.
[0203] In certain embodiments, the linkage between Z and the moiety comprising an immune system activator (e.g., either a T cell epitope or a B cell epitope, or both epitopes) may be via a bivalent linker. An example of a bivalent linker is a reactive PEG derivative of the formula:
[0204] [ka]
[0205] where n, x, and y are positive integers, and R and R' are reactive functional groups.
[0206] In certain embodiments, n is selected from 1 to 20, preferably 1 to 10, more preferably 1 to 5, such as 1, 2, 3, 4, or 5. In another particular embodiment, x and y are independently selected from 1, 2, or 3. In another particular embodiment, R and R' are independently selected from carboxylic acid or a derivative thereof, such as ester, anhydride, acyl halide, tosyl, and N-hydrosuccinimide (NHS).
[0207] In a more particular embodiment, the linker is
[0208] [ka]
[0209] or a salt thereof.
[0210] In some embodiments, functionalization at the C4 position of the triterpene domain with a moiety comprising either i) at least one T cell epitope, ii) at least one B cell epitope, or iii) at least one T cell epitope and at least one B cell epitope may be achieved by reacting a saponin having a C4-aldehyde substituent (e.g., a compound of formula (III) or formula (V)) with an immune system activator that contains the following aminooxy reactive group:
[0211] [ka]
[0212] formulation Another aspect of the present application relates to a formulation or pharmaceutical composition comprising a compound according to the invention or a pharma- ceutically acceptable salt thereof, a pharma- ceutically acceptable carrier, and optionally an antigen.
[0213] In some embodiments, the pharmaceutical composition comprises a compound of Formula (I) or a pharma- ceutically acceptable salt thereof, a pharma- ceutically acceptable carrier, and an antigen.
[0214] As used herein, the term "antigen" refers to a substance capable of generating a specific immune response and inducing the formation of specific antibodies or specially sensitized T cells or both. Thus, in the context of the present invention, an antigen is capable of activating lymphocytes and is therefore a complete antigen, i.e. it has de novo antigenic properties and is capable of generating an immune response by itself. The antigen is characterized by a molecular weight of more than 14 kDa and has a complex chemical composition, ideally containing aromatic groups. The antigens belong to four main groups: proteins, polysaccharides, nucleic acids, lipids, preferably proteins.
[0215] An "immune response" to an antigen or immunogenic composition is the generation in a subject of a humoral and / or cellular immune response to the antigen of interest or molecules present in the vaccine composition. For purposes of this invention, a "humoral immune response" is an antibody-mediated immune response, involving the induction and production of antibodies that recognize and bind with some affinity to the antigen in the immunogenic composition of the invention, and a "cell-mediated immune response" is an immune response mediated by T cells and / or other white blood cells.
[0216] "Cell-mediated immune response" also refers to the production of cytokines, chemokines, and other such molecules (including those derived from CD4+ and CD8+ T cells) produced by activated T cells and / or other white blood cells. The ability of a particular antigen or composition to stimulate a cell-mediated immune response can be determined by a number of assays, such as lymphoproliferation (lymphocyte activation) assays, CTL cytotoxicity cell assays, by assaying antigen-specific T lymphocytes in sensitized subjects, or by measuring cytokine production by T cells in response to restimulation with antigen. Such assays are well known in the art. See, for example, Erickson et al. (1993) J. Immunol. 151:4189-4199, and Doe et al. (1994) Eur. J. Immunol. 24:2369-2376.
[0217] The antigen may comprise at least one B cell epitope. In some embodiments, the B cell epitope may be selected from the group consisting of peptides, glycopeptides, and carbohydrates that can induce an immune response. The antigen may be selected from the group consisting of, for example, neurodegeneration-related antigens, infectious disease-related antigens (e.g., bacterial, viral, or protozoan-related antigens), or cancer-related antigens, also known as tumor-associated antigens or TACAs. Specific examples of TACAs for co-administration with the compound of formula (I) are listed above.
[0218] Further examples of antigens useful in the present invention include, but are not limited to, tetanus toxoid, ovalbumin, thyroglobulin, recombinant hemagglutinin B (rHagB) antigen, recombinant proteins from H1N1 influenza, and protective BpOmpW from Burkholderia pseudomallei.
[0219] In some embodiments, the pharmaceutical composition comprises a compound of formula (II) or a pharma- ceutically acceptable salt thereof and a pharma- ceutically acceptable carrier.
[0220] In certain embodiments, the pharmaceutical composition comprises a pharma- ceutically acceptable amount of the compound of the present application. In certain embodiments, the pharmaceutical composition comprises an immunologically effective amount of the antigen. In certain embodiments, the compound of the present application and the antigen form the active ingredient. In certain embodiments, only the compound of the present application forms the active ingredient. The amount of active ingredient that can be combined with the carrier materials to produce a single dosage form will vary depending on the host treated and the particular mode of administration. The amount of active ingredient that can be combined with the carrier materials to produce a single dosage form will generally be that amount of the compound that produces a therapeutic effect. In general, this amount will range from about 1% to about 99% of the active ingredient, preferably from about 5% to about 70%, most preferably from about 10% to about 30%, or from about 1% to 99%, preferably from 10% to 90%, 20% to 80%, 30% to 70%, 40% to 60%, 45% to 55%, or about 50%.
[0221] In certain embodiments, the formulations of the present application include injectable formulations.
[0222] In one aspect, the present application provides a formulation comprising MPL and a liposomal formulation of a compound of the present invention. In another aspect, the present application provides a formulation comprising MPL, a compound of the present invention, and a squalene emulsion. In another aspect, the present application provides a formulation comprising MPL, a compound of the present invention, and CpG7909 or CpG1018. MPL is a heterogeneous mixture of molecules from biological sources that includes both agonists and antagonists of TLR4. CpG7909 is an immunomodulatory synthetic oligonucleotide designed to specifically agonise Toll-like receptor 9 (TLR9).
[0223] In another aspect, the present application provides a formulation comprising an immunostimulating complex (ISCOM) or ISCOM matrix of the compound of the present invention. In another aspect, the present application provides a formulation comprising an ISCOM matrix of the compound of the present invention and an antigen. ISCOMs are open cage-like nanoparticle structures that contain saponin (here, the compound of the present invention), cholesterol, phospholipids, and antigen. ISCOM particles are typically spherical with a diameter of about 40 nm. ISCOMs have been shown in various experimental animal models to deliver antigens to the cytoplasm and promote antibody responses and induction of T helper cells and cytotoxic T lymphocyte responses. ISCOM matrix formulations (e.g., ISCOMATRIX and Matrix-M) contain the same components and have the same structure as ISCOMs, but do not incorporate antigens.
[0224] Wetting agents, emulsifying agents, lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring, and perfuming agents, preservatives, and antioxidants can also be present in the composition.
[0225] Non-limiting examples of pharma- ceutically acceptable antioxidants include water-soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfite, sodium metabisulfite, sodium sulfite, and the like; oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, α-tocopherol, and the like; and metal chelators, such as citric acid, ethylenediaminetetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.
[0226] Suspensions may contain, in addition to the active compounds, suspending agents such as ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, and tragacanth, and mixtures thereof.
[0227] Non-limiting examples of suitable aqueous and non-aqueous carriers that may be used in the pharmaceutical compositions of the present application include water, alcohols (including but not limited to methanol, ethanol, butanol, etc.), polyols (including but not limited to glycerol, propylene glycol, polyethylene glycol, etc.), and suitable mixtures thereof, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
[0228] These compositions may also contain additives such as preservatives, wetting agents, emulsifying agents, and dispersing agents. Prevention of the action of microorganisms on the subject compounds can be ensured by the inclusion of various antibacterial and antifungal agents, for example, parabens, chiorobufanoi, phenol sorbic acid, and it may be desirable to include isotonic agents, such as sugars, sodium chloride, and further agents that delay absorption, such as aluminum monostearate and gelatin, to delay absorption of injectable agents.
[0229] In some cases, in order to prolong the effect of the formulation, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This can be accomplished by using a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the drug then depends on its rate of dissolution, which may depend on the size and crystalline form of the crystals.
[0230] Regardless of the route of administration selected, the compounds of the present application, which may be used in a suitable hydrated form, and / or the pharmaceutical compositions of the present application, are formulated into pharma- ceutically acceptable dosage forms by conventional methods known to those of skill in the art.
[0231] Actual dosage levels of the active ingredients in the pharmaceutical compositions of the present application may be varied to obtain an amount of the active ingredient that is non-toxic to the patient and effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration.
[0232] The selected dosage level will depend upon a variety of factors, including the activity of the particular compound of the present application, or esters, salts, or amides thereof, being used, the route of administration, the time of administration, the rate of excretion or metabolism of the particular compound being used, the duration of treatment, other drugs, compounds, and / or materials used in combination with the particular compound employed, the age, sex, weight, condition, general health, and medical history of the patient being treated, and like factors well known in the medical arts.
[0233] A physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required. For example, the physician or veterinarian can start the dosage of the compounds of the present application used in the pharmaceutical composition at a level lower than that required to achieve the desired therapeutic effect and then gradually increase the dosage until the desired effect is obtained.
[0234] In some embodiments, the compounds or pharmaceutical compositions of the present application are provided to a subject on a chronic basis. Chronic treatment includes any form of repeated administration over a long period of time, such as repeated administration over a period of one month or more, one month to one year, one year or more, or more. In many embodiments, long-term treatment includes repeated administration of the compounds or pharmaceutical compositions of the present application over the life of the subject. Preferred long-term treatment includes regular administration, for example, one or more times per day, one or more times per week, or one or more times per month, and generally, a suitable dosage, such as a daily dosage, of the compounds of the present application is the minimum dosage of the compound effective to produce a therapeutic effect. Such an effective dosage will generally depend on the factors described above.
[0235] In general, the dosage of the compounds of the present application to a patient, when used for the indicated effects, ranges from about 0.0001 to about 100 mg per kg of body weight per day. Preferably, the daily dosage ranges from 0.001 to 50 mg of compound per kg of body weight, more preferably from 0.01 to 10 mg of compound per kg of body weight. However, lower or higher dosages can be used, and in some embodiments, the dosage administered to a subject may be modified depending on physiological changes in the subject due to age, disease progression, body weight, or other factors.
[0236] In some embodiments, the adjuvant compounds provided herein are administered as a pharmaceutical composition or a vaccine. In certain embodiments, it is contemplated that the amount of adjuvant compound administered is 1-2000 μg. In certain embodiments, it is contemplated that the amount of adjuvant compound administered is 1-1000 μg. In certain embodiments, it is contemplated that the amount of adjuvant compound administered is 1-500 μg. In certain embodiments, it is contemplated that the amount of adjuvant compound administered is 1-250 μg. In certain embodiments, it is contemplated that the amount of adjuvant compound administered is 100-1000 μg. In certain embodiments, it is contemplated that the amount of adjuvant compound administered is 100-500 μg. In certain embodiments, it is contemplated that the amount of adjuvant compound administered is 100-200 μg. In certain embodiments, it is contemplated that the amount of adjuvant compound administered is 250-500 μg. In certain embodiments, it is contemplated that the amount of adjuvant compound administered will be between 10 and 1000 μg. In certain embodiments, it is contemplated that the amount of adjuvant compound administered will be between 500 and 1000 μg. In certain embodiments, it is contemplated that the amount of adjuvant compound administered will be between 50 and 250 μg. In certain embodiments, it is contemplated that the amount of adjuvant compound administered will be between 50 and 500 μg.
[0237] In some embodiments, the adjuvant compound provided herein is administered as a pharmaceutical composition or a vaccine. In certain embodiments, it is contemplated that the amount of adjuvant compound administered is 1-2000 mg. In certain embodiments, it is contemplated that the amount of adjuvant compound administered is 1-1000 mg. In certain embodiments, it is contemplated that the amount of adjuvant compound administered is 1-500 mg. In certain embodiments, it is contemplated that the amount of adjuvant compound administered is 1-250 mg. In certain embodiments, it is contemplated that the amount of adjuvant compound administered is 100-1000 mg. In certain embodiments, it is contemplated that the amount of adjuvant compound administered is 100-500 mg. In certain embodiments, it is contemplated that the amount of adjuvant compound administered is 100-200 mg. In certain embodiments, it is contemplated that the amount of adjuvant compound administered is 250-500 mg. In certain embodiments, it is contemplated that the amount of adjuvant compound administered is 10-1000 mg. In certain embodiments, it is contemplated that the amount of adjuvant compound administered will be between 500 and 1000 mg. In certain embodiments, it is contemplated that the amount of adjuvant compound administered will be between 50 and 250 mg. In certain embodiments, it is contemplated that the amount of adjuvant compound administered will be between 50 and 500 mg. In certain embodiments, it is contemplated that the amount of adjuvant compound administered will be between 0.01 and 215.4 mg.
[0238] In certain embodiments, it is contemplated that the amount of adjuvant administered is 1000-5000 μg / kg. In certain embodiments, it is contemplated that the amount of adjuvant administered is 1000-4000 μg / kg. In certain embodiments, it is contemplated that the amount of adjuvant administered is 1000-3000 μg / kg. In certain embodiments, it is contemplated that the amount of adjuvant administered is 1000-2000 μg / kg. In certain embodiments, it is contemplated that the amount of adjuvant administered is 2000-5000 μg / kg. In certain embodiments, it is contemplated that the amount of adjuvant administered is 2000-4000 μg / kg. In certain embodiments, it is contemplated that the amount of adjuvant administered is 2000-3000 μg / kg. In certain embodiments, it is contemplated that the amount of adjuvant administered is 3000-5000 μg / kg. In certain embodiments, it is contemplated that the amount of adjuvant administered is 3000-4000 μg / kg. In certain embodiments, it is contemplated that the amount of adjuvant administered is 4000-5000 μg / kg. In certain embodiments, it is contemplated that the amount of adjuvant administered is 1-500 μg / kg. In certain embodiments, it is contemplated that the amount of adjuvant administered is 500-1000 μg / kg. In certain embodiments, it is contemplated that the amount of adjuvant administered is 1000-1500 μg / kg. In certain embodiments, it is contemplated that the amount of adjuvant administered is 1 mg / kg. In certain embodiments, it is contemplated that the amount of adjuvant administered is 2 mg / kg. In certain embodiments, it is contemplated that the amount of adjuvant administered is 3 mg / kg. In certain embodiments, it is contemplated that the amount of adjuvant administered is 4 mg / kg. In certain embodiments, it is contemplated that the amount of adjuvant administered is 5 mg / kg. In certain embodiments, it is contemplated that the amount of adjuvant administered is between 0.0029 and 5 mg / kg, hi certain embodiments, the amount of adjuvant administered in females is less than the amount of adjuvant administered in males.In certain embodiments, the amount of adjuvant administered in an infant is less than the amount of adjuvant administered in an adult. In certain embodiments, the amount of adjuvant administered in a pediatric recipient is less than the amount of adjuvant administered to an adult. In certain embodiments, the amount of adjuvant administered in an immunocompromised recipient is greater than the amount of adjuvant administered in a healthy recipient. In certain embodiments, the amount of adjuvant administered in an elderly recipient is greater than the amount of adjuvant administered in a non-elderly recipient.
[0239] If desired, an effective dose of the active compound can be administered as two, three, four, five, six or more subdoses administered separately at suitable intervals throughout the day, optionally in unit dosage forms. Although the compounds of the present application can be administered alone, in certain embodiments, the compounds are administered in pharmaceutical formulations or compositions as described above.
[0240] The compounds of the present application, like other pharmaceuticals, may be formulated for administration in any convenient way for use in human or veterinary medicine.
[0241] The present application provides kits comprising pharmaceutical formulations or compositions of the compounds of the present application. In certain embodiments, such kits comprise a combination of a compound of Formula I and / or Formula II and an antigen. The agents may be packaged separately or together. The kits optionally include instructions for prescribing the agents, and in certain embodiments, the kits include multiple doses of each agent. The kits may include sufficient amounts of each component to treat one or more subjects for one week, two weeks, three weeks, four weeks, or several months. The kits may include a full cycle of immunotherapeutic agents. In some embodiments, the kits include a vaccine comprising one or more bacterial, viral, protozoan, neurodegenerative disease, or cancer associated antigens and one or more of the provided compounds.
[0242] Uses of the Compounds of the Invention and Methods of Use Thereof: Adjuvants and Vaccines The compound of formula (I) or its salt may be used as an adjuvant in a vaccine to enhance the immune response to an antigen or to enhance a specific activity of cells from the immune system.Furthermore, the compound of formula (II) or its salt covalently linked to a moiety containing at least one B cell epitope and a moiety containing at least one T cell epitope or a moiety containing both epitopes may be used as a self-adjuvanting vaccine.
[0243] Another aspect of the present application relates to a compound of the invention, e.g. a compound of formula (I) and / or (II), or a pharmaceutical composition thereof, for use in medicine, more particularly for use in the treatment and / or prevention of cancer, an infectious disease, or a neurodegenerative disease.
[0244] When referring to a compound of formula (I) that does not contain an antigen or epitope in its structure, it is understood that its use in therapy requires the administration of the compound in combination with the antigen to which a response is desired. In a preferred embodiment, the compound of formula (I) can be formulated in an immunogenic composition together with the antigen. In this case, any reference to the medical use of a compound of formula (I) should be understood as a reference to the medical use of an immunogenic composition comprising a compound of formula (I) and an antigen. Similarly, any reference to a pharmaceutical composition of a compound of formula (I) should be understood as a composition comprising an antigen. In contrast, since compounds of formula (II) are self-adjuvanted, these compounds can be included in a pharmaceutical composition soley in the presence of a pharma- ceutical acceptable vehicle without the need for an antigen.
[0245] Another aspect of the present application relates to a method for treating and / or preventing a disorder in a subject, the method comprising administering to the subject an effective amount of a compound of the present invention, e.g., a compound of Formula (I) and / or (II), or a pharmaceutical composition thereof, wherein the disorder is cancer, an infectious disease, or a neurodegenerative disease.
[0246] Another aspect of the application relates to a compound of the invention, such as a compound of Formula (I) and / or (II), or a pharmaceutical composition thereof, for use in immunizing a subject.
[0247] Another aspect of the present application relates to a method for immunizing a subject, comprising administering to the subject an effective amount of a compound of the present invention, e.g., a compound of formula (I) and / or (II), or a pharmaceutical composition thereof.
[0248] Any animal that may experience the beneficial effects of the compositions of the present application is within the scope of subjects to be treated, and in some embodiments, the subject is a mammal. In some embodiments, the subject is a human.
[0249] The vaccines of the present application can be used to confer resistance to infection by either passive or active immunization. When the vaccines of the present application are used to confer resistance by active immunization, the vaccines of the present application are administered to an animal to induce a protective immune response that prevents or reduces a proliferative or infectious disease. When the vaccines of the present application are used to confer resistance to infection by passive immunization, the vaccines are provided to a host animal (e.g., a human, a dog, or a mouse) and the antisera induced by the vaccine are collected and provided directly to a recipient suspected of having an infection or disease or exposed to a causative organism.
[0250] Thus, the present application relates to and provides a means for preventing or ameliorating proliferative diseases caused by organisms or tumor cells that bear an antigen that is recognized and bound by antisera generated in response to the immunogenic antigens contained in the vaccines of the present application. As used herein, a vaccine is said to prevent or ameliorate a disease if its administration to an animal completely or partially alleviates (i.e., suppresses) the symptoms or condition of the disease or immunizes the animal completely or partially against the disease.
[0251] Administration of the vaccine (or the antisera elicited by the vaccine) may be for either a "prophylactic" or "therapeutic" purpose. When provided prophylactically, the vaccine is provided before any symptoms of the proliferative disease appear. Prophylactic administration of the vaccine serves to prevent or reduce any subsequent manifestations of the disease. When provided therapeutically, the vaccine is provided upon or after detection of symptoms indicating that the animal may be infected with a pathogen or suffer from a particular cancer. Therapeutic administration of the vaccine serves to reduce any actual disease symptoms. Thus, the vaccine can be provided before the onset of disease growth (to prevent or reduce expected infection or cancer) or after the onset of actual growth.
[0252] Thus, in one aspect, the application provides a vaccine comprising one or more antigens (e.g., one or more bacterial, viral, protozoan, neurodegenerative disease, or tumor associated antigens) in combination with one or more compounds of the invention. In some embodiments, the vaccine comprises a single bacterial, viral, protozoan, neurodegenerative disease, or tumor associated antigen in combination with one compound of the invention. In some embodiments, the vaccine comprises two or more bacterial, viral, protozoan, neurodegenerative disease, or tumor associated antigens in combination with a single compound of the invention. In some embodiments, the vaccine comprises two or more bacterial, viral, protozoan, neurodegenerative disease, or tumor associated antigens in combination with two or more compounds of the invention. In some embodiments, the vaccine comprises a single bacterial, viral, protozoan, neurodegenerative disease, or tumor associated antigen in combination with two or more compounds of the invention.
[0253] In some embodiments, one or more antigens of the provided vaccines are bacterial-associated antigens.
[0254] In certain embodiments, one or more antigens of the vaccines provided are virus-associated antigens.
[0255] In certain embodiments, one or more antigens of the vaccines provided are protozoan-associated antigens.
[0256] In certain embodiments, one or more antigens of the vaccines provided are neurodegenerative disease-associated antigens.
[0257] In certain embodiments, one or more of the antigens of the vaccines provided are cancer or tumor associated antigens, including, for example, those listed above.
[0258] In certain embodiments, one or more antigens are contained within the structure of the compounds of the invention, for example, in the compound of formula (II), and therefore administration of additional antigens is not required, although possible.
[0259] Those skilled in the art will understand that the vaccine may optionally include a pharmaceutically acceptable excipient or carrier. Thus, according to another aspect, the vaccine provided may include one or more antigens, optionally associated with a pharmaceutically acceptable excipient or carrier. In some embodiments, the one or more antigens are covalently bound to the pharmaceutically acceptable excipient. In other embodiments, the one or more antigens are non-covalently associated with the pharmaceutically acceptable excipient.
[0260] As noted above, adjuvants can be used to enhance the immune response to an antigen. According to the present application, the provided vaccines can be used to generate an immune response when administered to a subject. In certain embodiments, the immune response to an antigen can be enhanced by administering to a subject the provided vaccine in an amount effective to enhance the subject's immune response to the antigen.
[0261] As mentioned above, the compounds of the present application may be combined with the tumor-associated antigens listed above as adjuvants in cancer vaccines. In certain embodiments, the vaccine may be for the treatment or prevention of neoplasms. In certain embodiments, the neoplasm is a benign neoplasm. In other embodiments, the neoplasm is a malignant neoplasm. The compounds of the present invention may be used with antigens to treat any cancer.
[0262] In certain embodiments, the malignancy is a hematological malignancy.
[0263] The compounds of Formula I and II may also be used to treat other cancers besides hematological malignancies, hi certain embodiments, the cancer is a solid tumor.
[0264] In certain embodiments, the compounds and pharmaceutical compositions of the present application may be used in combination therapy, i.e., the compounds and pharmaceutical compositions may be administered simultaneously with, prior to, or after one or more other desired therapeutic agents or medical treatments. The particular combination of therapies (therapeutic agents or treatments) to be used in a combination regimen will take into consideration the compatibility of the desired therapeutic agent and / or treatment with the desired therapeutic effect to be achieved. It will also be understood that the therapeutic agents used may achieve the desired effect on the same disorder (e.g., the compound of the present invention may be administered simultaneously with another antiproliferative agent) or may achieve a different effect (e.g., control of any side effects).
[0265] For example, other treatments or anti-cancer agents that may be used in combination with the anti-cancer agents of the present application include surgery, radiation therapy (such as gamma radiation, neutron radiation therapy, electron beam radiation therapy, proton therapy, brachytherapy, and systemic radioisotopes, to name a few), endocrine therapy, biological response modifiers (such as interferons, interleukins, and tumor necrosis factor (TNF)), hyperthermia and cryotherapy, agents to reduce any side effects (e.g., antiemetics), as well as alkylating agents (mechlorethamine, chlorambucil, cyclophosphamide, melphalan, ifosfamide), antimetabolites (methotrexate), purine antagonists and pyrimidine antagonists (6-mercaptopurine, 5-fluorouracil, cytarabir, gemcitabine), spindle poisons (bintoclamide, cyclophosph ... Other approved chemotherapeutic agents include, but are not limited to, blastine, vincristine, vinorelbine, paclitaxel), podophyllotoxins (etoposide, irinotecan, topotecan), antibiotics (doxorubicin, bleomycin, mitomycin), nitrosoureas (carmustine, lomustine), inorganic ions (cisplatin, carboplatin), enzymes (asparaginase), and hormones (tamoxifen, leuprolide, flutamide, and megestrol). Additionally, the present invention encompasses the use of certain cytotoxic or anticancer agents currently in clinical trials that may ultimately be approved by the FDA, including, but not limited to, epothilones and their analogs, geldanamycin and its analogs. For a more comprehensive discussion of current cancer treatments, see www.nci.nih.gov, the list of FDA-approved oncology drugs at www.fda.gov / cder / cancer / druglistframe.htm, and The Merck Manual, Seventeenth Ed. 1999, the contents of which are incorporated herein by reference in their entireties.
[0266] In another aspect, the application provides a method of treating an infectious disease in a subject, comprising administering to the subject a therapeutically effective amount of a compound of formula (I) and an antigen or a therapeutically effective amount of a compound of formula (II). In some embodiments, the infectious disease is bacterial. In some embodiments, the infectious disease is viral. In some embodiments, the infectious disease is protozoal. Examples of infectious disease include, but are not limited to, malaria, acquired immune deficiency syndrome, hepatitis, and tuberculosis. In some embodiments, the subject is a human.
[0267] In another aspect, the present application provides a method of treating a neurodegenerative disease in a subject, comprising administering to the subject a therapeutically effective amount of a compound of formula (I) and an antigen or a therapeutically effective amount of a compound of formula (II). In some embodiments, the present application can be used to treat a neurodegenerative disease (e.g., Alzheimer's disease).
[0268] It is to be understood that the scope of the present disclosure includes all possible combinations of the embodiments disclosed herein.
[0269] The following examples are merely illustrative of certain embodiments of the invention and should not be construed as limiting the invention in any way. EXAMPLES
[0270] General Information – Materials and Methods All commercially available materials were used without further purification, except for boron trifluoride diethyl etherate and trifluoromethanesulfonic anhydride, which were distilled under N2 at 1 atm from calcium hydride and phosphorus pentoxide, respectively. All manipulations with air-sensitive reagents and chemical reactions were carried out under a dry argon atmosphere using standard Schlenk techniques. Air- and moisture-sensitive liquids and solutions were transferred by syringe. When anhydrous conditions were required, the appropriate reagents were dried by azeotropic removal of water with dry toluene. Molecular sieves were activated at 350 °C, crushed immediately before use, and then dried under vacuum. Organic solutions were concentrated by rotary evaporator under reduced pressure at <40 °C. Column chromatography was performed using 230-400 mesh silica gel. Analytical thin-layer chromatography (TLC) was performed using aluminum-backed sheets precoated with 230-400 mesh silica gel 60 containing a fluorescent indicator (F254). Preparative TLC (Analtech Uniplates) was performed using glass-backed sheets precoated with 500 microns of silica gel containing a fluorescent indicator (F254). TLC plates were visualized under UV light (254 nm) by staining with cerium ammonium molybdate (CAM), phosphomolybdic acid (PMA), or a 5% sulfuric acid solution in ethanol.
[0271] 1 H, APT 13 C, COSY, and HSQC nuclear magnetic resonance (NMR). 1 H, APT 13 C, COSY, and HSQC spectra were obtained on a Bruker Avance III instrument (600 MHz 1 H NMR and APT at 151MHz 13 C NMR). Chemical shifts are expressed in parts per million (δ scale) downstream from tetramethylsilane and referenced to residual protons in the NMR solvent (CDCl3: δ 7.26 for 1H NMR; 13 C NMR δ 77.00; Methanol-d4: 1 H NMR shows δ 3.31. 13δ 49.15 for C NMR). Data are expressed as follows: chemical shift, multiplicity (s=singlet, brs=broad singlet, d=doublet, t=triplet, q=quartet, m=multiplet and / or multiple resonances), coupling constants in Hertz (Hz), integration, assignment.
[0272] RP-HPLC / LC-MS and ESI+-MS. All reversed-phase RP-HPLC analyses / purifications were performed on a Waters 1525 binary gradient system (solvent A = 0.05% TFA in HO; solvent B = 0.05% TFA in CHCN) equipped with a Waters 2998 photodiode array detector (PDA) coupled to a low-resolution single quadrupole mass spectrometer (SQD2 Waters Corporation). Absorbance was monitored at wavelengths between 190-400 nm or 210-600 nm. Low-resolution mass spectra were recorded on a Waters SQD2 equipped with an electrospray ionization source (ESI) coupled to the Waters RP-HPLC system described above.
[0273] HR-ESI-MS. High-resolution electrospray ionization mass spectrometry (HR-ESI-MS) was performed on a Waters LCT Premier XE (Waters, Milford, MA, USA) in W-optics positive ionization scan mode. Mass spectrometry parameters were optimized to achieve the best signal-to-noise ratio: capillary voltage 1 kV, sample cone voltage 100 V, desolvation gas flow rate 600 Lh. -1 , Cone gas flow rate 50Lh -1, desolvation temperature 350 °C, power supply temperature 150 °C. The instrument was calibrated in the range of m / z 200-2000 using a standard NaI solution (1 μM) before the measurements. To minimize the accuracy of the measurements, leucine enkephalin was used as the lock mass reference [2M+Na], m / z 1111,5459. Data analysis was performed using Masslynx software version 4.1 (Waters, Milford, MA, USA). Characterization by MS was confirmed after comparing the experimental isotopic patterns with the theoretical isotopic patterns.
[0274] MALDI-TOF-HR-MS: Compounds 23 and 24 were desalted using ZipTip® C4 microcolumns (Millipore) and eluted onto a GroundSteel massive384 target (Bruker Daltonics) using 0.5 μL of SA (sinapic acid, 10 mg / ml, in [70:30] acetonitrile:0.1% trifluoroacetic acid) matrix. Matrix-assisted laser desorption / ionization time-of-flight high-resolution mass spectrometry (MALDI-TOF-HR-MS) analysis was performed on an Autoflex III Samrtbeam MALDI-TOF spectrometer (Bruker Daltonics) in linear mode with the following settings: 8,000-100,000 Th window, linear positive mode, ion source 1: 20 kV, ion source 2: 18.5 kV, lens: 9 kV, 120 ns ion delay extraction, high gated ion suppression up to 1000 Mr. Mass calibration was performed externally using a protein 1 standard calibration mixture (Bruker Daltonics) of the same range as the samples. Data acquisition was performed using FlexControl 3.0 software (Bruker Daltonics), and peak peaking and subsequent spectral analysis was performed using FlexAnalysis 3.0 software (Bruker Daltonics).
[0275] Solid-phase peptide synthesis (SPPS). All (glyco)peptides were synthesized using a standard 9-fluorenylmethoxycarbonyl (Fmoc) / tert-butyloxycarbonyl (tBu) protection strategy. Automated SPPS was performed on a CEM Liberty Blue™ microwave-assisted synthesizer using default cycles. Fmoc deprotection cycles were performed using 20% piperidine in DMF at 85-90 °C for 1 min under microwave irradiation. Amino acid (AA) couplings were performed using 5 equivalents of AA (0.2 M) in the presence of N,N'-diisopropylcarbodiimide (DIC) and ethyl cyano(hydroxyimino)acetate (Oxyma Pure) at 85-90 °C for 2 min under microwave irradiation. Once the sequence was completed, the resin was transferred to a solid-phase peptide synthesis vessel equipped with a sintered glass filter and washed extensively with MeOH before being treated with cleavage cocktail. Sugar-amino acid building block 17 (Scheme S2) was coupled manually by suspending the resin in a solid-phase peptide synthesis vessel after adding the reagents and gently mixing the suspension with a stream of N2.
[0276] Synthesis Example Example 1: Prior art compound 13 [CP-III-066]
[0277] [ka]
[0278] 13[CP-III-066](C 59 H 95 NO 20 ) data were consistent with a previous report by Ghirardello et al. (Chem. Commun. 2020, 56(5), 719-722).
[0279] HPLC: R = 17.57 min, gradient = 20 to 100% B solvent (30 min), λ max = 200 nm. LRMS (ESI + -MS): m / z (monoisotropic) [M+H] +Calculated for 1138.65, Found 1138.72. HRMS (MALDI-TOF): m / z (monoisotropic) [M+Na] + The calculated value was 1160.6336 and the actual value was 1160.6293. 1 H-NMR (600MHz, CD3OD) characteristic resonance: δ 9.31(s, 1H), 5.38(d, J=1.9Hz, 1H), 5.34(d, J=7.9Hz, 1H), 5.31(t, J=3.5, 1H), 4.50~4.47(m, 2H), 4.34-4.30(m, 1H), 3.95-3.90(m, 3H), 3.87-3.75(m, 4H), 3.69(td, J=6.6, 1.7Hz, 1H), 3.57-3.49(m, 2H), 3.46(ddd, J=10.4, 8.9, 5.4Hz, 1H), 3.41(dd, J=11.6, 6.9Hz, 1H), 3.23-3.17(m, 2H), 2.94(dd, J=14.3, 4.6Hz, 1H), 1.41(s, 3H), 1.02(s, 3H), 1.01(s, 3H), 0.96(s, 3H), 0.88(s, 3H), 0.78(s, 3H).
[0280] Example 2: Synthesis of Compound 25 (General Formula (I))
[0281] [ka]
[0282] QA (oxime) adjuvant 25 [RF-IV-045]. A solution of NH2OH·HCl (10.3 mg, 21.4 equiv.) and NaOAc (5.8 mg, 32.3 equiv.) in HO / CH3CN (1:3, 2.4 mL) was added to saponin mutant 13 (4.4 mg, 1.0 equiv.), followed by aqueous NH2OH 50% (100 μL, 490 equiv.). The reaction mixture was stirred at 45 °C for 4 h and then directly purified by RP-HPLC (30% acetonitrile in water with 0.05% TFA for 5 min, then 30–64% for 12 min). The main peak was collected and lyophilized to give saponin oxime 25 (4.1 mg, 92% yield) as a white foam.
[0283] HPLC: R = 17.25 min, gradient = 20–100% acetonitrile / water (30 min), λ max= 200 nm. LRMS(ESI + -MS): m / z (monoisotropic) [M+2H] 2+ Calculated for 577.33, Found: 577.49; [M+H] + Calculated value: 1153.66, actual value: 1153.65. 1H NMR(400MHz, メタノール-d4):δ 7.13(s, 1H, CHNOH), 5.37(d, J=1.9 Hz, 1H, H-1 Rha), 5.34(d, J=7.7Hz, 1H, H-1 N-Gal), 5.30(t, J=3.6Hz, 1H, H-12 QA), 4.51-4.46(m, 2H, H-1 Xyl, H-16 QA), 4.34-4.31(m, 1H, H-4 N-Gal), 3.96-3.90(m, 3H, H-3 & H-2 N-Gal, H-2 Rha), 3.90-3.75(m, 3H, H-5a Xyl, H-5 & H-3 Rha), 3.69(td, J=6.6, 1.7Hz, 1H, H-5 N-Gal), 3.58-3.45(m, 4H, H-4 Rha, H-3 QA, H-4 Xyl, H-6a N-Gal), 3.45-3.38(m, 1H, H-6b N-Gal), 3.36-3.11(m, 3H, H-3 & H-2 Xyl, H-5b Xyl), 2.94(dd, J=14.2, 4.5Hz, 1H, H-18 QA), 2.40-2.23(m, 5H, H-19a QA, CH2(a)CONH & CH2(a’)CO2H アシル), 2.02-1.87(m, 4H, H-11a,b, H-22a & H-21a QA), 1.87-1.74(m, 1H, H-22b QA), 1.74-1.55(m, 9H, H-2a,b, H-9, H-1a & H-15a QA, CH 2(b) CH2CONH & CH 2(b’) CH2CO2H アシル), 1.55-1.40(m, 3H, H-7a, H-15b & H-6a QA), 1.39-1.24(m, 20H,[1.39 s, 3H, CH3C-27 QA], H-7b & H-6b QA, CH3Rha, 6×CH 2(c)internal acyl), 1.21-1.11(m, 1H, H-21 QA), 1.11-0.98(m, 9H,[1.03 s, 3H, CH3C-24 QA],[1.01 s, 3H, CH3C-25 QA], H-1b, H-19b & H-5 QA), 0.96(s, 3H, CH3C-30 QA), 0.88(s, 3H, CH3C-29 QA), 0.77(s, 3H, CH3C-26 QA). 13 C NMR (101MHz, methanol-d4): δ 178.5(CONH acyl), 177.8(CO2H acyl), 177.1(CO[C-28] QA), 161.0(CNOH), 144.8(C-13 QA), 123.3(C-12 QA), 107.0(C-1 Xyl), 101.4(C-1 Rha), 95.5(C-1 N-Gal), 84.2(C-4 Rha), 78.3(C-3 Xyl), 76.5(C-3 QA), 76.3(C-5 N-Gal), 76.1(C-2 Xyl), 74.8(C-3 & C-2 N-Gal), 74.7(C-16 QA), 72.2(C-3 Rha), 71.9(C-2 Rha), 71.0(C-4 Xyl), 68.9(C-5 Rha), 67.3(C-5 Xyl), 61.7(C-6 N-Gal), 52.9(C-5 QA), 52.5(C-4 N-Gal), 50.0(C-17 QA), 48.2(C-9 QA), 48.0(C-19 QA), 47.4(C-4 QA), 42.7(C-14 QA), 42.3(C-18 QA), 41.1(C-8 QA), 39.7(C-1 QA), 37.7(C-10 QA), 36.8(CH 2(a) CONH Acyl), 36.5(C-15 & C-21 QA), 35.0(CH 2(a’) CO2H Acyl QA), 33.8(C-7 QA), 33.4(CH3C-29), 32.0(C-22 QA), 31.3(C-20 QA), 30.6, 30.5, 30.4, 30.3, 30.2(6×CH 2(c) Internal acyl), 27.23(CH 2(b)CH2CONH acyl), 27.20(CH3C-27 QA), 27.0(C-2 QA), 26.1(CH 2(b’) CO2H acyl), 24.9(CH3C-30 QA), 24.5(C-11 QA), 20.9(C-6 QA), 18.4(CH3Rha), 17.8(CH3C-26 QA), 16.6(CH3C-25 QA), 12.0(CH3C-24 QA).
[0284] Example 3: Synthesis of Compounds 1-2 (General Formula (III)) and Compounds 3-4 (General Formula (II)) The synthesis of compounds 1 to 4 is shown in the following scheme.
[0285] [ka]
[0286] Description: DMF (dimethylformamide), DIPEA (N,N-diisopropylethylamine), RT (room temperature), TFA (trifluoroacetic acid). Yields after RP-HPLC purification and lyophilization are given in brackets.
[0287] 3.1. Preparation of MUC1 and TnMUC1 B cell epitopes plus polyethylene glycol (PEG) spacer MUC1 peptide “GVTSAPDTRPAPGSTA” (5) [CP-I-018, CP-I-052].
[0288] [ka]
[0289] Resin-bound sequence 15 was synthesized on 192 mg of Rink Amide MBHA resin (loading = 0.520 mmol / g) by microwave-assisted automated SPPS (CEM Liberty Blue™) using commercially available amino acids (Novabiochem®). Upon completion of the sequence, the resin was washed with MeOH (5 × 10 mL), transferred to a 50 mL Falcon tube, and treated with 10 mL of TFA / TIS / H2O (95 / 2.5 / 2.5) cocktail. After gentle agitation (rocker platform) for 2 h at room temperature, the filtrate was added to ice-cold Et2O to induce precipitation of crude peptide 5. After three cycles of (i) centrifugation (3000 rpm at room temperature), (ii) removal of the supernatant, and (iii) resuspension in ice-cold Et2O, the precipitate was dried under vacuum to give 150 mg of crude product 5 as a white powder. Purification of the crude product was performed by RP-HPLC (5% solvent B for 5 min, then 5–15% for 25 min) and the collected fractions were lyophilized to give 65.28 mg of 5(C 61 H 102 N 20 O 23 ) was obtained as a white foam in 44% overall yield.
[0290] HPLC: R = 13.03 min, gradient = 5–40% B solvent (30 min), λ max = 200 nm. LRMS (ESI + -MS): m / z (monoisotropic) [M+2H] 2+ Calculated for 742.38, found 742.41; [M+H] + Calculated value for 1483.75, found value 1483.61. HRMS (ESI + -MS): m / z (monoisotropic) [M+Na] + The calculated value was 1505.7324 and the actual value was 1505.7296.
[0291] compound 17
[0292] [ka]
[0293] Fmoc-Thr(Ac3-α-GalNAc)-CO2H 17[CP-I-024,CP-I-054] (C 33 H 38 N2O 13 ) data were consistent with a previous report by Payne et al. (J. Am. Chem. Soc. 2007, 129(44), 13527-13536).
[0294] HPLC: R = 18.27 min, gradient = 20 to 100% B solvent (30 min), λ max = 200 nm. LRMS (ESI + -MS): m / z (monoisotropic) [M+H] + Calculated value for 671.25, found value 671.32. HRMS (ESI + -MS): m / z (monoisotropic) [M+Na] + The calculated value was 693.2272 and the actual value was 693.2315. 1 H-NMR (600MHz, CDCl3 / CD3OD 1:1 v / v, major rotamers reported) δ 7.76(d, J=7.6Hz, 2H), 7.66-7.62(m, 2H), 7.39-7.35(m, 2H), 7.32-7.28(m, 2H), 5.37-5.36(m, 1H), 5.03(dd, J=11.5, 3.3Hz, 1H), 4.94(d, J=3.9Hz, 1H), 4.54-4.35(m, 4H), 4.30-4.03(m, 6H), 2.14(s, 3H), 2.03(s, 3H), 1.96(s, 3H), 1.92(s, 3H), 1.24(d, J=6.5Hz, 3H).
[0295] TnMUC1 glycopeptide “GVTSAPDT(αGalNAc)RPAPGSTA” (6) [CP-I-050, CP-I-056, CP-I-058, CP-I-062, CP-I-068].
[0296] [ka]
[0297] Resin-bound sequence 16 was synthesized on 192 mg of Rink Amide MBHA resin (loading = 0.520 mmol / g) by microwave-assisted automated SPPS (CEM Liberty Blue™) using commercially available amino acids (Novabiochem®). The functionalized resin was then transferred to a solid-phase peptide synthesis vessel equipped with a sintered glass filter, and coupling of the sugar amino acid Fmoc-Thr(Ac3-α-GalNAc)-CO2H 17 was performed manually (Z. Wu, et al. Chem. Commun. 2010, 46, 5773-5774). After two cycles of swelling (10 min) / solvent filtration, first with CH2Cl2 and then with DMF, sequence 16 was suspended in 2.0 mL of DMF. In a separate flask, a mixture of DIPEA (80 μL, 0.46 mmol, 4.6 equiv), HATU (60.0 mg, 0.158 mmol, 1.6 equiv), HOAt (21.0 mg, 0.154 mmol, 1.5 equiv), and 17 (112.65 mg, 0.168 mmol, 1.7 equiv) in 5.0 mL DMF was stirred at room temperature for 10 min and then added to the reactor. The suspension was stirred using a stream of N2, and after 4 h at room temperature, the solvent was removed through a filter and the resin was washed with CHCl2 (5 × 10 mL) and DMF (5 × 10 mL). The resin-bound sequence 18 was then transferred back to the peptide synthesizer, and fragment 19 was completed by automated SPPS. The resin was transferred to a glass reactor, washed with MeOH (5 × 10 mL), and treated with 60% hydrazine in MeOH for 2 h at room temperature under a stream of N2 to remove the acetyl protecting group. After washing with MeOH (5 × 10 mL) and CHCl (5 × 10 mL), the resin was finally transferred to a 50 mL Falcon tube and treated with 10 mL of TFA / TIS / H0 (95 / 2.5 / 2.5) cocktail. After three cycles of gentle agitation (rocker platform) at room temperature for 2 h, the filtrate was added to ice-cold Et0 to induce precipitation of crude glycopeptide 6. After (i) centrifugation (3000 rpm at room temperature), (ii) removal of the supernatant, and (iii) resuspension in ice-cold Et0, the precipitate was dried under vacuum to give 170 mg of crude product 6 as a white powder.Purification of the crude product was performed by RP-HPLC followed by 5–15% for 25 min) and the collected fractions were lyophilized to give 62.41 mg of TnMUC1 glycopeptide 6 (C69H115N21O28) as a white foam in 37% overall yield.
[0298] HPLC: R = 12.74 min, gradient = 5–40% B solvent (30 min), λ max = 200 nm. LRMS (ESI + -MS): m / z (monoisotropic) [M+3H] 3+ Calculated for 562.95, found 563.07; [M+2H] 2+ Calculated for 843.92, found 844.15; [M+H] + Calculated for 1686.83, Found 1686.30. HRMS (MALDI-TOF): m / z (monoisotropic) [M+H] + The calculated value was 1686.8289 and the actual value was 1686.8384.
[0299] compound 20
[0300] [ka]
[0301] 20[CP-III-030] (C 16 H 30 O7) data were consistent with a previous report by Wittmann et al. (J. Org. Chem. 1998, 63(15), 5137-5143).
[0302] HPLC: R = 18.42 min, gradient = 20 to 100% B solvent (30 min), λ max = 200 nm. LRMS (ESI + -MS): m / z (monoisotropic) [M+H] + Calculated value 335.21, measured value 335.27, [M+Na] + Calculated value for 357.19, found value 357.31. HRMS (ESI+ -MS): m / z (monoisotropic) [M+Na] + The calculated value was 357.1925 and the actual value was 357.1889. 1 H-NMR (600MHz, CDCl3) δ 4.01(s, 4H), 3.75-3.66(m, 8H), 1.46(s, 18H).
[0303] para-Nitrophenol-activated diethylene glycol (DEG)-derived homobifunctional linker (7) [CP-III-032].
[0304] [ka]
[0305] A solution of 3,6,9-trioxaundecane-1,11-dioic acid di-tert-butyl ester 20 (1.038 g, 3.07 mmol, 1.0 equiv) in a mixture of TFA / CHCl (1:1, 3.0 mL) was stirred at room temperature for 4 h. The solvent mixture was removed under high vacuum through a Schlenk tube and coevaporated with dry toluene (3 × 1 mL). The resulting diacid was dissolved in dry CHCl (7.0 mL) and the resulting solution was cooled to 0 °C. Oxalyl chloride (1.6 mL, 18.63 mmol, 6.1 equiv) and a catalytic amount of dry DMF (60 μL) were added and the mixture was stirred at 0 °C for 10 min and then passively warmed to room temperature over 1 h. To remove volatiles, the reaction mixture was concentrated under reduced pressure in a Schlenk tube and dry CHCl (7.0 mL) was added. This procedure was repeated twice and then the reaction mixture was cooled to 0 °C again. In a separate flask, azeotropically dried (dry toluene: 3 × 1 mL) paranitrophenol (940 mg, 6.76 mmol, 2.2 equiv.) was dissolved in a CHCl / THF (1:1, 14 mL) mixture and the resulting solution was cooled to -20 °C. To this solution, the mixture containing the activated diacid was added via cannula, followed by dry pyridine (550 μL, 6.94 mmol, 2.3 equiv.). The reaction mixture was stirred at -20 °C for 15 min and then passively warmed to room temperature. After 2 h, the reaction mixture was diluted with CHCl (120 mL) and washed with 1% aqueous AcOH (50 mL). The organic phase was dried over MgSO, filtered, and the solvent was removed under vacuum to give 1.54 g of a brown solid as crude product. The residue was purified by silica gel flash chromatography (eluent: 0–20% AcOEt in toluene) to give 836 mg of linker 7 (C 20 H 20 N2O 11 ) was obtained as a white solid in 59% yield over two steps.
[0306] HPLC: R = 23.56 min, gradient = 20 to 100% B solvent (30 min), λ max = 200 nm. LRMS (ESI + -MS): m / z (monoisotropic) [M+H] +Calculated value for 465.11, measured value 465.12. HRMS (ESI + -MS): m / z (monoisotropic) [M+Na] + Calculated value 487.0965, measured value 487.0955. TLC:R f =0.32(toluene / AcOEt, 7:3, v / v). 1 H-NMR(600MHz, CDCl3) δ 8.28-8.25(m, 4H, Ph), 7.33-7.29(m, 4H, Ph), 4.45(s, 4H, COCH2O) 3.86-3.83(m, 4H, O-CH2CH2-O), 3.78-3.76(m, 4H, O-CH2CH2-O). 13 C NMR (151MHz, CDCl3): δ=168.26(CO), 154.98(Ph), 145.72(Ph), 125.41(Ph), 122.36(Ph), 71.38(O-CH2CH2-O), 70.87(O-CH2CH2-O), 68.72(COCH2).
[0307] para -nitrophenol-activated DEG-containing MUC1 and TnMUC1 sequences ( 8 and 9 ) [CP-I-118, CP-III-016, CP-III-046, CP-III-090, CP-III-092].
[0308] [ka]
[0309] To a stirred solution of 5 or 6 (1.0 equiv.) in dry DMF containing DIPEA (2.5 equiv.) was added a solution of 7 (5.0 equiv.) in dry DMF (final concentration = 32 mM for 7). The reaction mixture immediately turned yellow and was continued stirring at room temperature. After 1 h, the reaction was quenched by slow addition of 0.05% TFA solution in H2O / CH3CN (1:1) until the yellow color disappeared, then directly purified by RP-HPLC (15% solvent B for 5 min, then 15-50% for 25 min). The collected fractions were lyophilized to afford the title compound as a white foam.
[0310] Data 8 (C 75 H 117 N 21 O 31 ): Prepared on a 9.62 μmol scale, yield 12.71 mg, 73%. HPLC:t R = 17.10 min, gradient = 5–70% B solvent (30 min), λ max = 200 nm. LRMS (ESI + -MS): m / z (monoisotropic) [M+3H] 3+ Calculated for 603.62, found 603.52; [M+2H] 2+ Calculated for 904.92, found for 904.68; [M+H] + Calculated for 1808.83, Found 1808.49. HRMS (MALDI-TOF): m / z (monoisotropic) [M+H] + The calculated value was 1808.8293 and the actual value was 1808.8181.
[0311] 9(C 83 H 130 N 22 O 36 ) data: Prepared on a scale of 9.47 μmol, yield 13.40 mg, 70%. HPLC:t R = 16.73 min, gradient = 5–70% B solvent (30 min), λ max = 200 nm. LRMS (ESI + -MS): m / z (monoisotropic) [M+3H] 3+ Calculated for 671.31, found 671.38; [M+2H] 2+ Calculated value 1006.46, measured value 1006.47; [2M+3H] 3+ Calculated value 1341.61, measured value 1341.51; [3M+4H] 4+ Calculated for 1509.18, found 1508.87; [M+H] + Calculated value 2011.91, measured value 2012.21. HRMS (ESI + -MS): m / z (monoisotropic) [M+H] + The calculated value was 2011.9087 and the actual value was 2011.9045.
[0312] 3.2. Preparation of the Two-Component Conjugates QA-MUC1 (1) and QA-TnMUC1 (2) Prior art compound 10 [CP-I-100]
[0313] [ka]
[0314] 10[CP-I-100](C 53 H 86 N2O 18 ) data were consistent with a previous report by Fernandez-Tejada et al. (Nat. Chem. 2014,6(7),635-643).
[0315] HPLC: R = 12.64 min, gradient = 20 to 100% B solvent (30 min), λ max = 200 nm. LRMS (ESI + -MS): m / z (monoisotropic) [M+H] + Calculated for 1039.60, Found 1039.68. HRMS (MALDI-TOF): m / z (monoisotropic) [M+Na] + The calculated value was 1061.5764 and the actual value was 1061.5720. 1H-NMR (600MHz, CD3OD) Characteristic resonances: δ 9.31(s, 1H), 5.42(d, J=1.8Hz, 1H), 5.34(t, J=3.5Hz, 1H), 5.31(d, J=3.6Hz, 1H), 4.51-4.48(m, 2H), 4.37(dd, J=4.7, 1.7Hz, 1H), 3.96(dd, J=9.5, 4.7Hz, 1H), 3.91-3.80(m, 5H), 3.79-3.76(m, 1H), 3.72(td, J=6.5, 1.8Hz, 1H), 3.59-3.51(m, 2H), 3.49-3.41(m, 2H), 3.24-3.17(m, 2H), 2.94-2.91(m, 3H), 2.43-2.27(m, 3H), 2.02-1.90(m, 4H), 1.41(s, 3H), 1.34(d, J=6.1Hz, 3H), 1.08-1.04(m, 1H), 1.02(s, 3H), 1.01(s, 3H), 0.95(s, 3H), 0.88(s, 3H), 0.77(s, 3H).
[0316] Two-component synthetic vaccine containing MUC1 and TnMUC1 (1 and 2) [CP-I-128, CP-III-052, CP-III-098, CP-III-124, CP-III-128].
[0317] To a vial containing amino-terminal saponin 10 (1.0 equiv.) as well as para-nitrophenol-activated (glyco)peptides 8 or 9 (1.5 equiv.), a solution of DIPEA (3.0 equiv.) in dry DMF was added (final concentration = 2.5 mM for 10). The reaction mixture quickly turned to a yellow solution, which was stirred at room temperature for 1 h. The reaction was quenched by slow addition of a 0.05% TFA solution in H2O / CH3CN (1:1) until the yellow color disappeared, and then directly purified by RP-HPLC (20% solvent B for 5 min, then 20-100% for 25 min). The collected fractions were lyophilized to give the title compound as a white foam.
[0318] 1(C 122 H 198 N 22 O46 ) data: Prepared on a 3.18 μmol scale, yield 7.72 mg, 90%. HPLC:t R = 11.98 min, gradient = 20 to 100% B solvent (30 min), λ max = 200 nm. LRMS (ESI + -MS): m / z (monoisotropic) [M+3H] 3+ Calculated for 903.47, Found 903.45; [M+2H] 2+ Calculated value 1354.70, measured value 1355.00; [2M+3H] 3+ Calculated value 1805.93, measured value 1805.96; [3M+4H] 4+ Calculated value 2031.55, measured value 2031.06; [4M+5H] 5+ Calculated value 2166.91, measured value 2166.90; [5M+6H] 6+ Calculated value 2257.16, found value 2257.63; [M+H] + Calculated for 2708.39, Found 2708.56. HRMS (MALDI-TOF): m / z (monoisotropic) [M+H] + The calculated value was 2708.3900 and the actual value was 2708.3990.
[0319] 2(C 130 H 211 N 23 O 51 ) data: Prepared on a 3.59 μmol scale, yield 8.75 mg, 84%. HPLC:t R = 12.00 min, gradient = 20 to 100% B solvent (30 min), λ max = 200 nm. LRMS (ESI + -MS): m / z (monoisotropic) [M+3H] 3+ Calculated value 971.16, measured value 971.02; [3M+5H] 5+ Calculated value 1747.29, measured value 1746.49; [2M+3H] 3+ Calculated value 1941.31, measured value 1940.99; [3M+4H] 4+ Calculated value 2183.85, measured value 2184.16; [4M+5H]5+ Calculated value 2329.38, measured value 2329.22; [5M+6H] 6+ Calculated for 2426.39, found 2426.70; [M+H] + Calculated for 2911.47, found 2911.94. HRMS (MALDI-TOF): m / z (monoisotropic) [M+H] + The calculated value was 2911.4703 and the actual value was 2911.4693.
[0320] 3.3. Preparation of Ternary Conjugates QA(PV)-MUC1 (3) and QA(PV)-TnMUC1 (4) Aminoxy-functionalized PV 103~115 Peptide (11) [CP-III-034].
[0321] [ka]
[0322] Resin-bound sequence 12 was synthesized on 94 mg of FmocThr(tBu)Wang resin (loading = 0.530 mmol / g) by microwave-assisted automated SPPS (CEM Liberty Blue™) using commercially available amino acids (Novabiochem®). The functionalized resin was then transferred to a solid-phase peptide synthesis vessel equipped with a sintered glass filter, washed with MeOH (5 × 5 mL), and subjected to two cycles of swelling (10 min) / solvent filtration, first with CHCl and then with DMF. Resin 12 was suspended in 2.0 mL of DMF, then DIPEA (8.75 μL, 0.05 mmol, 1.0 equiv) and Boc-aminooxyacetic acid N-hydroxysuccinimide ester (57.65 mg, 0.20 mmol, 4.0 equiv) were added, and the suspension was stirred using a stream of N. After 2 h at room temperature, the resin was washed with DMF (5 × 5 mL), MeOH (5 × 5 mL), and CHCl (5 × 5 mL), transferred to a 50 mL Falcon tube, and treated with 5 mL of TFA / 50% aqueous NHOH / TIS / DTT HO (90 / 5 / 2.5 / 2.5) cocktail. After 2 h of gentle agitation (rocker platform) at room temperature, the filtrate was added to ice-cold EtO to induce precipitation of crude peptide 11. After three cycles of (i) centrifugation (3000 rpm at room temperature), (ii) removal of the supernatant, and (iii) resuspension in ice-cold EtO, the precipitate was dried under vacuum, resuspended in 10 mL of 1% aqueous AcOH, and lyophilized to give 103 mg of crude product 11 as a white powder. Purification of the crude product was performed by RP-HPLC (5% solvent B for 5 min, then 5–65% for 25 min) and the collected fractions were lyophilized to give 30.35 mg of 11 (C 81 H 124 N 18 O 21 ) was obtained as a white foam in 36% overall yield.
[0323] HPLC: R = 10.49 min, gradient = 20 to 100% B solvent (30 min), λ max = 200 nm. LRMS (ESI + -MS): m / z (monoisotropic) [M+3H] 3+Calculated for 562.65, found 562.78; [M+2H] 2+ Calculated for 843.47, found for 843.57; [M+H] + Calculated value 1685.93, found value 1685.94. HRMS (ESI + -MS): m / z (monoisotropic) [M+H] + The calculated value was 1685.9266 and the actual value was 1685.9308.
[0324] PV 103~115 MUC1- and TnMUC1-containing three-component synthetic vaccines [CP-III-040, CP-III-058, CP-III-112, CP-III-126], containing peptide sequences (3 and 4).
[0325] 1 or 2 (1.0 equiv., 1.5 mM) and aminooxy-functionalized PV in a mixture of H2O / CH3CN (2:1) containing 0.05% TFA 103~115 A solution of peptide 11 (2.0 equiv.) was stirred and heated at 40° C. for 24 h. The reaction mixture was directly purified by RP-HPLC (30% solvent B for 5 min, then 30-80% for 25 min). The collected fractions were lyophilized to give the title compound as a white foam.
[0326] 3(C 203 H 320 N 40 O 66 ) data: Prepared on a scale of 1.14 μmol, yield 4.46 mg, 89%. HPLC:t R = 12.90 min, gradient = 20 to 100% B solvent (30 min), λ max = 200 nm. LRMS (ESI + -MS): m / z (monoisotropic) [M+6H] 6+ Calculated for 730.06, Found 730.32; [M+5H] 5+ Calculated for 875.87, found 876.04; [M+4H] 4+ Calculated for 1094.58, found 1094.78; [M+3H] 3+ Calculated value 1459.10, measured value 1459.34; [2M+5H]5+ Calculated for 1750.72, found 1750.70; [M+2H] 2+ Calculated value for 2188.15, measured value 2188.30. HRMS (ESI + -MS): m / z (monoisotropic) [M+H] + The calculated value was 4375.2982 and the actual value was 4375.2856.
[0327] 4(C 211 H 333 N 41 O 71 ) data: Prepared on a 0.86 μmol scale, yield 2.87 mg, 73%. HPLC:t R = 12.59 min, gradient = 20 to 100% B solvent (30 min), λ max = 200 nm. LRMS (ESI + -MS): m / z (monoisotropic) [M+6H] 6+ Calculated for 763.90, found 764.32; [M+5H] 5+ Calculated for 916.48, Found 916.86; [M+4H] 4+ Calculated for 1145.35, found 1145.46; [M+3H] 3+ Calculated value 1526.80, measured value 1527.14; [2M+5H] 5+ Calculated for 1831.96, found 1832.14; [M+2H] 2+ Calculated for 2289.69, Found 2289.18. HRMS (MALDI-TOF): m / z (monoisotropic) [M+H] + The calculated value was 4578.3785 and the actual value was 4578.3799.
[0328] Example 4: Synthetic Saponin-PV 103~115 Synthesis of conjugate (14) (compound of formula IV) [CP-III-136]
[0329] [ka]
[0330] 13 (2.07 mg, 1.82 μmol, 1.0 equiv.) and aminooxy-functionalized PV in a mixture of HO / CHCN (1:2) containing 0.05% TFA 103~115 A stirred solution of peptide 11 (6.48 mg, 3.84 μmol, 2.1 equiv.) (final concentration = 1.5 mM for 13) was heated at 40 °C for 24 h. The reaction mixture was directly purified by RP-HPLC (20% solvent B for 5 min, then 20-100% for 25 min). The collected fractions were lyophilized to give 2.72 mg of 14 (C140H217N19O40) as a white foam in 53% yield.
[0331] HPLC: R = 15.80 min, gradient = 20 to 100% B solvent (30 min), λ max = 200 nm. LRMS (ESI + -MS): m / z (monoisotropic) [M+3H] 3+ Calculated for 935.86, Found 935.64; [M+2H] 2+ Calculated value 1403.28, measured value 1403.58; [2M+3H] 3+ Calculated value 1870.71, measured value 1871.08; [3M+4H] 4+ Calculated value 2104.42, measured value 2105.25; [4M+5H] 5+ Calculated value 2244.65, found value 2245.01; [M+H] + Calculated value 2805.56, observed value 2805.39; (most intense peak of isotopic cluster r) [M+H] + Calculated for 2806.56, Found 2806.55. HRMS (MALDI-TOF): m / z (monoisotropic) [M+Na] + The calculated value was 2827.5419 and the actual value was 2827.5482.
[0332] Example 5: PV 103~115 Peptide (22) [CP-III-042]
[0333] [ka]
[0334] Resin-bound sequence 21 was synthesized on 94 mg of FmocThr(tBu)Wang resin (loading = 0.530 mmol / g) by microwave-assisted automated SPPS (CEM Liberty Blue™) using commercially available amino acids (Novabiochem®). Upon completion of the sequence, the resin was washed with MeOH (5 x 5 mL), transferred to a 50 mL Falcon tube, and treated with 5 mL of TFA / thioanisole / TIS / DTT (96 / 2 / 2 / 2) cocktail. After gentle agitation (rocker platform) at room temperature for 2 h, the filtrate was added to ice-cold Et2O to induce precipitation of crude peptide 22. After three cycles of (i) centrifugation (3000 rpm at room temperature), (ii) removal of the supernatant, and (iii) resuspension in ice-cold Et2O, the precipitate was dried under vacuum, resuspended in 10 mL of 1% aqueous AcOH, and lyophilized to give 101 mg of crude product 22 as a white powder. Purification of the crude product was performed by RP-HPLC (15% solvent B for 5 min, then 15–85% for 25 min) and the collected fractions were lyophilized to give 44.35 mg of 22 (C 79 H 121 N 17 O 19 ) was obtained as a white foam in 55% overall yield.
[0335] HPLC: R = 9.61 min, gradient = 20~100% B solvent (30 min), λ max = 200 nm. LRMS (ESI + -MS): m / z (monoisotropic) [M+3H] 3+ Calculated for 538.31, found 538.42; [M+2H] 2+ Calculated value 806.96, measured value 806.81; [2M+3H] 3+ Calculated for 1075.61, found for 1075.93; [M+H] + Calculated for 1612.91, Found 1612.78. HRMS (MALDI-TOF): m / z (monoisotropic) [M+H] +The calculated value was 1612.9103 and the actual value was 1612.9175.
[0336] Example 6: MUC1 and TnMUC1 functionalized BSA (23 and 24) [CP-III-018-020-068] Figure 3 shows the preparation of BSA conjugates 23 and 24. To a stirred solution of BSA (Fisher Scientific, CAS:9048-46-8, 1.0 equiv.) in PBS (10 mM, pH 7.4) at a concentration of 37.5 μM, a solution of 8 or 9 (30 equiv.) in DMF (200 μL) was added. The reaction mixture was stirred at room temperature and gradually turned yellow. After 24 h, the reaction was quenched by slowly adding a 0.05% TFA solution in HO until the yellow color disappeared, and then directly purified by RP-HPLC (5% solvent B for 5 min, then 5-70% for 25 min). The collected fractions were lyophilized to give the title compound as a white foam.
[0337] Data for 23: Prepared on BSA at 0.030 μmol scale, yield: 1.85 mg, n=approximately 6.3.
[0338] Data for 24: Prepared on BSA at 0.045 μmol scale, yield: 2.86 mg, n=approximately 3.0.
[0339] "n" was calculated as follows: n = (MALDI-BSA) / EPITOPE; where "MALDI" is the most intense peak observed by MALDI-MS, "BSA" corresponds to the molecular weight of the native protein (66,463 Da), and "EPITOPE" corresponds to the mass increase of the conjugate relative to one unit of either the MUC1 (1,669 Da) or TnMUC1 (1,872 Da) epitope.
[0340] Example 7: Synthesis of compounds 26 and 28 (general formula (III)) and 27 and 29 (general formula (II)) Two-component and three-component saponin conjugates based on tumor-associated carbohydrate antigens (Tn and Gb3) were synthesized.
[0341] 7.1. Preparation of Tn antigen + polyethylene glycol (PEG3) spacer The following scheme illustrates the synthesis of a Tn antigen moiety functionalized with a PEG-based carboxy-terminal linker.
[0342] [ka]
[0343] Protected Fmoc-Tn(Thr)-PEG3 tert-butyl ester (32).
[0344] [ka]
[0345] To a solution of Tn-Thr acid 30 (T. Buskas, et al. Angew. Chem. Int. Ed. 2005, 44, 5985-5988; Z. Wu, et al. Chem. Commun. 2010, 46, 5773-5774) (47 mg, 70.2 μmol) in DCM (0.9 mL) was added HATU (29.4 mg, 77.3 μmol, 1.1 equiv.) and amino-TEG 3-t-butyl ester linker 31 (22.07 μL, 84.3 μmol, 1.2 equiv.). The mixture was cooled to 0° C. and 2,4,6-collidine (10.2 μL, 77.3 μmol, 1.1 equiv.) was added. After stirring at 0° C. for 1 h, the reaction was allowed to warm to room temperature and consumption of starting material was confirmed after 1 h by TLC (95:5 DCM / methanol). The resulting crude product was concentrated and dried under vacuum, and the residue was purified by silica gel column chromatography (DCM to 97:3 DCM / methanol) to give Tn(Thr)-TEG3 tert-butyl spacer 32 (53.9 mg, 82% yield) as a glassy solid.
[0346] TLC:R f 0.40(DCM); 1<h2 style=";text-align:left;direction:ltr">H NMR(400MHz, CDCl3):δ 7.74(d, J=7.5Hz, 2H, Ar-H Fmoc), 7.65-7.59(m, 3H, Ar-H Fmoc, NH, NHCO[Tn-TEG]), 7.42-7.34(m, 2H, Ar-H Fmoc), 7.33-7.26(m, 2H, Ar-H, H-3), 4.86(d, J=3.6Hz, 1H, H-1), 4.53-4.44(m, 2H, H-2, CHHa Fmoc), 4.41- 4.33(m, 1H, CHHb Fmoc), 4.30-4.12(m, 4H, CH Fmoc, CHα NHFmoc, H-5, CHα CH3[Thr]), 4.11-3.98(m, 2H, H-6a,b), 3.65(t, J=6.4Hz, 2H, CH<h2 style=";text-align:left;direction:ltr"> 2(y) <h2 style=";text-align:left;direction:ltr"> TEG), 3.61-3.52(m, 8H, 4×CH<h2 style=";text-align:left;direction:ltr"> 2(z) <h2 style=";text-align:left;direction:ltr"> TEG), 3.52-3.42(m, 2H, CH<h2 style=";text-align:left;direction:ltr"> 2(y’) <h2 style=";text-align:left;direction:ltr"> TEG), 3.42-3.36(m, 2H, , CH<h2 style=";text-align:left;direction:ltr"> 2(x’) <h2 style=";text-align:left;direction:ltr"> TEG), 2.45(t, J=6.4Hz, 2H, CH<h2 style=";text-align:left;direction:ltr"> 2(x) <h2 style=";text-align:left;direction:ltr"> TEG), 2.13(s, 3H, CH3[AcO C-4]), 1.99(s, 3H, CH3[AcO C-6]), 1.97(s, 3H, CH3[NHAc C-2 Gal Tn]), 1.96(s, 3H, CH3[AcO C-3]), 1.40(s, 9H, 3×(CH3)[<h2 style=";text-align:left;direction:ltr"> t <h2 style=";text-align:left;direction:ltr"> Bu]), 1.25(d, J=6.3Hz, 3H, CH3[Thr]).<h2 style=";text-align:left;direction:ltr"> 13 <h2 style=";text-align:left;direction:ltr"> C NMR(101MHz, CDCl3):δ 171.2(CO2<h2 style=";text-align:left;direction:ltr"> tBu), 171.1(CONH[C-2 Gal Tn]), 171.0(CO[AcO C-3]), 170.62(CO[AcO C-4]), 170.57(CO[AcO C-6]), 170.5(NHCO[Tn-TEG]), 157.0(CO[Fmoc]), 143.8, 141.3(C quaternary [Fmoc]), 127.8, 127.2, 125.2, 125.1, 120.04, 120.02(Ar Fmoc), 100.3(C-1), 80.9(C quaternary [ t Bu]), 78.2(CHα CH3[Thr]), 70.5, 70.4, 70.2, 70.1(4×CH 2(z) TEG), 69.5(CH 2(y’) TEG), 68.9(C-3), 67.5(C-4), 67.23(CH2Fmoc), 67.20(C-5), 66.8(CH 2(y) TEG), 62.2(C-6), 58.7(CHα NHFmoc), 47.5(C-2), 47.2(CH Fmoc), 39.5(CH 2(x’) TEG), 36.2(CH 2(x) TEG), 28.1(3×(CH3)[ t Bu]), 22.9(AcNH[C-2 Gal]), 20.8(CH3[AcO C-3]), 20.7(CH3[AcO C-4]), 20.6(CH3[AcO C-6]), 18.1(CH 3[ HRMS(MALDI) m / z:[C 46 H 63 N3O 17 Na] + [M+Na] + The calculated value was 952.4048 and the actual value was 952.4033.
[0347] Protected AcHN-Tn(Thr)-PEG3 tert-butyl ester (33).
[0348] [ka]
[0349] Piperidine (240 μL, 0.04 equiv.) was added dropwise to a solution of Fmoc-protected Tn(Thr) moiety 32 (53.4 mg, 57.4 μmol) in DMF (1.0 mL). After 45 min, TLC (ethyl acetate) revealed that the starting material was consumed and the solvent was removed under vacuum. After further azeotropic drying with toluene, the crude residue was dissolved in pyridine (900 μL) and acetic anhydride (300 μL) was added dropwise. After 2 h, when TLC (ethyl acetate) showed complete conversion of the intermediate, the reaction mixture was concentrated to dryness and further dried with toluene. Purification by silica gel column chromatography (DCM / methanol 97.5:2.5 to 96.5:3.5) afforded AcHN-Tn(Thr)-TEG3 spacer 33 (40.2 mg, 93% yield) as a white solid.
[0350] TLC:R f 0.75 (9:1 DCM / MeOH); 1 H NMR(400 MHz, CDCl3):δ7.32 (t,J=5.4 Hz, 1H, NH, NHCO [Tn-TEG]), 6.66 (d,J=8.9 Hz, 1H, NH, NHAc [Thr]), 6.59 (d,J=9.5 Hz, 1H, NH, NHAc [C-2 Gal Tn]), 5.34 (d,J=3.6 Hz, 1H, H-4), 5.05 (dd,J=11.3, 3.2 Hz, 1H, H-3), 4.88 (d,J=3.6 Hz, 1H, H-1), 4.60 (dd,J=9.1, 2.4 Hz, 1H, CHα NHAc [Thr]), 4.57 - 4.49 (m, 1H, H-2), 4.23 (t,J=6.5 Hz, 1H, H-5), 4.16 (qd,J=6.3, 2.3 Hz, 1H, CHαCH3[Thr]), 4.11 - 3.98 (m, 2H, H-6a,b), 3.69 (t,J=6.3 Hz, 2H, CH 2(y) TEG), 3.63-3.55 (m, 8H, 4 × CH 2(z) TEG), 3.55-3.44 (m, 2H, CH 2(y’)TEG), 3.44 - 3.37 (m, 2H, CH 2(x’) TEG), 2.48 (t, J = 6.3 Hz, 2H, CH 2(x) TEG), 2.13 (s, 3H, CH3[AcO C - 4]), 2.09 (s, 3H, CH3[NHAc Thr]), 1.99 (s, 3H, CH3[AcO C - 6]), 1.99 (s, 3H, CH3[NHAc C - 2 Gal Tn]), 1.96 (s, 3H, CH3[AcO C - 3]), 1.42 (s, 9H, 3 × (CH3) t Bu]), 1.25 (d, J = 6.3 Hz, 3H, CH3[Thr]). 13 13C NMR(101MHz, CDCl3): δ 171.2(CO2 t Bu), 171.0(CO[AcO C - 3]), 170.8(CONH[NHAc Thr]), 170.78(CONH[C - 2 Gal Tn]), 170.5(CO[AcO C - 4 & C - 6]), 170.4(NHCO[Tn - TEG]), 100.5(C - 1), 80.9(C quaternary t Bu), 78.4(CHα CH3[Thr]), 70.6, 70.5, 70.4, 70.3(4×CH 2(z) TEG), 69.5(CH 2(y’) TEG), 69.1(C - 3), 67.5(C - 4), 67.3(C - 5), 66.9(CH 2(y) TEG), 62.3(C - 6), 56.6(CHα NHAc[Thr]), 47.5(C - 2), 39.5(CH 2(x’) TEG), 36.3(CH 2(x) TEG), 28.2(3×(CH3) t Bu]), 23.3(AcNH[Thr]), 23.1(AcNH[C - 2 Gal]), 20.88(CH3[AcO C - 3]), 20.86(CH3[AcO C - 4]), 20.7(CH3[AcO C - 6]), 18.3(CH 3[ Thr]). HRMS(MALDI) m / z: [C 33 H 55 N3O 16Na] + [M+Na] + The calculated value was 772.3473 and the actual value was 772.3416.
[0351] AcHN-Tn(Thr)-PEG3 tert-butyl ester (34).
[0352] [ka]
[0353] To a suspension of 33 (33 mg, 44 μmol) in MeOH (1.0 mL), hydrazine (50 μL) was added, giving a clear solution. The reaction was monitored by HPLC and after 90 min, toluene was added. The mixture was concentrated and the residue was purified by silica gel chromatography using a Buchi Pure C-850 automated system (DCM / MeOH 90:10 to 82:18) to give the deacetylated Tn(Thr)-TEG3 tert-butyl ester 34 (37.2 mg, 84% yield) as a glassy solid.
[0354] TLC:R f 0.22(9:1 DCM / MeOH); 1 H NMR (600MHz, methanol-d4):δ 4.85(d, J=3.7Hz, 1H, H-1), 4.52(d, J=2.6Hz, 1H, CHα NHAc[Thr]), 4.26-4.19(m, 2H, H-2, CHα CH3[Thr]), 3.91-3.86(m, 2H, H-4, H-5), 3.75(dd, J=11.0, 3.2Hz, 1H, H-3), 3.73-3.68(m, 4H, H-6a,b, CH 2(y) TEG), 3.66-3.57(m, 8H, 4×CH 2(z) TEG), 3.55-3.50(m, 2H, CH 2(y’) TEG), 3.50-3.45(m, 1H, CHHa (x’) TEG), 3.31-3.27(m, 1H, CHHb (x’)TEG), 2.48 (t, J = 6.2 Hz, 2H, CH 2(x) TEG), 2.09 (s, 3H, CH3[NHAc Thr]), 2.07 (s, 3H, CH3[NHAc C-2 Gal Tn]), 1.45 (s, 9H, 3×(CH3) t Bu]), 1.27 (d, J = 6.4 Hz, 3H, CH3[Thr]). 13 13C NMR (151 MHz, methanol-d4): δ 174.1 (CONH[C-2 Gal Tn]), 173.6 (CONH[NHAc Thr]), 172.8 (CO2 t Bu), 172.3 (NHCO[Tn-TEG]), 101.0 (C-1), 81.7 (C quaternary t Bu]), 77.7 (CHα CH3[Thr]), 72.9 (C-5), 71.53, 71.47, 71.4, 71.3 (4×CH 2(z) TEG), 70.40 (C-3), 70.38 (CH 2(y’) TEG), 70.26 (C-4), 67.9 (CH 2(y) TEG), 62.7 (C-6), 58.4 (CHα NHAc[Thr]), 51.4 (C-2), 40.5 (CH 2(x’) TEG), 37.2 (CH 2(x) TEG), 28.4 (3×(CH3) t Bu]), 23.2 (AcNH[C-2 Gal]), 22.5 (AcNH[Thr]), 19.2 (CH3[Thr]). HRMS (ESI) m / z: [C 27 H 49 N3O 13 Na]+ [M + Na]+ calculated value for 646.3154, measured value 646.3128.
[0355] AcHN-Tn(Thr)-PEG3 acid (35)
[0356]
Chemical Structure
[0357] The tert-butyl ester 34 (26.5 mg, 42 μmol) was dissolved in a pre-cooled (0 °C) solution of TFA (0.8 mL). The reaction mixture was stirred at this temperature and its progress was monitored by HPLC. After 1 h, DCM was added and the contents were evaporated to dryness. The crude product was purified by reversed-phase (RP) chromatography using a Buchi Pure C-850 automated system [0–100% acetonitrile / water (0.05% TFA)] to give the deprotected Tn(Thr)-TEG3 carboxylic acid 35 (20.5 mg, 86% yield) as a white solid.
[0358] HPLC: R =13.56 minutes, λ max = 194.52 nm; 1 H NMR (600MHz, methanol-d4):δ 4.85(d, J=3.8Hz, 1H, H-1), 4.52(d, J=2.6Hz, 1H, CHα NHAc[Thr]), 4.26-4.20(m, 2H, H-2, CHα CH3[Thr]), 3.91-3.87(m, 2H, H-4, H-5), 3.77-3.70(m, 5H, H-3, H-6a, H-6b, CH 2(y) TEG), 3.65-3.58(m, 8H, 4×CH 2(z) TEG), 3.54-3.50(m, 2H, CH 2(y’) TEG), 3.50-3.45(m, 1H, CHHa (x’) TEG), 3.32-3.28(m, 1H, CHHb (x’) TEG), 2.58-2.54(m, 2H, CH 2(x) TEG), 2.09(s, 3H, CH3[NHAc Thr]), 2.07(s, 3H, CH3[NHAc C-2 Gal Tn]), 1.27(d, J=6.4Hz, 3H, CH3[Thr]). 13C NMR(151MHz, methanol-d4):δ 175.4(CO2H), 174.2(CONH[C-2 Gal Tn]), 173.7(CONH[NHAc Thr]), 172.4(NHCO[Tn-TEG]), 101.0(C-1), 77.7(CHα CH3[Thr]), 72.9(C-5), 71.54, 71.45, 71.4, 71.3(4×CH 2(z) TEG), 70.42(C-3), 70.40(CH 2(y’) TEG), 70.3(C-4), 67.8(CH 2(y) TEG), 62.7(C-6), 58.5(CHα NHAc[Thr]), 51.4(C-2), 40.5(CH 2(x’) TEG), 35.8(CH 2(x) TEG), 23.2(AcNH[C-2 Gal]), 22.5(AcNH[Thr]), 19.2(CH3[Thr]). HRMS(ESI) m / z:[C 23 H 41 N3O 13 Na] + [M+Na] + The calculated value was 590.2485 and the actual value was 590.2528.
[0359] 7.2. Preparation of Tn-containing vaccines Aminoacyl quilacic acid-Tn(Thr) saponin [QA-Tn] (26) [RF-III-162].
[0360] [ka]
[0361] To a solution of Tn(Thr)-spacer acid 35 (3.9 mg, 6.9 μmol, 1.5 equiv.), benzotriazol-1-yl-oxy]tripyrrolidinophosphonium hexafluorophosphate (PyBOP) (3.8 mg, 7.3 μmol, 1.6 equiv.) and quinoline saponin amine 10 (4.8 mg, 4.6 μmol, 1.0 equiv.) in DMF (1.6 mL), diisopropylethylamine (DIPEA) (2.4 μL, 13.8 μmol, 3.0 equiv.) was added dropwise. The reaction mixture was stirred at room temperature for 1 h and concentrated under high vacuum. The resulting residue was dissolved in 50% acetonitrile / water, filtered through a 0.2 μm PTFE filter disk, and purified by RP-HPLC on an XBridge preparative BEH300 C18 column (5 μm, 19 × 250 mm) using a linear gradient of 20–100% acetonitrile / water (0.05% TFA) for 30 min at a flow rate of 17 mL / min. The fractions containing the major peak were collected and lyophilized to give the desired quinoline saponin-Tn conjugate 26 (6.2 mg, 85% yield) as a white solid.
[0362] HPLC: R =22.56 minutes, λ max =193.5 nm. 1<h2 style=";text-align:left;direction:ltr">H NMR(600MHz, メタノール-d4):δ 9.31(s, 1H, H-23[CHO] QA), 8.16(t, J=5.6Hz, 1H, NH[CONH Thr-TEG]), 8.10(d, J=9.1Hz, 1H, NH[NHAc Thr]), 7.97(d, J=9.2Hz, 1H, NH[CONH C-4 N-Gal]), 7.44(d, J=9.2Hz, 1H, NH[NHAc C-2 Gal Tn]), 5.39(d, J=1.8Hz, 1H, H-1 Rha), 5.34(d, J=7.8Hz, 1H, H-1 N-Gal), 5.31(t, J=3.7Hz, 1H, H-12 QA), 4.86-4.83(m, 1H, H-1 Gal Tn), 4.56-4.51(m, 1H, CHα NHAc[Thr]), 4.51-4.47(m, 2H, H-1 Xyl, H-16 QA), 4.37-4.32(m, 1H, H-4 N-Gal), 4.27-4.19(m, 2H, H-2 Gal Tn, CHα CH3[Thr]), 3.97-3.87(m, 5H, H-3 & H-2 N-Gal, H-2 Rha, H-4 & H-5 Gal Tn), 3.87-3.78(m, 3H, H-3 & H-5 Rha, H-5a) xyl), 3.78-3.68(m, 7H, H-3 QA, H-6a,b & H-3 Gal Tn, CH<h2 style=";text-align:left;direction:ltr"> 2(y) <h2 style=";text-align:left;direction:ltr"> TEG, H-5 N-Gal), 3.65-3.58(m, 8H, 4×CH<h2 style=";text-align:left;direction:ltr"> 2(z) <h2 style=";text-align:left;direction:ltr"> TEG), 3.58-3.45(m, 6H, H-6a N-Gal, CHHa<h2 style=";text-align:left;direction:ltr"> (x’) <h2 style=";text-align:left;direction:ltr"> & CH<h2 style=";text-align:left;direction:ltr"> 2(y’) <h2 style=";text-align:left;direction:ltr"> TEG, H-4<h2 style=";text-align:left;direction:ltr"> (x’) <h2 style=";text-align:left;direction:ltr"> TEG, H-3 Xyl), 3.24-3.16(m, 4H, CH<h2 style=";text-align:left;direction:ltr"> 2(a’) <h2 style=";text-align:left;direction:ltr"> NHCO アシル, H-5b & H-2<h2 style=";text-align:left;direction:ltr"> 2(x)<h2 style=";text-align:left;direction:ltr">TEG), 2.37-2.28(m, 3H, CH<h2 style=";text-align:left;direction:ltr"> 2(a) <h2 style=";text-align:left;direction:ltr"> CONH (H-19a QA), 2.09(s, 3H, CH3[NHAcGal]), 2.07(s, 3H, CH3[NHAcThr]), 2.00-1.89(m, 4H, H-11a,b, H-22a & H-21a QA), 1.83-1.62(m, 8H, CH<h2 style=";text-align:left;direction:ltr"> 2(b) <h2 style=";text-align:left;direction:ltr"> CH2CONH (H-22b, H-9, H-1a, H-2a,b & H-15a QA), 1.60-1.43(m, 5H, CH<h2 style=";text-align:left;direction:ltr"> 2(b’) <h2 style=";text-align:left;direction:ltr"> CH2NHCO アシル, H-6a, H-7a & H-15b QA), 1.43-1.30(m, 10H, CH<h2 style=";text-align:left;direction:ltr"> 2(c) <h2 style=";text-align:left;direction:ltr"> CH2CH2CONH (H-7b & H-5 QA,[1.41 s, CH3C-27 QA],[1.33 d, J=6.3Hz, 3H, CH3Rha]), 1.27(d, J=6.4Hz, 3H, CH3Thr), 1.20-1.09(m, 2H, H-21b & H-1b QA), 1.09-1.03(m, 1H, H-19b QA), 1.02(s, 3H, CH3C-24 QA), 1.01(s, 3H, CH3C-25 QA), 0.95(s, 3H, CH3C-30 QA), 0.94-0.90(m, 1H, H-6b), 0.88(s, 3H, CH3C-29 QA), 0.77(s, 3H, CH3C-26 QA)。<h2 style=";text-align:left;direction:ltr"> 13C NMR(151MHz, メタノール-d4):δ 208.8(CHO QA), 178.2(CONH アシル[C-4 N-Gal]), 176.9(CO[C-28] QA-2), 176.9(CO[C-28] QA-2), 174.al. 173.8(CONH[TEG-アシル]), 173.7(CONH[NHAc Thr]), 172.4(NHCO[Tn-TEG]), 144.8(C-13 QA), 123.2(C-11 QA), 1-01 Xyl.0(C 101.0(C-1 Gal Tn), 95.6(C-1 N-Gal), 84.1(C-4 Rha), 78.2(C-3 Xyl), 77.7(CHα CH3[Thr]), 76.4(C-5 N-Gal), 76.2(C-2 N-Gal(C-Gal), 74.6(C-16 QA), 74.4(C-2 N-Gal), 72.94(C-5 Gal Tn), 72.87(C-3 QA), 72.2(C-3 Rha), 71.9(C-2 Rha), 71.54, 71.430, 47.×1. 2(z) TEG), 71.1(C-4 Xyl), 70.4(C-3 Gal Tn & CH 2(y’) TEG), 70.3(C-4 Gal Tn), 68.9(C-5 Rha), 68.3(CH 2(y) TEG), 67.3(C-5 Xyl), 62.7(C-6 Gal Tn), 61.7(C-6 N-Gal), 58.5(CHα NHAc[Thr]), 56.8(C-4 QA), 52.5(C-4 N-Gal), 51.4(C-0), Qn. 2 Gal 48.9(C-5 QA), 48.05(C-19 QA), 48.02(C-9 QA), 42.8(C-14 QA), 42.4(C-18 QA), 41.1(C-8 QA), 40.5(CH 2(x’) TEG), 40.3(CH 2(a’) NHCO アシル), 39.5(C-1 QA), 37.7(CH 2(x) TEG), 37.0(C-10 QA), 36.6(CH 2(a)CONH Acyl), 36.54(C-21 QA), 36.53(C-15 QA), 33.6(C-7 QA), 33.4(CH3C-29 QA), 32.0(C-22 QA), 31.3(C-20 QA), 30.1(CH 2(b’) CH2NHCO acyl), 27.5(CH 2(c) CH2CH2CONH Acyl), 27.2(CH3C-27 QA), 27.0(C-2 QA), 26.8(CH 2(b) CH2CONH Acyl), 24.9(CH3C-30 QA), 24.5(C-11 QA), 23.2(CH3[NHAc, Thr]), 22.6(CH3[NHAc, Gal]), 21.9(C-6 QA), 19.2(CH3Thr), 18.4 (CH3Rha), 17.8 (CH3C-26 QA), 16.3 (CH3C-25 QA), 9.5 (CH3 C-24 QA). HRMS (MALDI) m / z:[C 76 H 125 N5O 30 Na] + [M+Na] + The calculated value was 1610.8300 and the actual value was 1610.8349.
[0363] PV-aminoacylquilaic acid-Tn(Thr) saponin [QA(PV)-Tn] (27) [RF-III-165].
[0364] [ka]
[0365] QA saponin-Tn conjugate 26 (4.6 mg, 2.8 μmol, 1.0 equiv.) was coupled with aminooxypeptide PV11 (9.0 mg, 5.3 μmol, 1.8 equiv.) in acetonitrile / water (2:3, 0.05% TFA, 1.5 mL). After stirring at 40 °C for 16 h, the reaction mixture was HPLC purified [10–100% acetonitrile / water (0.05% TFA)]. Fractions containing the major peak were collected and lyophilized to give the desired QA(PV)-Tn conjugate 27 (4.9 mg, 52% yield) as a white solid.
[0366] HPLC: R =25.02 minutes, λ max =195.52 nm.MS(ESI) m / z:[C 157 H 259 N 23 O 50 ] +2 [M+2H] / 2 +2 Calculated value 1628.38, measured value 1629.31, [C 163 H 260 N 21 O 59 ] +3 [M+3H] / 3 +3 The calculated value was 1085.92 and the actual value was 1086.52.
[0367] 7.3. Preparation of Gb3 antigen + diethylene glycol (DEG) spacer The following scheme illustrates the synthesis of a Gb3 antigen moiety functionalized with a PEG-based amino-reactive linker.
[0368] [ka]
[0369] 3-Azidopropyl 2,3,4,6-tetra-O-benzyl-α-d-galactopyranosyl-(1→4)-2,3,6-tri-O-benzyl-β-d-galactopyranosyl-(1→4)-2,3,6-tri-O-benzyl-β-d-glucopyranoside (38) (RF-II-112).
[0370] [ka]
[0371] The acceptor disaccharide 36 (20.18 mg, 0.02 mmol, 1 equiv.) and the donor S-Stolyl monosaccharide 37 (14.16 mg, 0.021 mmol, 1.05 equiv.) were azeotroped with toluene. Activated molecular sieves (20 mg) were then added, followed by dry DCM / Et2O 2:1 (0.9 mL). After stirring for 5 min, the mixture was cooled to -78 °C and a solution of activated AgOTf (azeotropically dried with toluene) (16.23 mg, 0.063 mmol, 3.16 equiv.) in dry Et2O was added via syringe, followed by ρ-TolSCl without touching the glass wall. The reaction was stirred for 1 h while warming to room temperature and consumption of starting material was observed. The reaction mixture was filtered through Celite, rinsed twice with DCM and concentrated. The resulting crude product was dissolved in DCM and washed with NaHCO3 and brine. The organic layer was dried over MgSO, filtered, and concentrated. Purification by silica gel chromatography (96:4 toluene / ethyl acetate) afforded a clear oil (38) (20.95 mg, 70% yield) that could eventually be crystallized.
[0372] TLC:R f 0.64 (7:3 hexane / EtOAc); 1H NMR(600MHz, CDCl3) δ 7.42-7.10(m, 45H), 5.07(d, J=11.1Hz, 1H), 5.06(d, J=3.5Hz, 1H), 4.86(dd, J=11.3, 6.7Hz, 2H), 4.80-4.67(m, 7H), 4.54-4.42(m, 6H), 4.38-4.33(m, 3H), 4.30-4.23(m, 2H), 4.20-4.15(m, 1H), 4.13-4.06(m, 3H), 4.05-4.01(m, 2H), 4.00-3.93(m, 3H), 3.82(dd, J=10.8, 4.3Hz, 1H), 3.70(dd, J=10.8, 1.6Hz, 1H), 3.66-3.54(m, 3H), 3.53-3.48(m, 2H), 3.39-3.28(m, 6H), 3.18(dd, J=8.3, 4.6Hz, 1H), 1.93-1.81(m, 2H)。 13 C NMR(151MHz, CDCl3) δ 139.21, 139.07, 138.89, 138.82, 138.73, 138.56, 138.49, 138.17, 128.65, 128.49, 128.41, 128.38, 128.34, 128.27, 128.25, 128.07, 127.95, 127.80, 127.75, 127.73, 127.68, 127.60, 127.55, 127.53, 127.47, 127.27, 103.62, 102.95, 100.86, 82.74, 81.77, 79.56, 77.23, 76.74, 75.36, 75.23, 75.18, 75.13, 75.01, 74.94, 73.86, 73.42, 73.32, 73.19, 73.15, 72.58, 72.21, 69.57, 68.35, 67.97, 67.85, 66.59, 48.46, 29.38。
[0373] 3-Aminopropyl 2,3,4,6-tetrol-α-d-galactopyranosyl-(1→4)-2,3,6-triol-β-d-galactopyranosyl-(1→4)-2,3,6-triol-β-d-glucopyranoside (39) (RF-III-053).
[0374] [ka]
[0375] Azidopropyl Gb3 38 (30 mg, 0.02 mmol) and Pd / C 10% (108 mg, 0.10 mmol, 5 equiv.) were dissolved / suspended in a mixture of MeOH / DCM 3:1 (12 mL). A H2 balloon was attached to the flask and the atmosphere was purged and refilled with H2 five times. The mixture was stirred overnight and then monitored by direct injection into a mass spectrometer to confirm complete conversion. The mixture was then filtered through a syringe with a 0.45 μm PTFE disk filter, concentrated, and lyophilized to give the deprotected aminopropyl Gb3 39 (10.8 mg, 96% yield) as a white solid.
[0376] 1 H NMR(600MHz, D2O) δ 4.95(d, J=3.9Hz, 1H), 4.52(d, J=2.8Hz, 1H), 4.51(d, J=2.6Hz, 1H), 4.36(t, J=6.5Hz, 1H), 4.09-3.97(m, 4H), 3.96-3.88(m, 2H), 3.87-3.77(m, 5H), 3.77-3.68(m, 3H), 3.67-3.56(m, 4H), 3.35-3.30(m, 1H), 3.17(t, J=7.0Hz, 2H), 2.05-1.99(m, 2H). 13C NMR(151MHz, D2O) δ 103.9, 102.7, 100.9, 79.3, 78.0, 76.1, 75.5, 75.0, 73.5, 72.8, 71.5, 71.5, 69.8, 69.6, 69.2, 68.5, 61.1, 61.0, 60.6, 38.2, 27.3. MS(ESI) m / z:[C 21 H 39 NO 16 ] + [M+H] + The calculated value was 562.23 and the actual value was 562.33.
[0377] Gb3-DEG linker (40) (RF-III-057).
[0378] [ka]
[0379] When a solution of deprotected aminopropyl Gb3 39 (10.8 mg, 19.2 umol) in dry DMF (2.6 mL) and DIPEA (8.3 μL, 2.5 equiv.) was added to a solution of bis-activated DEG linker 7 (50 mg, 0.10 mmol, 5.6 equiv.) in dry DMF (0.48 mL) at room temperature, the solution changed from clear to yellow. After stirring for 1 h, the aminopropyl Gb3 was confirmed to be consumed by monitoring HPLC-MS. The reaction mixture was neutralized with 1.5 μL of TFA, and the solution changed from yellow to clear. After removing the DMF under vacuum with stirring at 30 °C, the resulting crude product was dissolved in H2O / MeCN 1:1. Purification by RP-HPLC and lyophilization of the fractions containing the desired product afforded the Gb3-linker conjugate 40 (7.88 mg, 46% yield).
[0380] HPLC: R =18.37 minutes, λ max = 193.52 nm and 271.52 nm. 1H NMR(600MHz, D2O) δ 8.40-8.33(m, 1H), 7.48-7.41(m, 2H), 4.95(d, J=4.0Hz, 1H), 4.60(d, J=2.3Hz, 2H), 4.50(d, J=7.7Hz, 1H), 4.45(d, J=8.0Hz, 2H), 4.36(t, J=6.3Hz, 1H), 4.24(s, 1H), 4.10-4.05(m, 2H), 4.07-4.01(m, 2H), 4.02-3.87(m, 6H), 3.89-3.65(m, 13H), 3.68-3.51(m, 4H), 3.40-3.26(m, 3H), 1.91-1.80(m, 2H). 13 C NMR(151MHz, D2O) δ 173.0, 171.1, 155.1, 146.2, 126.2, 123.2, 103.9, 102.6, 100.9, 79.3, 79.3, 78.0, 76.0, 75.4, 75.0, 73.5, 72.7, 71.5, 71.4, 71.1, 70.9, 70.6, 70.2, 70.2, 70.1, 70.1, 70.1, 70.1, 69.7, 69.5, 69.1, 68.4, 68.3, 68.2, 61.1, 60.9, 60.6, 36.5, 29.1. MS(ESI) m / z:[C 35 H 55 N2O 24 ] + [M+H] + The calculated value was 887.31 and the actual value was 887.68.
[0381] 7.4. Preparation of Gb3-containing vaccines Aminoacylchioric acid QA-Gb3 saponin (28) [RF-III-116].
[0382] [ka]
[0383] Saponin amine 10 (8.2 mg, 7.9 μmol, 1.0 equiv.) was acylated with activated ester-functionalized Gb3 linker 40 (11.3 mg, 12.7 μmol, 1.6 equiv.) in DMF (2.6 mL) via preactivation with DIPEA (2.7 μL, 15.8 μmol, 2.0 equiv.) for 1 h. After RP-HPLC purification (10–100% acetonitrile / water (0.05% TFA)) and lyophilization of the desired fractions including the major peak, quinoline saponin QA-Gb3 conjugate 28 (11.4 mg, 80% yield) was obtained as a white solid.
[0384] HPLC: R =23.72 minutes, λ max =194.52 nm. 1H NMR(800MHz, メタノール-d4) δ 9.31(s, 1H), 5.38(d, J=1.9Hz, 1H), 5.34(d, J=7.9Hz, 1H), 5.31(t, J=3.8Hz, 1H), 4.95(d, J=3.8Hz, 1H), 4.50-4.47(m, 2H), 4.42(d, J=7.2Hz, 1H), 4.34(dd, J=4.7, 1.8Hz, 1H), 4.30(d, J=7.8Hz, 1H), 4.26(t, J=6.2Hz, 1H), 4.01(s, 4H), 3.99(d, J=2.9Hz, 1H), 3.97-3.76(m, 16H), 3.75-3.67(m, 13H), 3.65-3.60(m, 1H), 3.59-3.50(m, 7H), 3.48-3.44(m, 1H), 3.44-3.37(m, 5H), 3.34-3.31(m, 1H), 3.28-3.24(m, 3H), 3.23-3.17(m, 3H), 2.94(dd, J=14.3, 4.7Hz, 1H), 2.36-2.28(m, 3H), 1.98-1.87(m, 4H), 1.86-1.63(m, 11H), 1.60-1.43(m, 5H), 1.41(s, 3H), 1.40-1.35(m, 2H), 1.34-1.31(m, 4H), 1.29(d, J=8.3Hz, 1H), 1.20-1.04(m, 3H), 1.02(s, 3H), 1.00(d, J=2.2Hz, 3H), 0.95(s, 3H), 0.94-0.89(m, 1H), 0.88(s, 3H), 0.77(s, 3H)。 13C NMR (201MHz, methanol-d4) δ 208.8, 178.2, 177.0, 172.6, 162.7, 162.5, 162.3, 144.8, 123.2, 107.0, 105.4, 104.2, 102.7, 101.3, 95.6, 84.1, 81.0, 79.8, 78.2, 76.5, 76.4, 76.3, 76.1, 74.9, 74.7, 74.4, 72.9, 72.8, 72.7, 72.2, 71.8, 71.3, 71.2, 71.1, 71.0, 70.6, 68.9, 68.6, 67.3, 62.7, 61.9, 61.7, 61.5, 56.8, 52.5, 50.0, 49.5, 48.0, 48.0, 42.8, 42.4, 41.1, 40.8, 39.9, 39.5, 37.5, 37.0, 36.5, 33.6, 33.4, 32.0, 31.3, 30.5, 30.3, 27.5, 27.2, 27.0, 26.8, 24.9, 24.5, 21.9, 18.4, 17.8, 16.3, 9.5. MS(ESI) m / z:[C 81 H 134 N3O 39 ] + [M+H] + The calculated value was 1786.87 and the actual value was 1787.17.
[0385] PV-Aminoacylchiraic acid-Gb3 saponin [QA(PV)-Gb3] (29) [RF-III-118]
[0386] [ka]
[0387] QAsaponin-Gb3 conjugate 28 (5.0 mg, 2.8 μmol, 1.0 equiv.) was coupled with aminooxypeptide PV11 (9.4 mg, 5.6 μmol, 2.0 equiv.) in acetonitrile / water (2:3, 0.05% TFA, 1.5 mL). After stirring at 40 °C for 16 h, the reaction mixture was HPLC purified [10–100% acetonitrile / water (0.05% TFA)]. Fractions containing the major peak were collected and lyophilized to give QA(PV)-Gb3 conjugate 29 (6.6 mg, 68% yield) as a white solid.
[0388] HPLC: R =24.88 minutes, λ max =193.52 nm.MS(ESI) m / z:[C 163 H 259 N 21 O 59 ] +2 [M+2H] / 2 +2 Calculated value 1727.39, measured value 1727.35, [C 163 H 260 N 21 O 59 ] +3 [M+3H] / 3 +3 The calculated value was 1151.93 and the actual value was 1152.20.
[0389] In vivo immunological evaluation Animals. Animals were maintained and handled in accordance with the Guidelines for the Care and Maintenance of Animals (European Convention for the Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes) and internal guidelines. Mice were housed in standard cages with an automatic water system and fed standard chow ad libitum. All experimental procedures were approved by the appropriate local authorities. The CIC bioGUNE animal facility is fully accredited by AAALAC Intl.
[0390] Quantification of antibody production. Antibody titers against OVA protein or, in the case of the self-adjuvanted vaccine construct, against MUC1 and TnMUC1 peptides were measured by indirect enzyme-linked immunosorbent assay (ELISA). Briefly, ELISA plates (Thermo Scientific) were coated with 0.05 μg / well of BSA-MUC1 or BSA-TnMUC1 conjugates in carbonate buffer (pH 9.5) and the plates were incubated overnight at 4° C. After washing the wells (PBS, 10 mM, with 0.05% Tween 20), the plates were blocked with 10% fetal calf serum (FCS, Biowest) in PBS buffer for 1 h. Serial dilutions of mouse serum in blocking buffer (10% FCS in PBS buffer) were added to the appropriate control wells and incubated for 1 h at room temperature. After washing, goat anti-mouse total IgG (Jackson Immuno Research) antibody conjugated to horseradish peroxidase (HRP) was added at 1 / 1000 dilution in blocking buffer and incubated for 1 h at room temperature. KPL SureBlue reserve™ commercial solution (100 μL / well, SeraCare) containing 3,3',5,5'-tetramethylbenzidine (TMB) was added as peroxidase substrate and incubated for 10 min before stopping the reaction with 2N H2SO4 (100 μL / well). Absorbance (OD, 450 nm) was measured immediately using a BioTek® Synergy HT multidetection microplate reader.
[0391] In vivo study 1: Comparison of the adjuvant activity of compound 25 versus prior art compound 13 A simple proof-of-principle in vivo experiment was performed to directly compare the adjuvant activity of prior art compound 13 and compound 25 of the present invention with respect to IgG antibody production using chicken ovalbumin (OVA) as a model antigen. Two groups of C75BL6 mice were each given three biweekly subcutaneous injections containing non-toxic OVA antigen (20 μg) combined with either QA-based adjuvant 13 (50 μg) or the new QA (oxime) adjuvant 25 (50 μg). In addition, one group was injected with non-toxic OVA (20 μg) alone as a no-adjuvant control group, and the other group was injected with PBS alone as a negative control. Endpoint sera after three immunizations were probed by ELISA assay by coating 96-well plates with non-toxic OVA (0.5 μg / ml) and total IgG optical density (OD) values (day 42) were calculated (Figure 4). The data show that compound 25 [QA(oxime)] of the present invention induced a significant anti-OVA IgG antibody response that was significantly higher than the response observed with OVA alone and with OVA in the presence of prior art compound 13. Notably, these results demonstrate that the introduction of a C4-oxime group results in a saponin variant with improved adjuvant activity capable of inducing increased levels of antigen-specific IgG antibodies.
[0392] In vivo experiment 2: Saponin conjugate 3 [QA(PV)-MUC1] as a self-adjuvanted vaccine To evaluate the ability of the saponin conjugates to generate anti-MUC1 IgG antibodies, a primary immunization was performed in a group of five mice (C57BL / 6). This in vivo study used a series of MUC1 peptide-related compounds and formulations administered according to a subcutaneous immunization schedule with a prime injection (day 0) and two boosts (days 14 and 28) for a total of three biweekly immunizations (Figure 5). Midpoint sera were obtained on day 21 (one week after the second immunization) and endpoint sera were collected on day 42 (two weeks after the third immunization). In this initial experiment, four groups of mice (Groups A-D) were immunized with the following synthetic molecules: (A) MUC1 peptide antigen alone (compound 5) [Group A], (B) a mixture of MUC1 peptide (5) and PV Th epitope (compound 22) [Group B], (C) a mixture of binary saponin-MUC1 conjugate 1 and Th epitope (22) [Group C], and (D) a ternary saponin construct incorporating both MUC1 and PV peptides, QA(PV)-MUC1(3) [Group D]. Each mouse received 50 μg of MUC1 and equimolar antigen in a single injection in a volume of 100 μL.
[0393] ELISA assays were performed by coating 96-well plates with MUC1-functionalized BSA protein conjugates (23) (FIG. 6). Graphs of serial dilutions versus optical density (OD, 450 nm) showed that only mice immunized with self-adjuvanted vaccines of the invention, such as tripartite QA(PV)-MUC1 construct 3, were capable of producing high titers of total anti-MUC1 IgG antibodies. The strength of the antibody response induced by tripartite vaccine 3 was already noticeable at day 21.
[0394] Additionally, anti-MUC1 IgG subtypes were consistently higher in mice immunized with the tripartite QA(PV)-MUC1 construct 3 (FIG. 7).
[0395] In vivo experiment 3: Saponin conjugate 4 [QA(PV)-TnMUC1] as a self-adjuvanted vaccine Further in vivo studies were performed using the TnMUC1 glycopeptide antigen (Figure 8). Three immunization groups received the TnMUC1 glycopeptide (6) co-administered with either (i) a known QA-based saponin adjuvant 13 [Group B], (ii) a mixture of QA saponin 13 and the PV epitope 22 [Group C], or (iii) a newly synthesized QA saponin-(PV) conjugate (i.e., molecule 14) [Group F]. Two immunization groups received the binary QA saponin-TnMUC1 construct 2 alone [Group D] or mixed with the PV epitope [Group E], and another group was injected with the ternary QA(PV)-TnMUC1 construct 4 incorporating both the PV and TnMUC1 peptides [Group G]. Finally, a negative control group receiving only PBS was included [Group A]. In previous experiments, each mouse was injected with an antigen dose equimolar to 50 μg of TnMUC1 in one injection in a volume of 100 μL, and the QA saponin adjuvant was administered at a fixed dose of 50 μg according to previous protocols. As the difference in total IgG titers between days 21 and 42 was not particularly significant, it was decided to reduce the immunization schedule to two biweekly injections (one primary injection on day 0 followed by one boost injection on day 14). Midpoint sera were collected on day 10 and endpoint sera were collected on day 24, 10 days after the second immunization.
[0396] In this setting, anti-TnMUC1 IgG antibody titers (day 24) induced by the tripartite construct 4 of the invention were significantly higher than those observed in the other groups (Figure 9), which is in agreement with the good results obtained in previous immunization experiments with the corresponding tripartite vaccine 3. Similarly, the induced IgG isotypes were also consistently higher for mice immunized with tripartite construct 4 (Figure 10).
[0397] All these data demonstrate that the incorporation of an oxime group (-C=NO-) at the C4 position of the new triterpene glycoside saponin adjuvants developed in this invention results in a much more pronounced adjuvant capacity compared to the known C-4 aldehyde variants. Furthermore, by derivatization at the C4-aldehyde position via an oxime bond and functionalization of the acyl chains added to the carbohydrate domain, etc., a potent self-adjuvanting vaccine was constructed by linking to the saponin scaffold moiety that can stimulate immune responses.
[0398] List of references TIFF2024544007000080.tif195144TIFF2024544007000081.tif216144
Claims
1. A compound selected from: - a compound of formula (I) or a pharma- ceutically acceptable salt thereof 【Chemistry 1】 wherein G is hydrogen, a branched trisaccharide of formula (VI) or a stereoisomer of formula (VI); 【Chemistry 2】 In the formula, R p Each occurrence of is independently hydrogen or OR q and R q Each occurrence is independently hydrogen, or a 6-10 membered aryl, benzyl, C 1~6 aliphatic or C having 1 to 2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur 1~6 or two R q taken together form a 5-7 membered heterocycle having 1-2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; --- is a single bond or a double bond, V is H or OR x and Y is CH 2 , —O—, —S—, —NR, or —NH—; Z is a carbohydrate domain having the structure: 【Chemistry 3】 【Chemistry 4】 In the formula, R 1 Each occurrence of R X or a carbohydrate domain having the structure: 【Chemistry 5】 During the ceremony, each occurrence of a, b, c is independently 0, 1, or 2; D is an integer from 1 to 5, the bracketed structures of each d may be the same or different, provided that the bracketed structure of d represents a furanose or pyranose moiety, and the sum of b and c is 1 or 2; R 0 is hydrogen; an oxygen protecting group selected from the group consisting of alkyl ether, benzyl ether, silyl ether, acetal, ketal, ester, carbamate, and carbonate; or acyl, C 1~10 aliphatic, C 1~6 an optionally substituted moiety selected from the group consisting of heteroaliphatic, 6-10 membered aryl, arylalkyl, 5-10 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, 4-7 membered heterocyclyl having 1-2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; R a , R b , R c , and R d Each occurrence of is independently hydrogen, halogen, OH, OR, OR x , N.R. 2 , NHCOR, or acyl, C 1~10 aliphatic, C 1~6 an optionally substituted group selected from heteroaliphatic, 6- to 10-membered aryl, arylalkyl, 5- to 10-membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 4- to 7-membered heterocyclic groups having 1-2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; R 2 is hydrogen, halogen, OH, OR, OC(O)R 4 , O C (O) O R 4 , O C (O) NHR 4 , OC(O)NRR 4 , O.C.(O)SR 4 , NHC(O)R 4 , NRC(O)R 4 , NHC(O)OR 4 ,NHC(O)NHR 4 ,NHC(O)NRR 4 , N.H.R. 4 , N(R 4 ) 2 , N.H.R. 4 , N.R.R. 4 , N 3 , or C 1~10 aliphatic, C 1~6 an optionally substituted group selected from heteroaliphatic, 6- to 10-membered aryl, arylalkyl, 5- to 10-membered heteroaryl having 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, and 4- to 7-membered heterocyclyl having 1-2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; R 3 is hydrogen, halogen, CH 2 OR 1 , or acyl, C 1~10 aliphatic, C 1~6 an optionally substituted group selected from the group consisting of heteroaliphatic, 6- to 10-membered aryl, arylalkyl, 5- to 10-membered heteroaryl having 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, and 4- to 7-membered heterocyclyl having 1-2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; R 4 is -T-R z , -C(O)-T-R z , -NH-T-R z , -O-T-R z , -S-T-R z , -C(O)NH-T-R z , C(O)O-T-R z , C(O)S-T-R z , C(O)NH-T-O-T-R z , -O-T-R z , -T-O-T-R z , -T-S-T-R z or 【Chemistry 6】 and During the ceremony, X is -O-, -NR-, or T-R z and T is a covalent bond or a divalent C 1~26 saturated or unsaturated, linear or branched, aliphatic or heteroaliphatic chains, R z is hydrogen, halogen, -OR, -OR x , -OR 1 , -SR, NR 2 , —C(O)OR, —C(O)R, —NHC(O)R, —NHC(O)OR, —NC(O)OR, or acyl, arylalkyl, heteroarylalkyl, C 1~6 an optionally substituted group selected from aliphatic, 6- to 10-membered aryl, 5- to 10-membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and 4- to 7-membered heterocyclyl having 1-2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; R x each occurrence of is independently hydrogen or an oxygen protecting group selected from the group consisting of alkyl ethers, benzyl ethers, silyl ethers, acetals, ketals, esters, carbamates, and carbonates; Each occurrence of R is independently hydrogen, acyl, arylalkyl, 6- to 10-membered aryl, C 1~6 aliphatic or C having 1 to 2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur 1~6 an optionally substituted group selected from heteroaliphatic; or two R on the same nitrogen atom together with the nitrogen atom form a 4-7 membered heterocycle having 1-2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; and A compound of general formula (II) or a pharma- ceutically acceptable salt thereof 【Chemistry 7】 (In the formula, --, G, V, and Y have the same meaning as in formula (I), W is H or a moiety that contains either i) at least one T cell epitope, ii) at least one B cell epitope, or iii) at least one T cell epitope and at least one B cell epitope; Z* represents Z as defined in formula (I) optionally linked to a moiety comprising either i) at least one T cell epitope, ii) at least one B cell epitope, or iii) at least one T cell epitope and at least one B cell epitope; provided that at least one T cell epitope and at least one B cell epitope are present in the compound of formula (II); The at least one T cell epitope is in all cases independently selected from a helper T cell epitope or a CD8 epitope).
2. A compound selected from the following: A compound of formula (III) or a pharma- ceutically acceptable salt thereof 【Chemistry 8】 (wherein --, G, V, and Y have the same meanings as in claim 1, and Z* represents that Z defined in formula (I) of claim 1 is linked to a moiety comprising any one of i) at least one T cell epitope selected from a helper T cell epitope or a CD8 epitope, ii) at least one B cell epitope, or iii) at least one T cell epitope and at least one B cell epitope selected from a helper T cell epitope or a CD8 epitope.) and A compound of general formula (IV) or a pharma- ceutically acceptable salt thereof 【Chemistry 9】 (wherein --, G, V, Y and Z have the same meanings as in claim 1, W is a moiety that includes either i) at least one T cell epitope selected from a helper T cell epitope or a CD8 epitope, ii) at least one B cell epitope, or iii) selected from a helper T cell epitope or a CD8 epitope, at least one T cell epitope and at least one B cell epitope).
3. In the formula, G is hydrogen or 【Chemistry 10】 and --- is a single bond or a double bond, V is H or OH; Y is -O-; Z is a carbohydrate domain having the structure: 【Chemistry 11】 During the ceremony, R 1 is independently H or 【Chemistry 12】 R 2 However, N.H.R. 4 and R 3 But, CH 2 OH, R 4 is -T-R z , -C(O)-T-R z , -NH-T-R Z , -O-T-R z , -S-T-R z , -C(O)NH-T-R z , C(O)O-T-R z , C(O)S-T-R z , C(O)NH-T-O-T-R z , -O-T-R z , -T-O-T-R z , -T-S-T-R z or 【Chemistry 13】 and During the ceremony, X is -O-, -NR-, or T-R z and T is a covalent bond or a divalent C 1~26 a saturated or unsaturated, linear or branched aliphatic or heteroaliphatic chain; R z is hydrogen, halogen, -OR, -OR x , -OR 1 , -SR, -NR 2 , —C(O)OR, —C(O)R, —NHC(O)R, —NHC(O)OR, —NC(O)OR, or acyl, arylalkyl, heteroarylalkyl, C 1~6 an optionally substituted group selected from aliphatic, 6- to 10-membered aryl, 5- to 10-membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and 4- to 7-membered heterocyclyl having 1-2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; R x is independently hydrogen or an oxygen protecting group selected from the group consisting of alkyl ethers, benzyl ethers, silyl ethers, acetals, ketals, esters, carbamates, and carbonates; R is independently hydrogen, acyl, arylalkyl, 6- to 10-membered aryl, C 1~6 Aliphatic or C having 1 to 2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur 1~6 an optionally substituted group selected from heteroaliphatic; or The compound according to claim 1 or 2, wherein two R on the same nitrogen atom together with the nitrogen atom form a 4- to 7-membered heterocycle having 1 to 2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur.
4. In the compounds of formula (I) and (IV), R 4 comprises a functional group of a specific binding pair, said functional group being one member of the following binding pair: i) aldehydes, ketones, isothiocyanates, carboxylic acids or derivatives thereof, such as esters, anhydrides, acyl halides, tosyl, and N-hydrosuccinimide (NHS)--amines; ii) Alkyne or phosphine ---Azide; iii) cycloalkenes, cycloalkynes, cyclopropanes, isonitriles (isocyanides), or vinylboronic acids---tetrazines; iv) alkyne or maleimide---thiol; v) conjugated dienes---substituted alkenes; vi) Alkenes, alkynes, or copper acetylides---nitrones; vii) Aldehydes or Ketones---alkoxyamines, hydroxylamines, hydrazines, or hydrazides; wherein in the compounds of formula (II) and (III), the binding of Z to a moiety comprising either i) at least one T cell epitope, ii) at least one B cell epitope, or iii) at least one T cell epitope and at least one B cell epitope is achieved by a bond derived from one of said binding pairs. The compound according to any one of claims 1 to 3.
5. In the compound of formula (II), R 4 is selected from: 【Chemistry 14】 【Chemistry 15】 wherein A is a moiety comprising either H, i) at least one T cell epitope selected from a helper T cell epitope or a CD8 epitope, ii) at least one B cell epitope, or iii) at least one T cell epitope selected from a helper T cell epitope or a CD8 epitope and at least one B cell epitope, preferably A is a moiety comprising at least one B cell epitope. The compound of claim 1.
6. The compound of formula (II) is selected from the group consisting of: 【Chemistry 16】 【Chemistry 17】 wherein W and A are independently H or a moiety comprising either i) at least one T cell epitope selected from a helper T cell epitope or a CD8 epitope, ii) at least one B cell epitope, or iii) at least one T cell epitope and at least one B cell epitope selected from a helper T cell epitope or a CD8 epitope; With the proviso that the compound of formula (II) comprises at least one T cell epitope and at least one B cell epitope, The compound of claim 1.
7. The compound according to any one of claims 1 to 6, wherein the B cell epitope or the CD8 T cell epitope is selected from the group consisting of peptides, glycopeptides, and carbohydrates capable of inducing an immune response against a neurodegenerative disease, an infectious disease, or a cancer cell.
8. 8. The compound of claim 7, wherein the B cell epitope or the CD8 T cell epitope is or is found within an immunogenic region of a cancer associated antigen selected from the group consisting of: - Tn carbohydrate antigens such as MUC1 peptide, TnMUC1 glycopeptide, Gb3 carbohydrate, and Tn(Thr) antigen; - glycoproteins such as PSA, mucins such as MUC1, MUC2, MUC4, MUC5AC, MUC6, MUC16, mucin-derived carbohydrate antigens such as Tn, TF, STn, gangliosides such as GM2, GM3, GD2, GD3, globosides such as Gb4, Gb5, Globo-H; -5T4, 8H9, avbeta6 integrin, alpha fetoprotein (AFP), B7-H6, CA-125, carbonic anhydrase 9 (CA9), CD19, CD20, CD22, CD30, CD33, CD38, CD44, CD44v6, CD44v7 / 8, CD52, CD123, CD171, carcinoembryonic antigen (CEA) antigen (CEA), EGFRvIII, epithelial glycoprotein 2 (EGP-2), epithelial glycoprotein 40 (EGP-40), ErbB1 / EGFR, ErbB2 / HER2 / neu / EGFR2, ErbB3, ErbB4, epithelial tumor antigen (ETA), FBP, fetal acetylcholine receptor (AchR), folate receptor a, G250 / CAIX, ganglioside 2 (GD2), ganglioside 3 (GD3), HLA-A1, HL A-A2, high molecular weight melanoma associated antigen (HMW-MAA), IL-13 receptor a2, KDR, k light chain, Lewis Y (LeY), L1 cell adhesion molecule, melanoma associated antigen (MAGE-A1), mesothelin, murine CMV infected cells, mucin-1 (MUC1), mucin-16 (MUC16), natural killer group 2 member D (NKG2D) ligand, neural cell adhesion molecule (NCAM), NY-ESO-1, oncofetal antigen (h5T4), prostate stem cell antigen (PSCA), prostate specific membrane antigen (PSMA), receptor tyrosine kinase-like orphan receptor 1 (ROR1), TAA targeted by mAb IgE, tumor associated glycoprotein 72 (TAG-72), tyrosinase, and vascular endothelial growth factor (VEGF) receptor; - human Her2 / neu, Her1 / EGF receptor (EGFR), Her3, A33 antigen, B7H3, CD5, CD19, CD20, CD22, CD23 (IgE receptor), C242 antigen, 5T4, IL-6, IL-13, vascular endothelial growth factor VEGF (e.g. VEGF-A) VEGFR-1, VEGFR-2, CD30, CD33, CD37, CD40, CD44, CD51, CD52, CD56, CD74, CD 80, CD152, CD200, CD221, CCR4, HLA-DR, CTLA-4, NPC-1C, tenascin, vimentin, insulin-like growth factor 1 receptor (IGF-1R), alpha-fetoprotein, insulin-like growth factor 1 (IGF-1), carbonic anhydrase 9 (CA-IX), carcinoembryonic antigen (CEA), integrin av beta 3, integrin a5 beta 1, folate receptor 1, transmembrane glycoprotein NMB, Fibroblast activation protein alpha (FAP), glycoprotein 75, TAG-72, MUC1, MUC16 (or CA-125), phosphatidylserine, prostate-specific membrane antigen (PMSA), NR-LU-13 antigen, TRAIL-R1, tumor necrosis factor receptor superfamily member 10b (TNFRSF10B or TRAIL-R2), SLAM family member 7 (SLAMF7), EGP40 pan-cancer (pa ncarcinoma antigen, B cell activating factor (BAFF), platelet derived growth factor receptor, glycoprotein EpCAM (17-1A), programmed death 1, protein disulfide isomerase (PDI), regenerating liver phosphatase 3 (PRL-3), prostatic acid phosphatase, Lewis Y antigen, GD2 (disialoganglioside expressed in tumors derived from neuroectodermal tumors), glypican 3 (GPC3), or mesothelin; - associated antigens belonging to specific gene products of mutated or modified cellular genes, in particular cyclin-dependent kinases, p15lnk4b, p53, AFP, B-catenin, caspase 8, p53, Bcr-abl fusion products, MUM-1, MUM-2, MUM-3, ELF2M, HSP70-2M, HST-2, KIAA0205, RAGE, myosin / m, 707-AP, CDC27 / m, ETV6 / AML, TEL / Amll, Dekcain, LDLR / FUT, Pm1-RARa, TEL / AMLI, cancer testis (CT) antigens, members of the MAGE family, BAGE, DAM-6, DAM-10, members of the GAGE family, NY-ESO-1, N A-88A, CAG-3, RCC-associated antigen G250, tumor virus antigens, in particular the E6E7 oncoprotein from human papillomavirus (HPV), Epstein-Barr virus EBNA2-6, LMP-1, LMP-2, gp77, gp100, MART-1 / Melan-A, p53, tyrosinase, tyrosinase-related proteins 1 and 2, PSA, PSM, MC1R, ART4, CAMEL, CEA, CypB, epithelial cell adhesion molecule (EpCAM), HER2 / neu, HER-3, hTERT, hTRT, ICE, Muc1, Muc2, PRAME, RU1, RU2, SART-1, SART-2, SART-3, and WT1, and fragments and derivatives thereof; - CD19; CD123; CD22; CD30; CD171; CS-1 (also called CD2 subset 1, CRACC, SLAMF7, CD319, and 19A24); C-type lectin-like molecule-1 (CLL-1 or CLECLI); CD33; epidermal growth factor receptor variant III (EGFRvIII); ganglioside G2 (GD2); ganglioside GD3 (αNeuSAc(2-8) αNeuSAc(2-3) βDGaip(1-4) bDGlcp(1- 1)Cer); ganglioside GM3 (αNeuSAc(2-8)αNeuSAc(2-3)βDGaip(1-4)bDGlcp(1-1)Cer); GM-CSF receptor; TNF receptor superfamily member 17 (TNFRSF17, BCMA); B-lymphocyte cell adhesion molecule; Tn antigen ((TnAg) or (GaINAc-α-Ser / Thr)); prostate-specific membrane antigen (PSMA); receptor tyrosine kinase-like orphan receptor 1 (RORI); Tumor-associated glycoprotein 72 (TAG72); CD38; CD44v6; carcinoembryonic antigen (CEA); epithelial cell adhesion molecule (EPCAM); B7H3 (CD276); KIT (CD117); interleukin-13 receptor subunit alpha-2 (IL-13Ra2 or CD213A2); mesothelin; interleukin-11 receptor alpha (IL-11Ra); prostate stem cell antigen (PSCA); protease serine 21 (testisin or PRSS21); blood Vascular endothelial growth factor receptor 2 (VEGFR2); HLA class I antigen A-2 alpha; HLA antigen; Lewis (Y) antigen; CD24; platelet-derived growth factor receptor beta (PDGFR-beta); stage-specific fetal antigen-4 (SSEA-4); CD20; delta-like 3 (DLL3); folate receptor alpha; folate receptor beta, GDNF alpha 4 receptor, receptor tyrosine protein kinase, ERBB2 (Her2 / neu); mucin 1, cell surface associated (MUC1);APRIL receptor, ADP-ribosyl cyclase 1, Ephb4 tyrosine kinase receptor, DCAMKL1 serine threonine kinase, aspartate beta hydroxylase, epidermal growth factor receptor (EGFR), neural cell adhesion molecule (NCAM), prostase, prostatic acid phosphatase (PAP), elongation factor 2 mutated (ELF2M), ephrin B2, fibroblast activation protein alpha (FAP), insulin-like growth factor 1 receptor (IGF-I receptor), carbonic anhydrase IX (CAIX), proteasome (prosome, macropain) beta sarcopenia LMP2, glycoprotein 100 (gp100), oncogene fusion protein consisting of breakpoint cluster region (BCR) and Abelson murine leukemia virus oncogene homolog 1 (Abl) (bcr-abl), tyrosinase, ephrin type A receptor 2 (EphA2); ephrin type A receptor 3 (EphA3), fucosyl GM1; sialyl Lewis adhesion molecule (sLe); transglutaminase 5 (TGS5); high molecular weight melanoma-associated antigen (HMWMAA); o-acetyl-GD2 ganglioside (OAcGD2); folate receptor vector DATA; tumor endothelial marker 1 (TEM1 / CD248); tumor endothelial marker 7-related (TEM7R); six-transmembrane epithelial antigen I of the prostate (STEAP1); claudin 6 (CLDN6); thyroid-stimulating hormone receptor (TSHR); G protein-coupled receptor class C group 5, member D (GPRCSD); IL-15 receptor (IL-15); chromosome X open reading frame 61 (CXORF61); CD97; CD179a; anaplastic lymphoma kinase (ALK), polysialic acid, placenta-specific 1 (PLAC1), hexasaccharide portion of globoglycoceramide minute (GloboH), mammary differentiation antigen (NY-BR-1), uroplakin 2 (UPK2), hepatitis A virus cell receptor 1 (HAVCR1), adrenergic receptor beta 3 (ADRB3), pannexin 3 (PANX3), G protein-coupled receptor 20 (GPR20), lymphocyte antigen 6 complex, locus K9 (LY6K), olfactory receptor 51E2 (ORSIE2), TCR gamma alternative reading frame protein (TARP), Wilms tumor protein (WT1), cancer / testis antigen 1 (NY-ESO-1), cancer / testis antigen 2 (LAGE-1a);Melanoma associated antigen 1 (MAGE-A1); melanoma associated antigen 3 (MAGE-A3); melanoma associated antigen 4 (MAGE-A4); T cell receptor beta 2 chain C (T cell receptor beta 2 chain C) C); ETS translocation mutant gene 6 located on chromosome 12p (ETV6-AML); sperm protein 17 (SPA17); X antigen family, member 1A (XAGE1); angiopoietin-binding cell surface receptor 2 (Tie2); melanoma cancer testis antigen-1 (MADCT-1); melanoma cancer testis antigen-2 (MAD-CT-2); Fos-related antigen 1; tumor protein p53, (p53); p53 mutant; prostein; survivin; telomerase; prostate cancer tumor antigen-1 (PCTA-1 or galectin 8), melanoma antigen 1 recognized by T cells (MelanA or MARTI);Rat sarcoma (Ras) mutant, human telomerase reverse transcriptase (hTERT), sarcoma translocation breakpoints, melanoma inhibitor of apoptosis (ML-IAP), ERG (transmembrane protease, serine 2 (TMPRSS2) ETS fusion gene), N-acetylglucosaminyltransferase V (NA17), paired box protein Pax-3 (PAX3), androgen receptor, cyclin-Al, cyclin B1, v-myc avian myelocytomatosis viral oncogene neuroblastoma-derived homolog (MYCN), Ras homolog family member C (RhoC), tyrosinase-related protein 2 (TRP-2), cytochrome P450 1B1 (CYP IBI), CCCTC-binding factor (zinc finger protein)-like (BORIS or Brother of the Regulator of Imprinted Sites), squamous cell carcinoma antigen 3 recognized by T cells (SART3), paired box protein Pax-5 (PAXS), proacrosin-binding protein sp32 (OY-TESI), lymphocyte-specific protein tyrosine kinase (LCK), A-kinase anchor protein 4 (AKAP-4), peptidoglycan recognition protein, synovial sarcoma X breakpoint 2 (SSX2), receptor for advanced glycation end products (RAGE-I), renal ubiquitous 1 (RUI), renal ubiquitous 2 (renal ubiquitous 2) (RU2), legumain, human papillomavirus E6 (HPV E6), human papillomavirus E7 (HPV E7), intestinal carboxylesterase. heat shock protein 70-2 variant (muthsp70-2); CD79a; CD79b; CD72; leukocyte-associated immunoglobulin-like receptor 1 (LARI); Fc fragment of IgA receptor (FCAR or CD89); leukocyte immunoglobulin-like receptor subfamily A member 2 (LILRA2); CD300 molecule-like family member f (CD300LF); C-type lectin domain family 12 member A (CLEC12A); bone marrow stromal cell antigen 2 (BST2); EGF-like module containing mucin-like hormone receptor-like 2 (EMR2); lymphocyte antigen 75 (LY75); glypican 2 (GPC2); glypican 3 (GPC3);Fc receptor-like 5 (FCRL5); and Immunoglobulin lambda-like polypeptide 1 (IGLL1); and - CD150, 5T4, ActRIIA, B7, TNF receptor superfamily member 17 (TNFRSF17, BCMA), CA-125, CCNA1, CD123, CD126, CD138, CD14, CD148, CD15, CD19, CD20, CD200, CD21, CD22, CD23, CD24, CD25, CD26, CD261, CD262, CD30, CD33, CD362, CD37, CD38, CD4, CD40, CD4OL, CD44, CD46, CD5, CD52, CD53, CD54, CD56, CD66a-d, C D74, CD8, CD80, CD92, CE7, CS-1, CSPG4, ED-B fibronectin, EGFR, EGFRvIII, EGP-2, EGP-4, EPHa2, ErbB2, ErbB3, ErbB4, FBP, HER1-HER2 combination, HER2-HER3 combination, HERV-K, HIV-1 envelope glycoprotein gp120, HIV-1 envelope glycoprotein gp41, HLA-DR, HLA class I antigen alpha G, HM1.24, K-Ras GTPase, HMW-MAA, Her2, Her2 / neu, IG F-1R, IL-11Ralpha, IL-13Ralpha2, IL-2, IL-22Ralpha, IL-6, IL-6R, la, li, L1-CAM, L1 cell adhesion molecule, Lewis Y, LI-CAM, MAGEA3, MAGE-A1, MART-1, MUC1, NKG2C ligand, NKG2D ligand, NYESO-1, OEPHa2, PIGF, PSCA, PSMA, ROR1, T101, TAC, TAG72, TIM-3, TRAIL-R1, TRAIL-R1(DR4), TRAIL-R2(DR5), VEGF, VEGFR2, WT-I, G-tan Protein-coupled receptor, alpha-fetoprotein (AFP), angiogenesis factors, exogenous cognate binding molecule (ExoCBM), oncogene products, antifolate receptor, c-Met, carcinoembryonic antigen (CEA), cyclin (D1), ephrin B2, epithelial tumor antigen, estrogen receptor, fetal acetylcholine E receptor, folate binding protein, gp100, hepatitis B surface antigen, Epstein-Barr nuclear antigen 1, latent membrane protein 1, secreted protein BARF1, P2X7 purinergic receptor, syndecan-1, kappa chain, kappa light chain, kdr, lambda chain, livin, melanoma-associated antigen, mesothelin,Mouse double minute 2 homolog (MDM2), mucin 16 (MUC16), mutated p53, mutated ras, necrosis antigen, oncofetal antigen, ROR2, progesterone receptor, prostate specific antigen, tEGFR, tenascin, β2-microdiopulin, Fc receptor-like 5 (FcRL5).
9. The compound according to any one of claims 1 to 8, wherein the helper T cell epitope is a peptide comprising up to about 20 amino acids and / or amino acid analogues.
10. The compound according to any one of claims 1 to 8, wherein the helper T cell epitope is selected from the group consisting of: - peptides derived from poliovirus, for example (PV103-115)KLFAVWKITYKDT; - pan-DR binding (PADRE) peptides, such as DAla-Lys-Cha-Val-Ala-Ala-Trp-Thr-Leu-Lys-Ala-Ala-DAla; - peptides derived from tetanus toxoid, such as (TT593-599) YSYFPSV, (TT830-843) QYIKANSKFIGITE, (TT830-844) QYIKANSKFIGITEL, (TT1084-1099) VSIDKFRIFCKANPK, (TT1174-1189) LKFIIKRYTPNNEIDS, (TT1064-1079) IREDNNITLKLDRCNN, and (TT947-967) FNNFTVSFWLRVPKVSASHLE; - peptides derived from Neisseria meningitidis, such as YAFKYARHANVGRNAFELFL ("YAF"); - Peptides derived from P. falciparum CSP, such as EKKIAKMEKASSVFNVNN.
11. 13. A method for synthesizing a compound of claim 1, comprising: i) a) providing a compound of formula (V) or a salt thereof; 【Chemistry 18】 (wherein, --, G, V, Y and Z have the same meanings as in claim 1). b) reacting the compound of formula (V) with NH 2 OH or a salt thereof to form a compound of formula (I) or a salt thereof; 【Chemistry 19】 (wherein, --, G, V, Y and Z have the same meanings as in claim 1). a method comprising: ii) a) providing a compound of formula (V) or a salt thereof; 【Chemistry 20】 (wherein --, G, V, Y and Z have the same meanings as in claim 1); b) combining said compound of formula (V) or a salt thereof with a moiety comprising either i) at least one T cell epitope selected from a helper T cell epitope or a CD8 epitope, ii) at least one B cell epitope, or iii) at least one T cell epitope and at least one B cell epitope selected from a helper T cell epitope or a CD8 epitope to form a compound of formula (III) or a salt thereof; 【Chemistry 21】 c) reacting the compound of formula (III) or a salt thereof with a compound of the following formula: 【Chemical 22】 or a salt thereof, wherein W is H or a moiety comprising either i) at least one T cell epitope selected from a helper T cell epitope or a CD8 epitope, ii) at least one B cell epitope, or iii) a helper T cell epitope or a CD8 epitope, at least one T cell epitope and at least one B cell epitope, to form a compound of formula (II) or a salt thereof; 【Chemistry 23】 a method comprising: a) providing a compound of formula (V) or a salt thereof; 【Chemistry 24】 (Wherein, --, G, V, Y and Z are claim 1, having the same meaning as in claim 1); b) reacting the compound of formula (V) or a salt thereof with a compound of the following formula: 【Chemistry 25】 or a salt thereof, wherein W is H or a moiety comprising either i) at least one T cell epitope selected from a helper T cell epitope or a CD8 epitope, ii) at least one B cell epitope, or iii) a helper T cell epitope or a CD8 epitope, at least one T cell epitope and at least one B cell epitope, to form a compound of formula (IV) or a salt thereof; 【Chemistry 26】 (The compound of formula (IV) corresponds to formula (II) when W is a moiety containing at least one T cell epitope selected from a helper T cell epitope or a CD8 epitope and at least one B cell epitope.) c) optionally combining said compound of formula (IV) or a salt thereof with a moiety comprising either i) at least one T cell epitope selected from a helper T cell epitope or a CD8 epitope, ii) at least one B cell epitope, or iii) a helper T cell epitope or a CD8 epitope, at least one T cell epitope and at least one B cell epitope to form a compound of formula (II) or a salt thereof; 【Chemical 27】 A method comprising: A method selected from the group consisting of
12. the below described: a compound of formula (I) according to claim 1 or a pharma- ceutically acceptable salt thereof, a pharma- ceutically acceptable carrier and an antigen, or - a compound of formula (II) according to claim 1 or a pharma- ceutically acceptable salt thereof and a pharma- ceutically acceptable carrier 13. A pharmaceutical composition comprising:
13. 10. A compound according to claim 1 for use in medicine.
14. 13. A compound according to claim 1 or a pharmaceutical composition according to claim 12 for use in the treatment and / or prevention of cancer, an infectious disease or a neurodegenerative disease.
